Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

2016

Inhibition of B Lymphopoiesis by Adipocytes and Myeloid-Derived
Suppressor Cells
Domenick Kennedy
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Immunology and Infectious Disease Commons

Recommended Citation
Kennedy, Domenick, "Inhibition of B Lymphopoiesis by Adipocytes and Myeloid-Derived Suppressor Cells"
(2016). Dissertations. 2591.
https://ecommons.luc.edu/luc_diss/2591

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2016 Domenick Kennedy

LOYOLA UNIVERSTIY CHICAGO

INHIBITION OF B LYMPHOPOIESIS
BY ADIPOCYTES AND
MYELOID-DERIVED SUPPRESSOR CELLS

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

PROGRAM IN MICROBIOLOGY AND IMMUNOLOGY

BY
DOMENICK EDWARD KENNEDY
CHICAGO, ILLINOIS
AUGUST 2016

Copyright by Domenick E. Kennedy, 2016
All rights reserved.

ii

ACKNOWLEDGEMENTS
I am extremely grateful for my mentor Dr. Katherine L. Knight, whose
mentorship has allowed me to grow as a scientist and as a person. Dr. Knight
provided me with a nurturing environment and encouraged me to think creatively
to answer complex questions. She bestowed upon me a countless number of
thoughtful insights that I will carry with me forever. Dr. Knight’s mentorship has
allowed me to flourish and has prepared me to excel in my future endeavors. My
experience with Dr. Knight was truly life-changing.
I am thankful for my dissertation committee members Dr. Jiwang Zhang,
Dr. Phong Le, Dr. Pamela Witte, and Dr. Neil Clipstone. They provided many
insightful comments that helped to shape my project, and truly cared about
advancing my progression scientifically and personally. I would also like to thank
the department of Microbiology and Immunology and the faculty that make
Loyola a special place.
I would like to thank my family for supporting my goals in life, and for
embracing my journey through higher education. I am grateful for my parents,
Michael and Rita Kennedy, who raised me and supported me through my
educational journey. I would also like to thank my siblings Michael Kennedy Jr.
and Anne Kennedy, as well as my grandparents Domenick and Columba
Sinibaldi and Frances Kennedy, who always encouraged me to work hard and do
iii

my best.
Last but not least, I would like to thank my growing family. Central to our
family unit is my wife Dr. Justine Kennedy, who is always there for me. Upon
meeting at Loyola our natural friendship blossomed into much more, and we
were married at Loyola University Chicago’s Madonna della Strada Chapel.
Justine is a talented scientist and loving person who inspires me to do great
things. She has always supported me through life’s obstacles, and I am very
blessed to have Justine as my collaborator for life. Words cannot describe the
amount of happiness Justine has brought to my world. Together we created our
son Niccolo in May, 2015 and are expecting our daughter Colette in July, 2016.
Niccolo has brought so much joy to our lives, and we are excited for even more
good times with Colette. I am honored to be part of such a loving family, and look
forward to continuing our journey together.

iv

For my loving wife Justine Kennedy, our son Niccolo, and our daughter Colette

I am still learning… Michelangelo

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ..................................................................................... iii
LIST OF TABLES ................................................................................................. xi
LIST OF FIGURES .............................................................................................. xii
LIST OF ABBREVIATIONS ................................................................................. xv
ABSTRACT ........................................................................................................ xxi
CHAPTER I: LITERATURE REVIEW ................................................................... 1
SECTION 1: B CELL DEVELOPMENT ............................................................ 1
B cell development ......................................................................................... 2
Mouse B cell development........................................................................... 2
VDJ recombination ................................................................................... 3
Human B cell development .......................................................................... 5
Rabbit B cell development ........................................................................... 6
Generation of rabbit antibody diversity in GALT ............................................. 8
The bone marrow microenvironment ............................................................ 10
Osteoblasts................................................................................................ 11
Reticular cells ............................................................................................ 12
Adipocytes ................................................................................................. 12
Stromal cell-derived supportive factors ......................................................... 13
CXCL12 ..................................................................................................... 13
IL-7 ............................................................................................................ 13
SCF, Flt3L, and IGF-1 ............................................................................... 14
Development in the context of different niches ............................................. 15
HSCs in the endosteal versus vascular niches .......................................... 15
Progression through the BM microenvironment during B cell
development ........................................................................................... 17
SECTION 2: DECLINE OF B LYMPHOPOIESIS IN MAMMALS .................... 19
Decline of B lymphopoiesis in mice .............................................................. 20
Decreased frequency and production of B lineage precursors with age .... 20
Mechanisms that contribute to declining B lymphopoiesis ......................... 22
The systemic environment and the decline of B cell development ......... 25
Decline of B lymphopoiesis in humans ......................................................... 26
Decreased frequency of B lineage cells with aging ................................... 26
Reduced B lineage potential in aged HSCs ............................................... 28
Changes to the BM microenvironment ...................................................... 28
MSCs and aging ..................................................................................... 29
Arrest of B lymphopoiesis in rabbits ............................................................. 29
Characterization of declining B cell development ...................................... 30
Allotype suppression experiments .......................................................... 30
vii

B lineage progenitor frequencies ............................................................ 31
B cell recombination excision circle analysis .......................................... 31
Mechanisms that negatively regulate B cell development ......................... 32
Loss of supportive microenvironment ..................................................... 33
Age-related changes to BM stromal cells ............................................... 35
Adipocytes fill the bone marrow with age................................................ 35
SECTION 3: THE IMPACT OF BONE MARROW FAT AND
INFLAMMATION ON LYMPHOPOIESIS ...................................................... 36
White, brown, and beige adipocytes ............................................................. 38
Brown adipocytes ...................................................................................... 38
Beige and white adipocytes ....................................................................... 39
Age-related change in BM adipose tissue phenotype ................................ 40
Regulated versus constitutive marrow fat ..................................................... 41
Adipocytes, inflammation and the decline of T lymphopoiesis ...................... 42
Adipose tissue derived molecules ................................................................ 43
Proteins ..................................................................................................... 44
Lipids ......................................................................................................... 44
Anti-inflammatory molecules......................................................................... 45
Adiponectin ................................................................................................ 45
Pro-inflammatory molecules ......................................................................... 45
IL-6 ............................................................................................................ 45
TNFα ......................................................................................................... 46
S100A8, S100A9, and S100A8/A9 ............................................................ 46
Complement factors .................................................................................. 47
Danger associated molecular patterns (DAMPS) ...................................... 48
Adipocyte mediated inhibition of B lymphopoiesis: direct block or change in
lineage potential? ...................................................................................... 48
Can cells other than adipocytes in the BM negatively regulate B cell
development? ............................................................................................ 49
SIGNIFICANCE .............................................................................................. 51
GOAL OF DISSERTATION ............................................................................ 51
CHAPTER II: EXPERIMENTAL MEHTODS ....................................................... 53
Mice .............................................................................................................. 53
Rabbits ......................................................................................................... 53
Tissue/cell culture reagents .......................................................................... 53
Flow cytometry ............................................................................................. 54
Microscopy ................................................................................................... 56
Preparation of bone marrow cells ................................................................. 56
Mouse ........................................................................................................ 56
Rabbit ........................................................................................................ 56
B lymphopoiesis assay (BM cultures) ........................................................... 56
Mouse ........................................................................................................ 56
Arginase and iNos studies ...................................................................... 57
IL-1 studies ............................................................................................. 57
viii

Hematopoietic progenitor studies ........................................................... 57
Inflammasome inhibitor studies .............................................................. 58
24 well plate format ................................................................................ 58
Transwell cultures ................................................................................... 58
Rabbit ........................................................................................................ 58
T cell proliferation assays ............................................................................. 58
Adipocyte differentiation and conditioned medium generation...................... 59
Mouse adipocytes ...................................................................................... 59
Rabbit adipocytes ...................................................................................... 60
MDSC generation ......................................................................................... 60
MDSC-CM .................................................................................................... 61
BM fat-conditioned medium .......................................................................... 61
Isolation of BM fat ...................................................................................... 61
Generation of conditioned medium ............................................................ 62
Isolation of cells from BM fat......................................................................... 62
Bone marrow sections .................................................................................. 63
Anion exchange chromatography ................................................................. 64
Quantitative PCR .......................................................................................... 66
Cytokine array .............................................................................................. 67
Statistical analysis ........................................................................................ 67
CHAPTER III: RESULTS .................................................................................... 68
SECTION 1: ADIPOCYTES AND THE INHIBITION OF B LYMPHOPOIESIS 68
Mechanism of adipocyte-mediated inhibition ................................................ 72
SECTION 2: MDSCs AND THE INHIBITION OF B LYMPHOPOIESIS ........... 80
Mechanism of MDSC-mediated inhibition of B lymphopoiesis ...................... 81
Do MDSCs require contact with target cells? ............................................ 85
Soluble factors produced by MDSCs ......................................................... 88
Do MDSCs inhibit B lymphopoiesis via IL-1?............................................. 91
Hematopoietic target of IL-1 ...................................................................... 93
SECTION 3: CHARACTERIZATION OF ADIPOCYTE-DERIVED
MOLECULES IN THE NEGATIVE REGULATION OF B LYMPHOPOIESIS 97
Do multiple adipocyte factors contribute to the inhibition of B
lymphopoiesis? .......................................................................................... 97
Are the inhibitory molecules in ACM protein in nature? ................................ 99
Purification of adipocyte derived-inhibitory factors...................................... 100
Which adipocyte-derived soluble factors induce MDSCs?.......................... 104
Can adipocyte factors be targeted to prevent MDSC accumulation? ......... 109
SECTION 4: CHARACTERIZATION OF RABBIT HEMATOPOIESIS ........... 111
SECTION 5: CONTRIBUTION OF THE BONE MARROW
MICROENVIRONMENT TO ALTERED HEMATOPOIESIS IN RABBITS .. 119
Do rabbit bone marrow myeloid cells inhibit B cell development? .............. 121
Characterization of inflammatory myeloid cells in bone the marrow of >2
month old rabbits ..................................................................................... 123
S100A9 and the inhibition of B lymphopoiesis ............................................ 126
ix

Hematopoietic target of S100A9 ................................................................. 128
CHAPTER IV: DISCUSSION ............................................................................ 133
The bone marrow microenvironment and the arrest of rabbit
B lymphopoiesis ...................................................................................... 134
Adipocytes and the accumulation of inhibitory myeloid-derived
suppressor cells ...................................................................................... 137
MDSCs and the production of IL-1 .......................................................... 138
Rabbit bone marrow: An accelerated model of bone marrow aging ........ 139
Bone marrow suppressor cells and declining B cell development .............. 141
Inflammation and the regulation of lymphopoiesis ...................................... 144
The BM as a source of inflammatory factors ........................................... 144
The effect of inflammasome activation on lymphopoiesis ........................ 144
S100A9 and the amplification of inflammation ............................................ 146
Therapeutic strategies to boost B lymphopoiesis during aging and obesity 147
Targeting the adipocyte .............................................................................. 148
Calorie restriction ..................................................................................... 148
Exercise ................................................................................................... 148
Diet and exercise .................................................................................... 149
Targeting myeloid-derived suppressor cells .............................................. 150
Deplete MDSCs ...................................................................................... 150
Block MDSC development ...................................................................... 150
Inactivate MDSC effector mechanisms ................................................... 151
Promote MDSC differentiation into non-suppressive myeloid cells.......... 151
Targeting adipocyte and/or MDSC effector molecules ............................... 152
IL-1 .......................................................................................................... 152
Preventing inflammasome activation ....................................................... 152
Statins, inflammasome activation, and B lymphopoiesis ............................ 153
The rabbit as a model system and remaining questions............................. 154
The rabbit as a model of bone marrow failure ............................................ 155
Maintaining adaptive immunity in the absence of B lymphopoiesis ............ 157
Understanding changes in MSCs before and after two months of age ....... 158
Conclusion .................................................................................................. 160
REFERENCES ................................................................................................. 164
VITA ................................................................................................................. 197

x

LIST OF TABLES
Table

Page

2.1 Mouse antibodies used in this study

54

2.2 Antibodies available for the detection of rabbit immune cell antigens

55

2.3 Mouse qPCR primers

66

2.4 Rabbit qPCR primers

67

xi

LIST OF FIGURES
Figure

Page

1.1 B cell developmental stages in mice

4

1.2 Human B cell developmental stages

6

1.3 Schematic of rabbit B lineage development stages

8

1.4 Rabbit B cell development and maturation in the BM and appendix

9

1.5 BM niches for B cell development

18

1.6 Skewing of hematopoietic lineage potential

50

2.1 Preparation of rabbit bone marrow for sectioning

64

3.1 Inhibitory potential of mouse adipocyte-derived factors in mouse and
rabbit B lymphopoiesis cultures

71

3.2 Characterization of cells resulting after treatment with adipocyte
factors

73

3.3 Phenotypic analysis of myeloid populations in ACM-treated and
untreated cultures

74

3.4 Phenotypic and functional characterization of ACM-generated
CD11bhiGr1+ cells

77

3.5 Ly6C vs Ly6G expression and morphology of CD11b+Gr1+ cells
isolated from ACM-treated or control BM cultures

79

3.6 Effect of MDSCs on B lymphopoiesis cultures

81

3.7 MDSC-mediated inhibition of B lymphopoiesis in the absence of
arginase and iNos

84

3.8 Effect of MDSC-derived soluble factors on B lymphopoiesis

87

xii

3.9 Profile of MDSC-derived soluble factors by cytokine array

89

3.10 Identification of MDSC-derived inhibitory factors

92

3.11 Identification of hematopoietic progenitors targeted by IL-1

95

3.12 Effect of <10kDa and >10kDa adipocyte molecules on B
lymphopoiesis

99

3.13 Purification of inhibitory molecules in ACM >10kDa

103

3.14 Characterization of adipocyte factors for the capacity to induce
CD11b+Gr1+ myeloid cells

106

3.15 Profile of adipocyte-derived soluble factors by cytokine array

108

3.16 Effect of glybenclamide treatment on MDSC accumulation

110

3.17 Characterization of bone marrow fat in rabbits

113

3.18 Characterization of rabbit bone marrow before and after two
months of age

116

3.19 Quantitative PCR anaysis of IL-1β expression in rabbit bone
marrow

118

3.20 Effect of BM fat-CM on rabbit B lymphopoiesis cultures

120

3.21 Effect of BM myeloid cells from >2 month old rabbits on B
lymphopoiesis in vitro

123

3.22 Characterization of S100A9+ myeloid cells in rabbit bone marrow

125

3.23 Effect of S100A9 on B lymphopoiesis in vitro

127

3.24 Impact of S100A9 treatment on hematopoietic progenitors

129

3.25 Effect of S100A9 treatment on bone marrow myeloid cells

132

4.1 Model of Adipocyte-mediated inhibition of B lymphopoiesis

134

4.2 Negative regulation of B lymphopoiesis in adipocyte-rich bone
marrow

161

xiii

4.3 Effect of S100A9 on hematopoiesis

xiv

162

LIST OF ABREVIATIONS
5-FU

5-fluorouracil

µg

microgram

ABC

aged B cell

ACM

adipocyte conditioned medium

ADI

adipocyte differentiation medium

alphaMEM

minimum essential medium alpha

Ang-1

angiopoietin-1

ANOVA

analysis of variance

Arg1

Arginase 1

ATRA

all-trans-retinoic acid

BCR

B cell receptor

BM

bone marrow

BM fat-CM

bone marrow fat-conditioned medium

BREC

B cell recombination excision circle

C5L2

C5-like receptor 2

CaCl2

calcium chloride

CAR

CXCL12hi reticular cells

CFSE

carboxyfluorescein succinimidyl ester

CFU-F

CFU-Fibroblasts
xv

CLP

common lymphoid progenitor

cMAT

constitutive marrow adipose tissue

CpG

C-phosphate-G

CVID

common variable immune deficiency

CXCL12

C-X-C motif ligand 12

CXCR4

C-X-C motif receptor 4

D

diversity

DAMP

danger associated molecular pattern

DC

dendritic cell

DMEM

Dulbecco’s Modified Eagle’s Medium

DNA

deoxyribonucleic acid

D-NMMA

NG-monomethyl-D-arginine

EB

early B lineage progenitor

EBF

early B cell factor

FcRγ

Fc receptor gamma

FCS

fetal calf serum

FcγRIIB

Fc receptor two B

Flt3L

Flt3 ligand

FPLC

fast protein liquid chromatography

GALT

gut associated lymphoid tissues

G-CSF

granulocyte colony stimulating factor

GM-CSF

granulocyte macrophage stimulating factor

xvi

GPCR

g-protein coupled receptor

H and E

hematoxylin and eosin

HGPRT

Hypoxanthine guanine phosphoribosyltransferase

HSC

hematopoietic stem cell

HSPC

hematopoietic stem and progenitor cell populations

IFN-γ

interferon gamma

Igκ

immunoglobulin kappa

Igµ

immunoglobulin mu

IGF-1

insulin-like growth factor

IgH

immunoglobulin heavy chain

Igλ

immunoglobulin lambda

IL-10

interleukin-10

IL-12(p40)

interleukin-12 40kDa subunit

IL-12(p70)

interleukin-12 70kDa subunit

IL-13

interleukin-13

IL-17

interleukin-17

IL-1RA

interleukin-1 receptor antagonist

IL-1α

interleukin-1alpha

IL-1β

interleukin-1beta

IL-2

interleukin-2

IL-3

interleukin-3

IL-4

interleukin-4

xvii

IL-5

interleukin-5

IL-6

interleukin-6

IL-7

interleukin-7

IL-7R

interleukin-7 receptor

IL-9

interleukin-9

iNos

inducible nitric oxide synthase

IVIG

intravenous immunoglobulin G

J

joining

kDa

kilo Dalton

L-NMMA

NG-monomethyl-L-arginine

LPMPS

lymphoid primed multipotent progenitors

M

molar

MCP

macrophage chemoattractant protein

MDI

isobutylmethylxanthine, dexamethasone, insulin medium

MDS

myelodysplastic syndrome

MDSC

myeloid-derived suppressor cells

MDSC-CM

myeloid-derived suppressor cell-conditioned medium

MIP-1α

macrophage inflammatory protein-1 alpha

MIP-1β

macrophage inflammatory protein-1 beta

ml

milliliter

MPP

multipotent progenitor

MSC

mesenchymal stem cell

xviii

NaCl

sodium cloride

NK

natural killer

NLRP3

nod-like receptor pyrin domain containing 3

Nor-NOHA

Nω-hydroxy-nor-arginine

Nos2

nitric oxide synthase 2

OCT

optimal cutting temperature support medium

Pax5

paired-box 5

PBSF

and pre B cell growth stimulating factor

PCR

polymerase chain reaction

PFAS

performic acid Schiff reagent

PPAR-γ

peroxisome proliferator-activated receptor gamma

PRR

PTH/PTH peptide receptor

qPCR

quantitative polymerase chain reaction

RANTES

regulated on activation, normal T cell expressed and
secreted

RBC

red blood cell

RDA

representational difference analysis

rLP

rabbit lymphoid progenitor

rMAT

regulated marrow adipose tissue

ROS

reactive oxygen species

S100A8

S100 calcium binding protein A8

S100A9

S100 calcium binding protein A9

xix

SCF

stem cell factor

SD

standard deviation

SDF

stromal derived factor

SDS

sodium dodecyl sulfate-polyacrylamide gel electrophoresis

sIgM

surface immunoglobulin M

siRNA

small interfering RNA

SNO

N-Cadherin+CD45- osteoblastic cell

STAT3

signal transducer and activator of transcription 3

SVF

stromal vascular fraction

Tdt

Terminal deoxynucleotidyl transferase

TLR

toll-like receptor

TLR9

toll-like receptor 9

TNFα

tumor necrosis factor alpha

UPC1

uncoupling protein1

V

variable

WT

wild-type

XLA

X-linked agammaglobulinemia

xx

ABSTRACT
B lymphopoiesis declines with age in humans, mice, and rabbits. Impaired
B lymphopoiesis correlates with increased fat in the bone marrow (BM),
suggesting that adipocytes negatively regulate this process. In fact, adipocyte
factors were found to inhibit B cell development in BM cultures.
Our goal was to understand the mechanism by which adipocytes inhibit B
cell development. Through culturing mouse BM cells on OP9 stromal cells in the
presence of adipocyte-conditioned medium (ACM), we found that adipocytes
promote the accumulation of CD11b+Gr1+ myeloid-derived suppressor cells
(MDSCs). These cells were not simply bystanders, as we report for the first time
that MDSCs potently inhibit B cell development.
ACM-generated MDSCs express high levels of arginase and iNos, which
are important for suppressing T cells. However, these effector molecules did not
mediate the loss of B lymphopoiesis. By cytokine array analysis of MDSC-CM,
we found that ACM-generated MDSCs produce IL-1. Further, neutralization of IL1 in BM cultures containing MDSCs restored B lymphopoiesis, suggesting that
MDSCs inhibit via IL-1. Inhibition by IL-1 did not directly block B lineage
development, but instead acted at the MPP stage of hematopoietic development
to drive myelopoiesis at the expense of B lymphopoiesis.

xxi

In contrast to humans and mice, where B lymphopoiesis declines in midto-late life, B lymphopoiesis arrests at two-to-four months of age in rabbits.
Characterization of rabbit BM showed an increased number of adipocytes, an
expanded myeloid compartment, and increased expression of inflammatory
factors when B lymphopoiesis is arrested. This reduction in B lymphopoiesis and
increase in myeloid cells was recapitulated in BM cultures treated with BM fatCM. These data coupled with the identification of an inhibitory myeloid
population, suggest that the BM microenvironment is responsible for the arrest of
B lymphopoiesis in rabbits.
Our study has uncovered potential targets for therapies aimed at boosting
B lymphopoiesis in scenarios with fatty BM, such as aging and obesity. For
example, blocking the NLRP3 inflammasome in ACM-treated BM cultures
prevented MDSC accumulation and enhanced B lymphopoiesis. We envision this
observation; along with our other findings will provide insight into mechanisms
that negatively regulate B cell development in fatty BM.

xxii

CHAPTER I
LITERATURE REVIEW
SECTION 1: B CELL DEVELOPMENT
Introduction
Production of B cells and antibodies are essential for effective immune
responses against infectious agents, and for robust immune responses to
vaccines. Genetic mutations impairing the generation of B cells (eg. X-linked
agammaglobulinemia (XLA)) or antibodies (eg. XLA and common variable
immune deficiency (CVID)) result in a severe immunocompromised state (Bonilla
and Geha, 2009, Bruton, 1952, Durandy et al., 2013). Patients with XLA and
CVID routinely receive intravenous IgG (IVIG) therapy to protect against
infections, highlighting the importance of antibodies in immune protection.
In otherwise healthy individuals, aging imposes changes to hematopoietic
progenitors and the BM microenvironment that result in reduced production of
new B cells (Crane et al., 1996, Jasper et al., 2003, McKenna et al., 2001, Miller
and Allman, 2005, Scholz et al., 2013). Decreased B lymphopoiesis contributes
to higher susceptibility to infection and poor immune responses to vaccines in
aged individuals. Therefore, an understanding of mechanisms that
negatively regulate B cell development will be valuable in developing
therapeutics to boost naïve B cell production in the elderly.
1

2

B cell development
B cell development takes place in the bone marrow (BM) of many
mammals, including humans, mice, and rabbits. The BM consists of
hematopoietic lineage cells that will differentiate into immune effector cells, as
well as stromal cells which support the development of immune cells. The normal
progression of B cell development begins with the hematopoietic stem cell
(HSC). The HSC has the potential to differentiate into all cell types of the immune
system, while cues from the microenvironment influence this differentiation
potential promoting one lineage over the other.
To generate B cells, the HSC differentiates through a series of multipotent progenitors, which can then differentiate into the common lymphoid
progenitor (CLP), pre-proB cell, proB cell, preB cell, and finally the immature B
cell that will exit the BM. With each subsequent differentiation step, the genetic
and epigenetic landscape changes while these cells gradually lose the potential
to differentiate into other lineages (eg. myeloid and T lineage) resulting in total
commitment to the B lineage (Hu et al., 1997, Maes et al., 2008, Ramirez et al.,
2010, Weishaupt et al., 2010).
Mouse B cell development. B lymphopoiesis is best characterized in
mice, due to an abundance of genetic models and reagents generated to study
this species. This process begins with the HSC, which differentiates through the
successive developmental stages of MPP, CLP (Lin-Sca1+c-kit+IL-7R+), pre-proB
cell (B220+c-kit-CD19-Flt3+CD24low/-CD43+IgM-), proB cell (B220+c-kit+CD19+Flt3CD24+CD43+IgM-), large preB cell (B220+c-kit-CD19+Flt3-CD24+CD43-IgM-), and
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small preB cell

(B220+c-kit-CD19+Flt3-CD24+CD43-IgM-FSClow)

before becoming

the immature B cell (B220+c-kit-CD19+Flt3-CD24+CD43-IgM+) that leaves the BM
and enters the periphery (Nagasawa, 2006) (Figure1). The timing of specific
differentiation or proliferative events at each of these developmental stages is
critical for successful B cell development. Alterations to these developmental
processes results in immune deficiencies such as XLA (Bruton, 1952,
Cunningham-Rundles and Ponda, 2005) or B cell cancers (Hamel et al., 2014).
VDJ gene recombination . Generation of a B cell pool with a diverse
antibody repertoire is necessary to protect a host from an array of pathogens.
The way many vertebrates generate this antibody diversity is through
combinatorial joining of various variable (V), diversity (D), and joining (J)
segments of the antibody loci. Because surface antibody or the B cell receptor
(BCR) is critical to B cell identity and function, successful rearrangement of the
heavy chain (Igµ) and light chain (Igκ or Igλ) loci are mandatory for successful
maturation to the immature B cell stage. Rearrangement of the Igµ locus begins
at the pre-proB cell stage with recombination of the diversity (D) and joining (J)
regions of this locus (Gellert, 2002, Jung et al., 2006). Upon successful DJ
rearrangement, this process continues in late proB cells with the joining of
variable (V) gene regions to the already formed DJ segment through
recombination. Successful heavy chain VDJ gene recombination allows for
expression of the Igµ locus which then complexes with surrogate light chain
(consisting of VpreB and λ5) to form the pre-BCR (Nishimoto et al., 1991). The
pre-BCR mediates expansion of large preB cells in conjunction with IL-7

4

signaling. Attenuation of IL-7 signaling and active pre-BCR signaling transitions
development to the small preB cell stage, where proliferation is halted and the
Igκ (light chain) locus becomes accessible for VJ recombination (Mandal et al.,
2015). Successful recombination and expression of the Igκ or Igλ loci allows for
functional BCRs present on the surface of immature B cells (Clark et al., 2014)
(Figure 1.1).

Figure 1.1 B cell developmental stages in mice. B cell development begins
with the HSC which progresses through various developmental stages before
reaching the immature B cell stage (B cell). VDJ gene recombination begins in
pre-proB cells with Igµ DJ rearrangement, followed by V-DJ recombination in
proB cells. The Igµ and surrogate light chain are expressed on the surface of
preB cells as the pre-BCR, followed by rearrangement of Igκ light chain.
Successful Igκ rearrangement and surface expression of the BCR complete
differentiation at the immature B cell stage. These cells then leave the BM and
enter the periphery to participate in immune responses. Each developmental
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stage can be identified with the presence or absence of the indicated cell
markers.

Human B cell development. The B cell developmental process in
humans is similar to that found in mice, although a different set of surface
markers is used to define each progenitor stage (Figure 1.2). Human B lineage
progenitors are defined as CLP (CD34+CD10+CD19-), Early B lineage progenitor
(EB) (CD34hiCD10+CD19-), ProB (CD34+CD10+CD19+), large preB (CD34CD19+), small preB (CD34-CD19+FSClo), and immature B cell (CD34CD19+sIgM+) (Blom and Spits, 2006, Galy et al., 1995, LeBien, 2000). VDJ gene
recombination occurs in successive developmental stages as occurs in mice
(LeBien, 2000), where recombination of the heavy chain locus occurs at the EB
cell stage (Jung et al., 2006). Upon successful IgH recombination, the heavy
chain pairs with surrogate light chain (consisting of VpreB and λ14.1) to form the
pre-BCR found on preB cells. Pre-BCR signaling is needed to induce Igκ light
chain VJ recombination in preB cells. Successful in-frame VJ rearrangements
and expression of Igκ then allow for formation of the mature BCR and localization
to the cell surface in immature B cells (Hystad et al., 2007, Schiff et al., 1990).
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Figure 1.2 Human B cell developmental stages. Human B cell development
begins with the HSC and MPP as defined above (Pieper et al., 2013, van Galen
et al., 2014). Early progenitors are followed by the CLP and Early B progenitors.
VDJ gene recombination begins in the Early B stage and is completed as
indicated in the subsequent developmental stages. Successful rearrangement of
the Igµ and Igκ loci result in sIgM expression on the surface of B cells that leave
the BM and enter the periphery. Each developmental stage is defined as
indicated above.

Rabbit B cell development. Many fundamental discoveries in the area of
B cell biology were performed using rabbits. These studies contributed to our
current understanding of allotypes and allelic exclusion, the antibody genetic
locus, antibody structure, and the localization of antibody on the cell surface
(Cebra et al., 1966, Feinstein, 1963, Fleischman et al., 1963, Gilman-Sachs et
al., 1969, Oudin, 1956, Pernis et al., 1965, Pernis et al., 1970, Sell and Gell,
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1965, Todd, 1963). Despite many early studies of B cells in rabbits, the number
of studies has declined over the years. While the B cell developmental process
appears to resemble that seen in humans and mice, not all of the developmental
stages have been resolved phenotypically. It is believed that this process starts
with the HSC (undefined) which can differentiate into the earliest described rabbit
B lineage progenitor, the rabbit lymphoid progenitor (rLP) (Kalis et al., 2007).
This population is thought to contain the equivalent of a CLP population seen in
human and mouse, and is defined as MHCII- IL7R+. Further analysis showed that
rLPs express Tdt, EBF, and Pax5, genes commonly expressed by B lineage
cells. Development continues with proB cells defined as CD79a+ cytoplasmic µsurface µ- (CD79a+Cµ- Sµ- ) (Jasper et al., 2003), preB cells (CD79a+Cµ+ Sµ- )
(Hayward et al., 1978, Jasper et al., 2003, McElroy et al., 1981), followed by B
cells (CD79a+Cµ+ Sµ+) (Jasper et al., 2003, Pernis et al., 1965, Sell and Gell,
1965) (Figure 1.3).
Rabbit B lineage progenitors also undergo VDJ gene recombination while
developing in the BM (Figure 1.3). Heavy chain DJ rearrangements are found in
proB cells, and successful VDJ gene rearrangements are found in preB cells,
showing a similar stage-specific process of recombination as seen in humans
and mice (Jasper et al., 2003). Unique to rabbits is the extent to which VDJ gene
recombination contributes to the diversity of the rabbit antibody repertoire.
Compared to humans and mice, which rely heavily on VDJ gene recombination
for antibody diversity, rabbits chiefly rearrange only one VH, VH1, the 3’-most VH
gene segment of the IgH locus, limiting the amount of diversity generated
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through this process (Becker et al., 1990, Friedman et al., 1994, Knight and
Becker, 1990, Raman et al., 1994, Tunyaplin and Knight, 1995). Alternatively,
rabbits do utilize many V and J regions during κ light chain rearrangement
(Sehgal et al., 1999). Future studies will be needed understand how light chain
diversity affects the overall diversity of the rabbit antibody repertoire.

Figure 1.3 Schematic of rabbit B lineage development stages. Rabbit B cell
development is thought to begin with a yet-to-be defined HSC population. The
earliest progenitor population defined is the rLP, followed by the proB cell, preB
cell, and B cell. VDJ gene recombination occurs in rabbit BM beginning in the
proB cell. Each stage is identified by the combination of markers indicated above.

Generation of antibody diversity in rabbit GALT
Limited usage of V regions during VDJ gene recombination does not result
in a restricted rabbit antibody repertoire. This is because rabbits use somatic
diversification in gut associated lymphoid tissues (GALT) to further diversity their
BCRs. In fact, naïve B cells, resulting from successful B lymphopoiesis in the

9

BM, leave the BM and home primarily to the appendix where they diversify the
BCRs through gene conversion and somatic hypermutation (Lanning et al., 2000,
Mage et al., 2006). This method of diversification is similar to that in chickens and
sheep, which also utilize GALT for B cell development and maturation (Alitheen
et al., 2010, Ratcliffe, 2006, Reynaud et al., 1987, Reynaud et al., 1995).
Therefore, rabbit B lymphopoiesis occurs in two phases; 1. early B cell
development that mirrors human and mouse generation of naïve B cells; 2.
Further maturation and diversification in GALT. The focus of this dissertation is
on B cell development in the BM, but the utilization of GALT for further
maturation of naïve B cells is important to note in generating additional antibody
diversity in rabbits.

Figure 1.4 Rabbit B cell development and maturation in the BM and
appendix. B lineage cells develop from hematopoietic stem and progenitors cells
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in the BM. VDJ gene recombination occurs in the BM, but to a limited extent (as
described in the text). Development in the BM serves as a source of naïve B cells
which travel to the appendix (and other GALT). In the appendix, naïve B cells
undergo expansion and somatic diversification. The primary mechanisms by
which rabbit B cells generate a diverse primary antibody repertoire is through
gene conversion and somatic hypermutation, occurring in GALT. (Adapted from
Kennedy et al., 2016).

The bone marrow microenvironment
As described above for mice, humans, and rabbits, B cell development is
an orchestrated process where any given differentiation (eg. Igµ VDJ gene
recombination, Igκ VJ gene recombination) or proliferation (expansion of large
preB cell) event must occur at the appropriate time. While these events appear to
occur intrinsically within B lineage progenitors, the timing of each step is
mediated by signals provided by supporting cells in the BM microenvironment
(Nagasawa, 2006). For example, mouse large preB cells expand before
transiting to the small preB cell stage to undergo κ light chain recombination.
Proliferation cannot occur simultaneously with DNA recombination, as this may
lead to DNA translocations that result in cell death or transformation (Hamel et
al., 2014). To separate expansion and recombination preB cells integrate signals
from the BM microenvironment. Large preB cells require IL-7 from the BM
microenvironment to proliferate, but must lose the IL-7 signal and gain pre-BCR
signaling to rearrange the Igκ locus (Johnson et al., 2008, Mandal et al., 2009,
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Ochiai et al., 2012). Therefore different stromal cell types form niches that
support successive stages of B lymphopoiesis.
The use of primary BM stromal cells and BM stromal cells lines (such as
OP9 cells) to support B lymphopoiesis in vitro (Collins and Dorshkind, 1987,
Holmes and Zuniga-Pflucker, 2009, Hunt et al., 1987, Whitlock and Witte, 1982,
Whitlock et al., 1987) further suggests that BM stromal cells produce molecules
important for this process. Additional studies identified several BM stromal cell
types that support B cell development including osteoblasts, reticular cells, and
endothelial cells (Calvi et al., 2003, Jacobsen and Osmond, 1990, Kiel et al.,
2005, Lichtman, 1981, Taichman et al., 1996, Tokoyoda et al., 2004, Weiss,
1976, Zhu et al., 2007).
Osteoblasts. Osteoblasts are derived from mesenchymal stem cells
(MSC) and can be identified by markers that include alkaline phosphatase, type I
collagen, and osterix (Fakhry et al., 2013, Murshed et al., 2005, Nakashima et
al., 2002). Aside from their function in bone building, they also serve an important
role during hematopoiesis. Mature osteoblasts are typically found along the
endosteal wall of cortical bone and have been visualized in close proximity with
hematopoietic stem and progenitor cells HSPCs) (Calvi et al., 2003, Zhang et al.,
2003). In vitro cultures suggest osteoblasts support B lymphopoiesis, and in vivo
ablation of these cells results in impaired B lineage development (Visnjic et al.,
2004). Osteoblasts support general hematopoiesis by providing a niche for
HSCs, and support B lymphopoiesis by producing factors such as CXCL12 and
IL-7.
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One example of osteoblast-mediated support came from a study of mice
with a genetic deletion that blocked signaling downstream of the PTH/PTH
peptide receptor (PRR) specifically in osteoblasts. Signaling through PRR on
osteoblasts is known to enhance support for B lineage development (Zhu et al.,
2007); therefore you would expect blockade of this pathway will result in altered
B cell development. In fact these mice displayed a decreased amount of
trabecular bone and impaired development from the proB to preB stage (Wu et
al., 2008). Interestingly, osteoblasts in these mice exhibited decreased
expression of IL-7, a critical factor for proB cell development.
Reticular Cells. Reticular cells are abundant in the BM microenvironment
and have been implicated in providing niches for B cell development (Tokoyoda
et al., 2004). CXCL12hi reticular cells support HSCs and early hematopoietic
progenitors. These cells often surround endothelial cells and are an important
component of the vascular HSC niche (described below). CXCL12hi reticular cells
were found to be distinct from IL-7 expressing stromal cells suggesting CXCL12
and IL-7 expressing stromal cells make up distinctive niches. Overall, these
reticular stromal cells and osteoblasts provide critical molecules for developing B
lineage progenitors.
Adipocytes. Adipocytes are a major contributor to the state of the BM
microenvironment. These cells, and how they contribute to hematopoiesis, will be
covered in Section 3, and are a key focus of this dissertation.
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Stromal cell-derived supportive factors
CXCL12. CXCL12 is a 10kDa chemokine that interacts with its receptor
CXCR4. CXCR4 is a seven transmembrane spanning G-protein coupled receptor
(GPCR). CXCL12 has the alternative names stromal derived factor 1 (SDF-1)
and preB cell growth stimulating factor (PBSF) alluding to its production by
stromal cells and its ability to stimulate B lineage progenitors. CXCL12-/- and
CXCR4-/- mice are embryonic lethal due to improper development of the heart,
nervous system, and vasculature. Additionally these mice have impaired B
lymphopoiesis and myelopoiesis resulting in the inability to recruit hematopoietic
progenitors to their niche (Nagasawa et al., 1994, Nagasawa et al., 1996, Peled
et al., 1999, Tachibana et al., 1998, Zou et al., 1998). To assess the requirement
of CXCL12-CXCR4 signaling during adult B cell development, fetal liver CXCR4-/hematopoietic progenitors were adoptively transferred into lethally irradiated WT
mice. Mice reconstituted with CXCR4-/- hematopoietic progenitors had defects in
B lineage development (Kawabata et al., 1999, Ma et al., 1999). A similar result
was seen in adult mice genetically engineered to remove the CXCR4 gene upon
poly(I)-poly(C) administration(Sugiyama et al., 2006), suggesting CXCL12CXCR4 signaling is required for normal B lymphopoiesis.
IL-7.This BM stromal cell-derived factor is required for B cell development.
In fact, von-Freeden-Jeffry reported in 1995 that IL-7-/- mice were the first
identified single cytokine knockout mouse with severe defects in lymphocyte
development (von Freeden-Jeffry et al., 1995). Together, studies of IL-7-/- and IL7R-/- mice identified IL-7 as a critical factor early in development as these mice
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exhibit a loss of B lymphopoiesis at the proB cell to preB cell stage (Peschon et
al., 1994, von Freeden-Jeffry et al., 1995). IL-7 promotes the expansion of proB
cells and large preB cells (Clark et al., 2005, Clark et al., 2014, Hardy et al.,
1991, Herzog et al., 2009), while later stages do not rely on this cytokine. IL-7R
signaling is lost in downstream B lineage progenitors, which is a requirement for
successful transition into the small preB cell stage and Igκ light chain
rearrangement (Clark et al., 2014, Johnson et al., 2008, Mandal et al., 2009,
Ochiai et al., 2012).
SCF, Flt3L, and IGF-1. Additional supportive molecules produced by the
BM microenvironment include stem cell factor (SCF), Flt3-Ligand (Flt3L), and
insulin-like growth factor (IGF-1). SCF binds hematopoietic cells through its
receptor c-kit. Evidence that the SCF-c-kit interaction supports B cell
development came from the study of mice with mutant c-kit, which exhibited
impaired B lymphopoiesis (Waskow et al., 2002). Additionally, Driessen et al.
found membrane bound SCF to be important for HSC attachment to the
endosteal HSC niche (Driessen et al., 2003). Similar to c-kit mutant mice, Flt3L-/mice (McKenna et al., 2000) and IL-7R-/-Flt3L-/- (Jensen et al., 2008, Sitnicka et
al., 2003) also have defects in B lineage development. For IGF-1, studies
suggest that stromal cell-derived IGF-1 is important for enhancing the
proliferative signal provided to proB cells by IL-7 (Gibson et al., 1993, Landreth et
al., 1992). These and other microenvironment-derived factors are important to
support B cell development, but successful development is only achieved when
these signals are provided at the correct time. Therefore different niches exist in
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the BM to support the development of each progenitor stage ranging from the
HSC to immature B cells which leave the BM.
Development in the context of different niches
B lineage progenitors require different signals from the BM
microenvironment to progress through successive stages of development. This
notion is supported by studies that visualized various B lineage progenitors in
close contact with stromal cells expressing cytokines required to support B cell
development in a stage dependent manner (Tokoyoda et al., 2004). Together,
these observations give rise to a model where micro-niches, made up of a subset
of BM stromal cells, usher B lineage progenitors through a series of
differentiation steps.
HSCs in the endosteal versus vascular niches. There are two primary
sites that serve as niches for HSCs in the BM; the endosteal niche and the
vascular niche (Figure 1.5). Calvi et al. and Zhang et al. (2003) described the
endosteal niche where HSCs are supported by osteoblasts lining the endosteal
bone surface (Calvi et al., 2003, Zhang et al., 2003). These osteoblasts are the
source of secreted, as well as membrane bound factors that promote HSC
maintenance. For example, osteoblasts produce the molecules Ang1,
osteopontin, and SCF. Ang1 and osteopontin help maintain HSC quiescence
(Arai et al., 2004, Guerrouahen et al., 2011, Nilsson et al., 2005), while SCF
through interactions with c-kit on HSCs promotes adherence of HSCs to this
niche (Driessen et al., 2003). Further, a specialized form of osteoblast in the
endosteal niche called the N-Cadherin+CD45- osteoblastic cell (SNO) was found
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to be in close contact with HSCs through an N-cadherin mediated mechanism
(Guerrouahen et al., 2011).
The visualization of HSCs located away from the bone surface, in close
contact with endothelial cells forming sinuses, provided evidence of what is now
known as the vascular niche (Kiel et al., 2005). Similar to the endosteal niche,
Sugiyama et al. found that the HSC vascular niche is dependent on CXCL12CXCR4 signaling (Sugiyama et al., 2006). In contrast, the source of CXCL12 was
believed to come from CXCL12hi reticular cells (CAR) (Tokoyoda et al., 2004)
that surround endothelial cells and are critical for support.
Studies of the endosteal and vascular HSC niches suggest these locations
have different roles in the maintenance of HSC quiescence. As described above,
the endosteal niche provides molecules, such as Ang-1, osteopontin, and SCF
that promote quiescence. Low oxygen levels (hypoxia) characterized in the
endosteal niche is thought to further promote quiescence. In contrast, the less
hypoxic vascular niche provides more oxygen for proliferation/differentiation and
therefore contains HSCs in a less quiescent state (Hermitte et al., 2006, Shima et
al., 2010, Suda et al., 2011, Wilson et al., 2008). In line with this idea, studies of
the vascular niche suggest it provides signals promoting
proliferation/differentiation. One such signal was found by Winkler et al., who
identified E-selectin as a critical factor expressed by endothelial cells in the
vascular niche. E-selectin promoted proliferation in HSCs, and when blocked
resulted in HSC quiescence (Winkler et al., 2012). Therefore, the endosteal and
vascular niches may exist to provide a balance between maintaining a long term
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HSC pool and repopulating the peripheral compartments in response to various
stimuli.
Progression through the BM microenvironment during B cell
development. Tokayoda et al. visualized various stages of B lineage progenitors
in the BM of mice, to understand their relationship with BM stromal cells
(Tokoyoda et al., 2004). Hematopoietic multipotent progenitors (MPP) and preproB cells were visualized in close contact with CXCL12hi reticular cells (CAR)
dispersed throughout the BM. While MPPs were localized with the processes of
CAR cells, pre-proB cells were found near the cell body. The next B lineage
progenitor, the proB cell was not associated with CXCL12hi CAR cells, but
instead localized with IL-7+ stromal cells. Furthermore, preB cells were visualized
away from both CXCX12 and IL-7 expressing cells. Instead, preB cells are
localized with galectin-1+ stromal cells. Galectin-1 is a stromal cell-derived ligand
for the pre-BCR, expressed on preB cells (Espeli et al., 2009, Gauthier et al.,
2002, Mourcin et al., 2011). Upon successful differentiation to the immature B
cell stage, these cells leave the BM and enter the periphery. In the periphery, the
B cells participate in immune responses, and some eventually mature to
plasmablasts. Plasmablasts express CXCR4 and home to the BM, where
terminally differentiated plasma cells are found localized to CXCL12hi reticular
cells (Tokoyoda et al., 2004) (Figure 1.5).
The BM is a complex space where many processes take place. In addition
to the cell types described above, the BM is also home to additional stromal cells
in different stages of maturity (eg. immature stages of osteoblasts and
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adipocytes). Alternatively, hematopoietic lineage cells, such as osteoclasts and
progenitors differentiating into lineages other than the B lineage also contribute to
the overall BM microenvironment. The identification of niches for each stage of
development clarifies how so many processes can occur.

Figure 1.5 BM niches for B cell development. HSCs can be found at the
endosteal and vascular niches. The endosteal niche is formed by osteoblasts
which line the bone surface, and provide important molecules to HSCs (indicated
in blue). The vascular niche is made up of endothelial cells and CXCL12hi
reticular cells which provide support for HSCs through molecules like E-selectin.
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MPPs are known to localize to the ends of

CXCL12hi reticular

cells, while pre-

proB cells are found at the cell body. ProB cells are found in a distinct niche in
contact with IL-7+ stromal cells. PreB cells migrate away from IL-7 producing
stromal cells and undergo pre-BCR activation from galectin-1 producing stromal
cells. Once reaching the immature B cell stage, these cells then leave the BM to
further mature and partake in antibody responses. Upon successful completion of
germinal center reactions in the periphery, plasmablasts traffic back to the BM
where terminally differentiated plasma cells are found in contact with CXCL12hi
reticular cells. (Adapted from Nagasawa, 2006).

SECTION 2: DECLINE OF B LYMPHOPOIESIS IN MAMMALS
B lymphopoiesis is first found in the fetal liver before moving to the BM in
humans, mice, and rabbits. The BM serves as the primary site of B cell
development post birth, producing naïve B cells which can then enter the
periphery. As these mammals age, changes to hematopoietic progenitors and
the BM microenvironment results in reduced production of new B cells. While this
process wanes on a different timeline in each species, many studies in humans,
mice, and rabbits have contributed to our current understanding of how this may
occur. Age-related defects to B cells and their development result in increased
susceptibility to infection and decreased immune responses to vaccination, as
seen in the elderly (Frasca et al., 2011, McElhaney and Effros, 2009). Therefore
understanding the mechanisms underlying these changes will identify targets for
therapeutics aimed at rejuvenating B cell development in aged individuals.
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Decline of B lymphopoiesis in mice
The B cell developmental process and age-related decline is best
characterized in mice. Multiple studies using different mouse strains have
characterized this decline and have started to uncover various intrinsic and
extrinsic mechanisms contributing to reduced B lymphopoiesis in aged mice.
Decreased frequency and production of B lineage precursors with
age. Several studies have characterized a reduction in frequency or absolute
number of specific B lineage precursors in aged mice. For example Stephan et
al. (1996) asked if the number of B lineage precursors in the BM of BALB/c mice
varied at 1,4,12, and 24 months of age (Stephan et al., 1996). Looking for preproB and proB cell numbers, no difference was found. Alternatively, the number
of preB cells was reduced as a consequence of aging. The decline in preB cell
number occurred in two steps; an initial reduction was found between 1 and 4
months of age, and further decreased between 12 and 24 months. This study is
further supported by others who reported reduced preB cell pools with age
(Kirman et al., 1998, Riley et al., 1991, Sherwood et al., 1998).
Consistent with observations of decreased preB cell number and
percentage in the BM with age, Johnson et al (2002) found the production rate of
preB cells was also reduced in aged mice (Johnson et al., 2002). While the rate
of new immature B cells downstream of the preB cells was not found to be
different between young and old mice, the authors suggest aged immature B
cells have impairments in refilling more mature B cell pools in the periphery.
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In addition to reduced preB cell pools in the BM of aged mice, several
other studies found reductions in additional B lineage precursor stages with age.
These observed differences in characterizing the decline of B lymphopoiesis can
be explained by mouse strain differences or by the use of additional markers to
define precursors. The studies discussed above characterized B cell
development in BALB/c mice, while the following studies performed experiments
using C57BL/6 mice and used AA4.1 as an additional B lineage marker. In
C57BL/6 mice, Miller and Allman assessed the absolute number and frequency
of EBP/CLPs (Lin− IL-7Rα+ AA4+ Sca-1low), pre-proB cells
(Ly6C− CD24/HSA−B220+ AA4+), and proB cells (B220+ CD43+ CD19+ AA4+) in
mice 2, 7, 10, 14, 20, and 24 months of age (Miller and Allman, 2003). In female
and male mice, each of these populations declined as a function of aging. In
females, EBP/CLPs made up 0.058% of BM at 2 months and 0.001% at 24
months, pre-proB cells 0.191% (2 month) vs. 0.047% (24 months), and proB cells
0.673% (2 months) vs. 0.084% (24 months). Assessing male mice, EBP/CLPs
made up 0.042% of BM at 2 months and 0.007% at 18 months, pre-proB cells
0.189% (2 month) vs. 0.051% (18 months), and proB cells 0.564% (2 months) vs.
0.078% (18 months). Overall these early B lineage precursors were found at
lower frequency and absolute number in aged mouse BM, leading the authors to
conclude that the decreased preB cell pool, often seen in aged mice by other
studies, could be in part due to diminished populations of earlier B lineage
precursors that occur with aging.
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A study by Min et al. also assessed the effect of senescence on B lineage
development (Min et al., 2006). The authors expected that exposing the
hematopoietic system to stress could uncover subtle impairments that normally
occur during aging. To this end, young and old mice were characterized for agerelated changes affecting early B lineage progenitors during homeostasis or after
5-fluorouracil (5-FU) treatment. In addition to confirming the observations by
Miller and Allman during normal aging (Miller and Allman, 2003), 5-FU treatment
uncovered proliferative defects in CLPs and pre-proB cells, as well as an
impaired differentiation capacity in CLPs from aged mice. The cumulative data
produced through all the aforementioned studies define the outcome of agerelated changes and how they affect B cell development. Upon establishing this
phenomenon, additional studies continue to expand our mechanistic
understanding of this decline.
Mechanisms that contribute to declining B lymphopoiesis. Successful
development from the HSC to immature B cell stage requires healthy
hematopoietic progenitors, as well as the appropriate BM stromal cell support.
Intrinsic changes in hematopoietic progenitors and extrinsic changes to the BM
microenvironment are both known to contribute to the decline of B lymphopoiesis
in aged mice. This becomes evident when comparing several studies that
performed adoptive transfers of aged HSCs/BM cells into young irradiated
recipients, and obtained conflicting results. The expectation is if intrinsic defects
in BM progenitors drive impaired B lymphopoiesis, then transfer of old BM
progenitors into a young BM microenvironment will not restore B lineage
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development. If the microenvironment is responsible for the decline, then transfer
of aged BM progenitors into a young BM microenvironment will restore B lineage
development from aged BM donors. In fact, several studies found normal B cell
development of aged BM progenitors when transferred into young recipients
(Chen et al., 1999, Miller and Allman, 2005, Morrison et al., 1996). Alternatively,
transfer experiments into young hosts by Sudo et al. did not yield B lineage cells,
while myeloid cells did develop (Sudo et al., 2000); suggesting age-related
intrinsic changes affect hematopoietic progenitor potential. Because both intrinsic
and extrinsic mechanisms result in declining B cell development, it is important to
understand how these changes affect different stages of development.
Aging affects even the earliest hematopoietic progenitors. HSC numbers
are increased in old mice compared to young mice, but their quality is reduced
(Geiger et al., 2013). A major characteristic of aging hematopoiesis is
unbalanced production of fewer lymphocytes and increased myeloid cells. This
may be due to intrinsic changes in HSCs, as gene expression profiling found
aged HSCs to have upregulated myeloid lineage and decreased expression of
lymphoid lineage genes (Rossi et al., 2005). This may also be due to intrinsic
differences in lymphoid and myeloid biased HSCs resulting in more myeloid
biased HSCs and fewer lymphoid biased HSCs maintained through aging
(Muller-Sieburg and Sieburg, 2008).
The reduced preB cell pool during aging observed by Stephan et al.
(1996) can be explained by changes in B lineage precursors, as well as the
environment. The authors found that preB cells from aged mice had a decreased
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ability to proliferate when cultured on BM stromal cells, compared to preB cells
from young mice (Stephan et al., 1996). Impaired responsiveness to IL-7 was
also found in earlier B lineage progenitors, such as proB cells in both BALB/c and
C57BL/6 mice (Miller and Allman, 2003, Stephan et al., 1998). Another difference
found is that preB cells from aged mice exhibit decreased expression of the SLC
components VpreB and λ5, which are necessary for pre-BCR surface expression
in preB cells (Sherwood et al., 1998, Sherwood et al., 2000). Whether due to a
lack of pre-BCR signaling or not, aged preB cells were found to be more
apoptotic upon isolation from BM and after in vitro culture (Kirman et al., 1998).
Multiple B lineage precursors have impaired responsiveness to IL-7 with
age, but BM stromal cells were also found to change with age. In fact, primary
BM stromal cells isolated from aged mice could not stimulate IL-7 dependent B
lineage cell lines as efficiently as BM stromal cells isolated from young mice
(Stephan et al., 1998). This suggests BM stromal cells from aged mice have a
lower supportive capacity for B cell development. BM stromal cells isolated from
young and old mice were actually found to have similar IL-7 protein levels, but
the defect in aged BM stromal cells appeared to be in IL-7 release.
One of the most powerful examples linking the aged microenvironment to
declining B lymphopoiesis came from Labrie et al (Labrie et al., 2004) In this
study, it was established that aged proB cells exhibit decreased V(D)J
recombinase activity. To demonstrate this impairment was due to the aged BM
microenvironment, the authors performed a series of transfer experiments. Aged
BM hematopoietic progenitors were transferred into young recipients, which
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resulted in restored V(D)J recombinase activity in proB cells. To complement this
experiment, young BM hematopoietic progenitors were transferred into aged
recipient mice, leading to impaired V(D)J recombination in developing proB cells.
Together, these results suggest altered V(D)J recombinase activity in proB cells
is dependent on changes to the BM microenvironment that accumulate during
aging.
The systemic environment and the decline of B cell development. In
addition to changes in hematopoietic progenitors and the BM microenvironment,
one study provides evidence that the peripheral B cell pool that accumulates with
age negatively regulates B lymphopoiesis. Keren et al. used three approaches to
deplete peripheral B cells in an attempt to boost B cell development (Keren et al.,
2011). By generating conditional BAFF receptor deficient mice, or using various
strategies to deplete peripheral B cells with anti-CD19, anti-B220, anti-CD22 and
anti-CD20 the authors were able to enhance B cell development. In aged mice,
depletion of B cells also resulted in increased B lymphopoiesis and an enhanced
antibody response. Although increased, B cell depleted aged mice did not
completely recover B lymphopoiesis and antibody responses to levels seen in
young mice. This suggests that while the peripheral B cell pool may contribute to
decreased B lineage development, intrinsic and BM extrinsic factors likely also
contribute.
The study by Keren et al. brings to light the idea that systemic factors,
whether generated locally or across the body, can regulate processes occuring in
the BM. Also, further studies will be needed to see if peripheral B cells negatively
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regulate B cell development through soluble factors, or if they traffic to the BM to
exert their effect. Consistent with this study, Montaudouin et al. found that the
amount of IgG in circulation can regulate the number of IgM producing B cells in
the periphery through an interaction with the inhibitory Fc receptor, FcγRIIB
(Montaudouin et al., 2013). It will be interesting to see if B lineage progenitors
also have a similar ability to quorum sense and regulate new B cell output based
on demand. Alternatively, aged B cells (ABC) which accumulate with age were
also found to inhibit B cell development through TNFα production (Ratliff et al.,
2013). Future studies will also be needed to determine if the depletion strategies
used by Keren et al. altered a quorum sensing system and/or depleted
inflammatory B cells to boost new B cell generation.
Decline of B lymphopoiesis in humans
Evidence of early B lymphopoiesis can be found in the yolk sac of the
human embryo, and appears in the fetal liver at day 8. At week 12, the BM
becomes the primary site of B cell production through 80 years of life (Nunez et
al., 1996). Several studies suggest that B lineage development declines with age
in humans. Although there are some conflicting data between studies, the
majority find reductions in B lineage progenitors and ability to differentiate to the
B lineage.
Decreased Frequency of B lineage cells with aging. Difficulty in
collection of BM from healthy donors often limits the number of extensive studies
performed on this population in humans. In spite of this restriction, several
investigators were able to characterize the frequency of B lineage progenitors in
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BM as a function of age. Rego et al. examined the frequency of

CD10+CD19+

B

lineage (proB cells) present in sternums from individuals of various ages (Rego
et al., 1998). Of the age groups analyzed, this study found the highest frequency
of CD10+CD19+ cells in the first four years of life. The frequency then decreased
with increased age being the lowest in individuals categorized as being >15
years of age.
Another study analyzed early B lineage cells from human rib sections
ranging in age from fetal development to 80 years of age (Nunez et al., 1996).
Several B lineage progenitor cell types were analyzed, including: CD19+sIgM-,
CD10+sIgM-, and CD24+sIgM-. Looking at CD19+sIgM- pro/preB cell frequencies
in human BM samples, the authors found an age-related decrease. The BM
mononuclear cells of a 19 week fetus and 3 year old contained 55% and 44%
CD19+sIgM- preB cells, whereas this population was reduced to 15% in the BM of
a 56 year old individual. Similarly identifying B lineage precursors as CD10+sIgMor CD24+sIgM-, there was a reduced frequency in the 56 year old BM sample.
A study by McKenna et al., also supports the above studies (McKenna et
al., 2001), finding a decreased frequency of B lineage precursors in BM samples
from aged individuals. However, a study by Rossi et al is inconsistent with the
other studies cited. These authors did not find significant age-related differences
in B lineage precursor frequencies in BM taken from hip surgeries (Rossi et al.,
2003). Overall, there are some inconsistencies between studies focused on
human B lymphopoiesis and aging. Obtaining enough healthy BM samples of
various ages is a limitation that affects the statistical power of these studies.
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Additionally, differences in BM collection methods and BM samples from different
types of bone likely contribute to inconsistencies between studies. Access to
tissues (including BM) from young and old healthy donors is often a limitation to
aging studies in humans. Establishment of a bank for such tissues was recently
discussed this past January 2016 at the “Effects of aging on hematopoiesis”
symposium at the National Institutes of Health (sponsored by the NIDDK and
NIA).
Reduced B lineage potential in aged HSCs. The reduction in B lineage
progenitors may be the result of a reduced capacity for HSCs to differentiate to
the B lineage. In fact, Pang et al. found this to be true (Pang et al., 2011). HSCs
isolated from human donors 20-35 years or >65 years were compared for their
potential to differentiate into the B lineage vs. myeloid lineage in vitro. Compared
to young HSCs, HSCs from individuals >65 years exhibited reduced B lineage
potential while maintaining myeloid potential. In addition, xenotransplantation of
human HSCs into immunodeficient mice resulted in a greater production of
myeloid cells compared to B lineage cells from aged human HSCs. These data,
in conjunction with aged HSCs showing increased expression of myeloid lineage
genes, provide mechanistic evidence for declining B lymphopoiesis in individuals
>65 years of age (Pang et al., 2011).
Changes to the BM microenvironment. In addition to reduced B lineage
potential by HSCs, changes to the BM microenvironment may also contribute to
the loss of B cell development. Alterations to mesenchymal stem cells (MSC) or
their progeny; osteoblasts and adipocytes may affect hematopoiesis. Osteoblasts
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are known to support B cell development, while adipocytes have a negative
impact on this process (Bilwani and Knight, 2012, Naveiras et al., 2009, Zhu et
al., 2007). Therefore decreases in osteoblasts and/or increases in BM adipocytes
could contribute to decreased B lineage development.
MSCs and aging. Several studies characterized the frequency of MSCs
found in human BM during aging. One study saw a decrease in frequency of
MSCs in BM occurring at 30 years of age compared to newborns (Caplan, 2007).
In contrast with this study, studies by Justesen et al., and Stenderup et al. did not
find decreases in MSC frequency between young and old (Justesen et al., 2002,
Stenderup et al., 2001). However, young was defined as approximately 20-40
years and old was defined as approximately 65-70 years in these later studies.
Additionally, variations in methods to identify MSCs may have also contributed to
these inconsistencies.
Whether or not MSC frequency changes with age in human BM, evidence
suggests these cells are different in aged individuals. One study found MSCs
taken from individuals >50 years old were more prone to undergo apoptosis
compared to MSCs from young donors. Aged MSCs also showed increased
senescence-associated β-galactosidase, required more time to divide, and had
reduced capacity to differentiate into osteoblasts (Zhou et al., 2008).
Arrest of B lymphopoiesis in rabbits
Consistent with human and mice, B cell development in rabbits is found in
the fetal liver, where preB cells can be found as early as 25 days into fetal
development (Hayward et al., 1978, McElroy et al., 1981). After birth, the BM is
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the primary site of hematopoiesis. In the first two weeks of life, preB cells peak,
comprising 9-19% of nucleated BM cells. The frequency of preB and proB cells
then drops dramatically by 2 months of age and these cells are undetectable by 4
months of age (Jasper et al., 2003).
Characterization of declining B cell development. Rabbit B cell
development arrests at 2 months of age (Jasper et al., 2003, Kennedy et al.,
2016), making the rabbit an accelerated model for declining B lymphopoiesis,
which usually occurs in the mid to late stages of life in humans and mice
(McKenna et al., 2001, Scholz et al., 2013). The early loss of B cell development
is well characterized in rabbits, as evidenced by allotype suppression
experiments, flow cytometry analysis of B lineage progenitor frequencies, and B
cell recombination excision circle (BREC) analyses.
Allotype suppression experiments. The idea that B lymphopoiesis is
short lived in rabbits came in the 1960s, when Dray performed allotype
suppression experiments. Antibodies specific for a particular paternal IgH
allotype were injected into neonate rabbits that were heterozygous for that
paternal IgH allotype. This treatment effectively depleted the target allotype
antibody in these rabbits (Dray, 1962). Looking as late as 2 years later, the
suppressed allotype did not reappear. It is not likely that this specific allotype is
being actively suppressed through the life of the rabbits, therefore these data
suggest that B cell development is arrested early in life (Eskinazi et al., 1979). In
fact, the paternal allotype never recovered even though a low frequency of
paternal allotype containing progenitors could be found (Simons et al., 1979).

31

Therefore, it was concluded that there must be a block in B cell development.
Because mouse B lymphopoiesis does not decline until late in life, you would
expect allotype suppression experiments would not produce a lasting effect. This
is the case, as one study performing allotype suppression experiments in young
mice found the suppressed allotype reappeared 6 weeks after suppression (Lalor
et al., 1989).
B lineage progenitor frequencies. Several studies have tracked various
B lineage progenitor frequencies as a function of time by flow cytometry. Jasper
et al., found that proB cells reach peak levels in the first few weeks following birth
(Jasper et al., 2003). Several other studies found that preB cells also reach their
highest frequencies shortly after birth (Gathings et al., 1981, Gathings et al.,
1982, Hayward et al., 1978, McElroy et al., 1981). Within the first month of life
proB and preB cells each comprise approximately 7% of hematopoietic cells in
the BM. By 2 months these populations were reduced to 1% of the BM, and
undetectable in the BM of 4 month old rabbits. These date indicate that active B
lineage development arrests by 2-4 months of age. Interestingly, Jasper et al.
(2003) noticed that as B lineage progenitors were lost, increased frequencies of
mature B cells could be found in the BM. This finding is consistent with that of
Nunez et al., who saw a similar phenomenon in human BM (Nunez et al., 1996).
B cell recombination excision circle analysis. The early decline of
rabbit B lymphopoiesis was further confirmed on the molecular level through
BREC analysis of rabbit BM. BRECs form in B lineage progenitors during VDJ
gene recombination and can be used as a measure of ongoing B cell
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development. Crane et al. utilized this method looking for BRECs formed from
VD and DJ rearrangements (Crane et al., 1996). As expected, BRECs were
found at high levels in newborn rabbits and reduced in adult rabbits. Consistent
with the percentages of B lineage progenitors found in rabbit BM, the highest
levels of BRECs could be detected in BM shortly after birth. Additionally, BREC
detection was reduced at 2 months of age, and was barely detectable at 4
months of age (Jasper et al., 2003). In control experiments, young (1-2 week)
and adult (4 month) mouse BM was analyzed for BRECs. Young and adult
mouse BM contained robust levels of BRECs, consistent with ongoing B
lymphopoiesis at this time in mice. Overall, these molecular and cellular studies
of B cell development lead us to conclude that rabbit B lymphopoiesis is lost by
2-4 months of age.
Mechanisms that negatively regulate B cell development. As reviewed
earlier, the decline in mouse B lymphopoiesis can be attributed to both intrinsic
defects in hematopoietic progenitors and extrinsic changes to the
microenvironment. To address whether intrinsic or extrinsic mechanisms
contribute to the arrest in rabbit B lymphopoiesis, Kalis et al. asked if rLPs from
the BM of >2 month old rabbits are capable of differentiating into B lineage cells
in vitro (Kalis et al., 2007). The authors cultured isolated MHCII-IL-7R+ rLPs with
OP9 BM stromal cells (Holmes and Zuniga-Pflucker, 2009), then assessed the
number of B lineage cells resulting from these cultures. Interestingly, rLPs
isolated from the BM of >2 month old rabbits were capable of differentiating into
B lineage cells. To complement this finding, the authors also adoptively
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transferred BM progenitors from >2 month old rabbits into young (<2 month old)
irradiated rabbits. Consistent with in vitro culture of rLPs, BM progenitors derived
from >2 month old rabbits were able to differentiate into B lineage cells after
transferred into young irradiated recipients. The ability of BM cells from >2 month
old rabbits to differentiate into B lineage cells suggests that the loss of B cell
development in rabbits is not due to intrinsic defects in hematopoietic
progenitors, and instead suggests changes to the BM microenvironment are
responsible for this arrest.
B lymphopoiesis is an orchestrated process, where even subtle changes
to the microenvironment can alter the output of naïve B cells. Changes in the BM
microenvironment fall into two major categories; the loss of supportive factors or
an increase in negative regulators. Several studies have assessed how each of
these categories contributes to the decline of B lymphopoiesis in rabbits.
Together, the studies reviewed next provide the basis for which B cell
development is lost.
Loss of supportive microenvironment. IL-7 is one of the most critical
supportive factors provided by the BM microenvironment. IL-7-/- mice have
impaired B cell development (Tsapogas et al., 2011, Wei et al., 2000), and
Stephan et al (1998) found that BM stromal cells from aged mice are defective in
their ability to supply hematopoietic progenitors with IL-7 (Stephan et al., 1998).
Further, high fat diet was found to impair B lineage development in mice, at least
in part through decreased expression of IL-7 in the microenvironment (Adler et
al., 2014). In rabbits, IL-7 was also found to be critical for B lymphopoiesis (Kalis
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et al., 2007). Therefore it is plausible that a reduction of IL-7 expression in BM
from >2 month old rabbits could result in impaired B cell development. To test
this, Kalis et al. (2007) analyzed IL-7 expression in the BM of <2 month and >2
month old rabbits by northern blot. Surprisingly, IL-7 was found to increase in the
older rabbits, suggesting decreased IL-7 is not responsible for the impairment. In
a separate study, an additional isoform of IL-7 identified as IL-7II, also increased
in the BM of older rabbits (Siewe et al., 2010). It was thought that this isoform
could possibly have a negative impact on B lymphopoiesis. However further
study of IL-7II, found that it bound IL-7R and acted similarly to canonical IL-7.
From these studies, we can conclude that changes in the supportive cytokine IL7 do not contribute to the decline of B lymphopoiesis in rabbits.
Siewe et al. set out to characterize BM stromal cells to identify supportive
factors that are altered with age (Siewe et al., 2011). The authors performed a
representational difference analysis (RDA), comparing MSCs isolated from a
newborn rabbit and a 2 year old rabbit. Several factors were identified as
downregulated in the 2 year old rabbit, with periostin (extracellular matrix protein)
being the lowest expressed. The authors hypothesized that the decrease in
periostin could contribute to the decline in B cell development. In vitro, the
authors found periostin to be required for rabbit B lineage development, as
siRNA knockdown of periostin in OP9 stromal cells inhibited their ability to
support development. Further gene expression analysis showed that in OP9 with
siRNA knock down, IL-7 and CXCL12 were also decreased. Periostin-/- mice are
readily available, and the authors found that B lymphopoiesis was not impaired in
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these mice, suggesting that in vivo loss of periostin may be masked by other
redundant supportive factors.
Expression of fibronectin, collagen type I, thrombospondin, the tumor
suppressor FAT, and frizzled 4 were also found to be decreased in BM stromal
cells from the 2 year old rabbit. To date, the decrease in these or other factors
have not been linked to the loss of B cell development in rabbits. Additional
studies assessed whether changes in support on the cellular level, as well as
increases in negative regulators contribute to decreased B cell development.
Age-related changes to BM stromal cells. To identify changes in BM
stromal cells at 2 months of age, Bilwani and Knight focused on MSCs which
give rise to osteoblasts and adipocytes (Bilwani and Knight, 2012). The authors
first examined if MSC number changes between young rabbits and older rabbits
(>2 months of age). Through analysis of the number of CFU-Fibroblasts (CFU-F)
(Mareschi et al., 2012), Bilwani and Knight found that MSC number was reduced
10-fold shortly after birth. In addition to decreased number, MSCs from rabbits >2
month old were more likely to differentiate into adipocytes rather than
osteoblasts. This study suggests that fewer osteoblasts in the BM could
contribute to decreased B lymphopoiesis, as osteoblasts support this process.
Adipocytes fill the bone marrow with age. The finding that rabbit MSCs
had increased potential toward the adipocyte lineage raises some questions; do
adipocytes increase in rabbit BM with age, and do adipocytes contribute to the
arrest of B cell development? Interestingly, adult rabbit BM has been reported to
contain significant amounts of fat (Bigelow and Tavassoli, 1984). In fact, the
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accumulation of adipose tissue in the BM of rabbits mimics that of aged humans,
where 50% of the femur and 70% of the tibia fills with adipose tissue (Li et al.,
2013). It should also be noted that while adipose tissue increases with age in
humans, mice, and rabbits (Chinn et al., 2012, Justesen et al., 2001, LeckaCzernik et al., 2010, Rosen et al., 2009, Tuljapurkar et al., 2011), the timing
correlates with declining B lymphopoiesis.
In the past, the prevailing view of BM fat was that it is inert and simply
filling unused space. Recent studies have now established adipocytes as major
producers of local and systemic factors that influence many processes. Because
adipocytes accumulate as B lymphopoiesis declines, Bilwani and Knight tested if
adipocytes influence B lineage development (Bilwani and Knight, 2012). Through
culture of rabbit BM progenitors with OP9 stromal cells in the presence or
absence of adipocyte-conditioned medium (ACM), it was found that cultures
containing ACM had fewer CD79a+ B lineage cells develop. This result suggests
that adipocytes produce molecules that actively inhibit B lymphopoiesis.
Therefore, the loss of B cell development in aged rabbits is likely due to having
decreased support from fewer osteoblasts and an increase in negative regulators
produced by adipocytes. While adipocytes inhibit B lymphopoiesis, the
mechanism by which this occurs is unknown.
SECTION 3: THE IMPACT OF BONE MARROW FAT AND INFLAMMATION
ON LYMPHOPOIESIS
Early studies of BM fat were performed in rabbits by Tavassoli and
colleagues during the 1970s. In recent years there has been renewed interest in
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understanding BM fat in humans, mice, and rabbits. Adipose tissue can be
described in multiple ways, such as by color (brown vs. beige vs. white),
inflammatory state (pro-inflammatory vs. anti-inflammatory), and in terms of its
ability to fuel hematopoiesis (regulated vs. constitutive). Here I will review critical
studies which have shaped our understanding of the relationship between
adipose tissue, hematopoiesis, aging, and obesity.
In addition to aging, adipocytes commonly accumulate in the BM of
patients following chemotherapy and irradiation. Therefore, it is important to
understand how adipocytes impact neighboring red marrow. Several studies
suggest that BM fat has a negative effect on hematopoiesis (Bilwani and Knight,
2012, Naveiras et al., 2009). Naveiras et al. compared BM from mouse thoracic
vertebrae (adipocyte free) and tail vertebrae (adipocyte rich) to understand if
adipocytes influence hematopoietic activity. Upon analysis of hematopoietic stem
and progenitor cell populations (HSPC), the frequency and number of progenitors
was significantly lower in adipocyte rich tail vertebrae compared to thoracic
vertebrae. A similar analysis of thoracic and tail vertebrae in fatless mice (AZIP/F1) showed no difference in adipocyte accumulation and similar numbers of
progenitors in these locations, suggesting that the presence of adipocytes
negatively affects hematopoietic progenitor numbers. Fat accumulates in the BM
after irradiation and is thought to negatively impact engraftment of newly
transplanted BM. To test this notion, the authors performed BM transplants in WT
or fatless mice with the expectation that fatless mice would have better recovery
of hematopoietic cells compared to WT. As expected, fatless mice had
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significantly less BM fat than WT mice after irradiation and exhibited better
recovery of leukocytes after BM transplantation. These results suggest that the
presence of adipocytes negatively impacts hematopoietic activity. Coupled with a
study by Bilwani and Knight that found B lymphopoiesis to be particularly
sensitive to adipocyte factors in human and rabbit cultures (Bilwani and Knight,
2012), these studies suggest strategies to limit adipocytes in BM would enhance
hematopoietic activity.
White, brown, and beige adipocytes
Adipocytes are typically referred to as white, brown, or beige. White
adipose tissue is best known for its role in energy storage, expanding in states of
nutrient excess and contracting with a negative energy balance. Recent
advances in adipose tissue biology have also identified white adipose tissue as
an endocrine organ, able to integrate metabolic signals and produce adipokines
that influence other organs (Ouchi et al., 2011). Consistent with its ability to
respond to nutrient state, adipose tissue is thought to become a source of proinflammatory cytokines in scenarios of high fat diet (Chatterjee et al., 2009, Ouchi
et al., 2011). The inflammatory state of adipose tissue will be discussed further
below.
Brown adipocytes. Brown adipocytes produce heat through the process
of thermogenesis. While brown adipocytes also accumulate lipids, they can be
distinguished from white adipocytes through their abundant numbers of
mitochondria and high levels of uncoupling protein1 (UPC1), which are critical
components for heat production (Cannon and Nedergaard, 2004).
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Thermogenesis from brown adipocytes is important to maintain body temperature
and is typically induced by cold stress (Peirce et al., 2014). This process requires
large amounts of energy, therefore making brown adipose tissue is an important
regulator of energy balance. In fact, Rothwell and Stock (1979) discovered diet
induced thermogenesis in rats, where heat production was activated by brown
adipose tissue in response to overeating (Rothwell and Stock, 1979). The
authors further suggested that brown adipose tissue may counteract obesity.
Lowell et al. tested if brown adipose tissue counteracts obesity by
generating two transgenic mouse lines that are deficient in brown adipocytes
(Lowell et al., 1993). Both mouse lines developed obesity, identifying a role for
brown adipose tissue in the prevention of obesity. Consistent with this result, one
of the transgenic mouse strains was able to recover brown adipose tissue over
time, which was coupled with the resolution of obesity in these mice. Similar
results were seen in a study by Feldman et al. while studying UCP1 deficient
mice (Feldmann et al., 2009). As expected the enormous amount of energy
utilized by brown adipocytes during thermogenesis is key to the anti-obesity
effect, as Cannon and Nedergaard found that mice kept in cooler temperatures
needed to eat more calories to maintain the same body weight as mice kept at
warmer temperatures. Mice kept at room temperature need to eat two thirds
more than mice kept at 30o to stay at a consistent body weight (Cannon and
Nedergaard, 2009, Peirce et al., 2014).
Beige and white adipocytes. Beige adipocytes are similar to brown
adipocytes in that they are capable of producing heat through thermogenesis
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(Vitali et al., 2012). Beige adipocytes are induced in white adipose tissue
suggesting that they share a precursor with white adipocytes, but they behave
like brown adipocytes which come from a distinct precursor cell (Seale et al.,
2008). In other terms, brown adipose tissue consists of UCP1+ brown adipocytes
capable of producing heat. White adipose tissue contains UCP1- white
adipocytes that store excess energy and produce various adipokines, while also
containing UCP1+ beige adipocytes which are induced to undergo thermogenesis
by various activators (Petrovic et al., 2010, Wu et al., 2013). Because beige
adipocytes expend large amounts of energy, they may also contribute to the
prevention of obesity (Harms and Seale, 2013). Therefore it is logical that
changes in adipose tissue leading to less brown/beige fat and increased white
fat, may contribute to the pro-inflammatory state seen during aging and obesity.
Age-related change in BM adipose tissue phenotype. Krings et al.
characterized BM fat in young/adult (5 months) and old mice (24-26 months) for
brown and white adipocyte characteristics (Krings et al., 2012). While BM
adipocytes were increased in aged mice, there were also specific changes in the
type of adipocytes present with increased age. BM adipose tissue was analyzed
for the expression of six genes characteristic of brown adipose tissue including
UCP1, as well as leptin and adiponectin which are characteristic of white adipose
tissue. Young/adult BM adipose tissue expressed genes characteristic of both
brown and white adipose tissue, suggesting BM fat has a brown and white, or
beige phenotype. This phenotype, however, changed with age. Compared to
young/adult mice, old BM adipose tissue lost features of brown adipose tissue,
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and more closely resembled white adipose tissue. The resemblance of aged BM
fat to white adipose tissue is also supported by an observation by Bainton et al.
who observed that yellow marrow stromal cells in adult rabbits had
characteristics of 3T3.L1 white adipocytes (Bainton et al., 1986). The changes in
BM adipose tissue phenotype with age, suggests there are also functional
consequences. Krings et al. found the age-related changes in BM adipose tissue
to be consistent with the phenotype of BM adipose tissue in yellow agouti
diabetic mice. Together these results led the authors to suggest the changes in
BM adipose tissue during aging and diabetes likely contribute to the negative
effect on hematopoiesis seen in these conditions.
Regulated versus constitutive marrow fat
Several studies suggest that fat has a negative effect on
hematopoiesis/lymphopoiesis (Bilwani and Knight, 2012, Naveiras et al., 2009).
In light of the studies described above (in this section), it is now clear that
adipose tissue and the types of adipocytes that comprise adipose tissue are very
complex. Therefore, it is likely that certain types of adipocytes support
hematopoiesis in young healthy mammals, but age and obesity related changes
to BM adipose tissue results in a negative impact on hematopoiesis.
In support of this idea, several studies have categorized marrow fat as
regulated or constitutive. This categorization refers to marrow fat and its
relationship to hematopoiesis. In the 1970s, Tavassoli observed two types of
adipocytes in rabbit BM differentiated by their fatty acid composition through
staining with performic acid Schiff reagent (PFAS) (Tavassoli, 1976). PFAS+

42

adipocytes are found in red marrow and are thought to fuel hematopoiesis, as
treatment of rabbits with hemolysis agents stimulated hematopoiesis and
depleted PFAS+ adipocytes. Therefore PFAS+ adipocytes in red marrow are now
referred to as regulated marrow fat rMAT (Scheller and Rosen, 2014). In contrast
to rMAT, PFAS- adipocytes are found in yellow marrow and are not deleted by
hematopoiesis. In fact, PFAS- marrow fat appears to be unresponsive to changes
in diet, as 10 days of starvation did not reduce the volume of fat in the distal tibia
of rabbits (Tavassoli, 1974). Therefore, this type of marrow fat was termed
constitutive marrow fat (cMAT). Similar to that seen in mice (Naveiras et al.,
2009), increased marrow fat was also found to correlate with reduced
hematopoiesis in rabbits (Bigelow and Tavassoli, 1984).
While more studies are needed to link the way various studies have
described adipocytes (color, inflammatory state, in terms of supporting
hematopoiesis), it is likely that the age/obesity related loss of brown
characteristics and dysregulation of white adipose tissue resulting in increased
danger signals and pro-inflammatory cytokines lead to a negative impact on
lymphopoiesis.
Adipocytes, inflammation and the decline of T lymphopoiesis
Inflammatory mediators and lipotoxic danger signals from adipose tissue
have been implicated in thymic atrophy and the decline of T cell development
during aging and obesity. Similar to the BM, adipose tissue accumulates in the
thymus during atrophy with age. Youm et al. hypothesized that increased
adipose tissue in the thymus provides pro-inflammatory danger signals that
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contribute to thymic decline. By comparing young and old (24 month) WT or
inflammasome deficient (NLRP3-/- or ASC-/-) mice, the authors found that blocking
inflammasome activation delayed thymic atrophy (Youm et al., 2012). This study
suggested that inflammatory danger signals that accumulate with age negatively
regulate T lymphopoiesis. Adipose tissue derived products and diet were further
linked to thymic decline as high fat diet accelerated and calorie restriction
delayed thymic atrophy (Yang et al., 2009a, Yang et al., 2009b). It is unknown
whether B lymphopoiesis is negatively regulated through inflammasome
activation. While B cell development is negatively regulated by adipocyte
products, the responsible molecules remain to be identified.
Adipose tissue derived molecules
Adipose tissue is made up of adipocytes, as well as infiltrating immune
cells. As a whole, the pro-inflammatory or anti-inflammatory state of adipose
tissue is representative of the molecules produced by adipocytes and immune
cells. Healthy adipose tissue is characterized by unstressed adipocytes and antiinflammatory immune cells (such as M2 suppressive macrophages) (Chawla et
al., 2011, Mraz and Haluzik, 2014). Adipose tissue seen in aging and obesity is
pro-inflammatory in nature, resulting in the production of danger associated
molecular patterns (from stressed adipocytes) and inflammatory cytokines (from
adipocytes and immune cells) (Chawla et al., 2011, Lago et al., 2007, Wen et al.,
2011, Youm et al., 2012, Youm et al., 2013). Pro-inflammatory adipose tissue is
also characterized by an increase in dying adipocytes, pro-inflammatory M1
macrophages, and interferon-γ producing TH1 cells (Chawla et al., 2011, Winer
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et al., 2009). While adipose tissue is the source of many molecules, some of the
most studied are highlighted below.
Adipocytes secrete many factors that influence processes throughout the
body, either acting as an endocrine organ or locally. Recent research has
identified adipose tissue as an immune organ. Adipocytes secrete many classes
of molecules including: Proteins and lipids.
Proteins. Adipocytes secrete many immune-modulatory proteins, such as,
adiponectin, TGFβ, and leptin. Adiponectin and TGFβ are known to inhibit B
lymphopoiesis indirectly by acting on stromal cells in mouse co-culture
experiments(Tang et al., 1997). Conversely, adipocytes also have the potential to
support B lymphopoiesis through the production of leptin(Claycombe et al.,
2008).
Lipids. Adipocyte-derived lipids consist of a variety of bioactive molecules
classified based on their relative insolubility in water and include steroids, fatty
acids, and fatty acids derivatives. For example, adipocytes can produce the
steroid estrogen(Bulun and Simpson, 1994, Grodin et al., 1973, Nelson and
Bulun, 2001, Yamada and Harada, 1990), which was found to inhibit B
lymphopoiesis by acting directly on the CLP and acting indirectly on stromal
cells(Kouro et al., 2001, Smithson et al., 1995, Yokota et al., 2008).
Prostaglandins, a fatty acid derivative, are also known to inhibit B lymphopoiesis
by directly acting on B lymphocyte progenitors(Yokota et al., 2003). Additionally,
adipocytes produce fatty acids. It is unclear whether fatty acids positively or
negatively regulate B lymphopoiesis, but fatty acids are known to activate TLRs
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on macrophages and adipocytes promoting the production of inflammatory
cytokines and reactive oxygen species (ROS)(Han et al., 2012, Huang et al.,
2012, Shi et al., 2006, Wong et al., 2009).
Anti-inflammatory molecules
Adiponectin. Adiponectin is an anti-inflammatory protein produced
primarily by adipocytes. This protein is at its highest concentration in healthy
individuals and is decreased in obese patients (Ryo et al., 2004). Oxidative
stress and pro-inflammatory cytokines produced in dysregulated adipose tissue
block the production of adiponectin by adipocytes (Berg and Scherer, 2005,
Hosogai et al., 2007, Ouchi et al., 2003). Reduced adiponectin is associated with
increased risk of type II diabetes (Li et al., 2009, Ouchi et al., 2003), while calorie
restriction was found to increase adiponectin production in BM adipose tissue,
making it the systemic source of this anti-inflammatory molecule (Cawthorn et al.,
2014). In terms of B lymphopoiesis, adiponectin was found to have a negative
effect (Yokota et al., 2003). Although, adipocyte factors other than adiponectin
were also found to inhibit B lymphopoiesis (Bilwani and Knight, 2012).
Pro-inflammatory molecules
IL-6. IL-6 is a pro-inflammatory cytokine produced by adipocytes and other
cells in adipose tissue (Fried et al., 1998, Van Snick, 1990). Increased IL-6 levels
are observed in obese individuals and individuals with type II diabetes.
Production of this cytokine appears to increase with increased adipose tissue
and can be controlled by diet, as IL-6 levels were reduced in patients after losing
weight (Esposito et al., 2003, Fried et al., 1998, Ouchi et al., 2011, Ziccardi et al.,
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2002). Similar to obesity, production of IL-6 from adipose tissue also increases
during aging (Starr et al., 2009, Tchkonia et al., 2010). This cytokine has many
immunomodulatory effects and, if available in niches containing HSPCs, has the
potential to inhibit B cell development (Maeda et al., 2005, Maeda et al., 2009).
IL-6 can also work with other factors to mediate various outcomes. For example,
IL-6 treatment in combination with TNFα was found to promote BM macrophage
differentiation into osteoclast-like cells (Yokota et al., 2014).
TNFα. TNFα production increases during obesity as adipocytes increase
in size and ultimately contributes to insulin resistance (Feingold et al., 1992,
Hotamisligil et al., 1994, Ouchi et al., 2011, Spiegelman et al., 1993). Myeloid
lineage cells are the main source of TNFα in adipose tissue. Similar to IL-6,
adipose tissue production of TNFα increases with obesity and type II diabetes
(Hotamisligil et al., 1993), and can be decreased by weight loss (Kern et al.,
1995, Ziccardi et al., 2002). If present in the BM, TNFα induces an inflammatory
state that promotes granulopoiesis (Ueda et al., 2004).
S100A8, S100A9, and S100A8/A9. Adipose tissue is the source of
S100A8 and S100A9. These proteins can form S100A8/A8 or S100A9/A9
homodimers in addition to S100A8/A9 heterodimers. S100A8 and S100A9
proteins have multiple functions intracellularly and extracellularly, which include
anti-microbial activity, intracellular calcium binding, and alarmin/pro-inflammatory
effects (Vogl et al., 2012). Activated and dying myeloid cells are the primary
source of extracellular S100A8 and S100A9 leading to a potent inflammatory
response (Ehrchen et al., 2009, Nacken et al., 2003). It was initially thought that
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S100A8/A9 was produced by adipocytes in adipose tissue, but recent evidence
suggests that S100A8 is primarily produced by adipocytes and S100A9 is
produced by macrophages within the adipose tissue (Sekimoto et al., 2012). The
expression of these molecules is upregulated in many tissues during aging and
obesity (Nagareddy et al., 2014, Schiopu and Cotoi, 2013, Sekimoto et al., 2012,
Swindell et al., 2013), however the impact these proteins have on B
lymphopoiesis is unknown.
Complement factors . Adipose tissue is a source of many complement
proteins, including C3a, C5a, factor B, and factor D (adipsin) (Pattrick et al.,
2009, Vlaicu et al., 2016). Complement proteins have important functions in the
maintenance of adipose tissue, but can also contribute to adipose tissue
inflammation. For example, a cleavage product of C3a, called C3adesArg is
critical to promote triglyceride synthesis in normal adipocytes and promote
differentiation of pre-adipocytes into mature adipocytes (MacLaren et al., 2008,
Maslowska et al., 2005, Saleh et al., 2011, Yasruel et al., 1991). The generation
of C3adesArg from C3a is mediated by the enzyme carboxypeptidase N.
C3adesArg is unable to bind the C3 receptor but instead binds the receptor C5like receptor 2 (C5L2), which can also be bound by C5a (Vlaicu et al., 2016). This
process contributes to the normal maintenance of healthy adipose tissue.
Alternatively, dysregulation of normal homeostasis in adipose tissue leads to
complement mediated inflammation, where both C3R and C5R have been
implicated in adipose tissue inflammation during obesity (Lim et al., 2013,
Mamane et al., 2009, Phieler et al., 2013). Consistent with IL-6 and TNFα serum
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levels (as reviewed above), C3a serum concentration is increased in obese
individuals and can be lowered through weight reduction (Nestvold et al., 2015,
Nilsson et al., 2014, Oberbach et al., 2011, Sleddering et al., 2014).
Danger associated molecular patterns (DAMPS). In inflammatory
adipose tissue, adipose tissue macrophages form crown-like structures that
surround dying adipocytes. These adipocytes become the source of additional
danger signals such as lipids and reactive oxygen species that trigger an
inflammatory profile in the macrophages. Adipose tissue macrophages are
commonly seen phagocytosing lipids and becoming lipid laden cells (Chawla et
al., 2011, Strissel et al., 2007). Free cholesterol, lipid crystals, ceramides, and
fatty acids derived from adipocytes and taken up by adipose tissue macrophages
induce inflammation through inflammasome activation (Coppack, 2001, Lago et
al., 2007, Vandanmagsar et al., 2011, Wen et al., 2011, Youm et al., 2012).
These danger signals are sensed by the nod-like receptor, NLRP3, triggering
inflammasome activation. Nod-like receptor activation results in association of
the receptor, adaptor protein ASC, and inactive caspase 1; leading to the
activation of caspase 1. Active caspase 1 then cleaves pro-IL-1β into active IL1β, which is a potent mediator of inflammation (Garlanda et al., 2013, Latz et al.,
2013).
Adipocyte mediated inhibition of B lymphopoiesis: direct block or change
in lineage potential?
Adipocyte soluble factors were shown to inhibit B lymphopoiesis in human
and rabbit BM cultures (Bilwani and Knight, 2012), but the mechanism for this is
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unknown. While B lineage cells were decreased in cultures treated with ACM,
this could be due to a block at a specific stage of B lineage development (eg.
proB cell) or due to a redirection of hematopoiesis away from the B lineage and
toward another (eg. myeloid, NK, T lineage). Given the large number of
molecules produced by adipose tissue and the potential for a synergistic effect
on hematopoiesis, it is reasonable to hypothesize that B lymphopoiesis is not
simply blocked. In fact, hematopoietic progenitors are able to sense changes in
their niche, which may lead to changes in differentiation potential. For example,
pathogen-derived TLR ligands can influence HSCs to differentiate into myeloid
lineage cells and can induce CLPs to differentiate into dendritic cells (DCs)
(Nagai et al., 2006, Welner et al., 2008a, Welner et al., 2008b) (Figure 1.6).
Since adipocytes produce fatty acids that can also activate TLRs, it is possible
that B cell development is rerouted rather than blocked by adipocyte-derived fatty
acids.
Can cells other than adipocytes in the BM negatively regulate B cell
development?
Hematopoietic lineage compartments are known to change in the BM in
response to aging, obesity, infection, etc., but how does this affect B lineage
development? The degree to which cells in the BM other than adipocytes (such
as other hematopoietic cells) contribute to declining B lymphopoiesis is not well
characterized. During aging, aged B cells (ABC) were shown to accumulate in
aged BM negatively regulating new B lineage development (Ratliff et al., 2013),
suggesting an altered BM hematopoietic compartment could incluence B cell
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development. However, additional studies will be needed to understand whether
other hematopoietic lineage cells can contribute to declining B cell development
in fatty BM. For example, Enioutina et al. found that myeloid derived suppressor
cells (MDSCs) accumulate in the BM of aged mice (Enioutina et al., 2011).
MDSCs are a heterogenous popluation of CD11b+Gr1+ immature myeloid cells
well known for their ability to suppress T cell responses in cancers (Gabrilovich
and Nagaraj, 2009). While suppressive to T cell responses, it is unknown
whether these cells can also affect B cell development. Further study will be
needed to understand how changes in stromal cells and neighboring
hematopoietic cells interact with developing B lineage cells.

Figure 1.6 Skewing of hematopoietic lineage potenial. Hematopoietic
potential can be re-routed away from the B lineage at different stages of
development. Progenitors sense different molecules in the microenvironment
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which may result in diversion from the B lineage, to any of the lineages
diagrammed above. Both TLR ligands and notch ligands have been described to
act on different stages of development, resulting in altered hematopoietic
potential. (Adapted from Welner et al., 2008)

SIGNIFICANCE
Increased susceptibility to infections and poor immune responses to
vaccination put elderly individuals at an increased risk of mortality.
Microenvironmental changes in the aged BM and thymus result in decreased
output of new lymphocytes into the periphery, limiting the immune system’s
ability to respond and clear new infections. Accumulation of adipose tissue in
aged BM was previously considered to be inert. But recent understanding of
adipocytes as immune regulators has allowed the scientific community to realize
that adipose tissue is actively influencing hematopoiesis. Multiple
studies(Naveiras et al., 2009, Yang et al., 2009a, Youm et al., 2009, Youm et al.,
2010) have now shown that adipose tissue negatively regulates the development
of new immune cells in the BM and thymus. But detailed study of the
mechanisms by which adipocyte-derived factors negatively regulate
hematopoiesis is imperative, in order to develop therapeutics aimed at
rejuvenating immune cell development in aged individuals.
GOAL OF DISSERTATION
The goal of this dissertation is to understand the mechanism by which
adipocyte factors inhibit B cell development. We hypothesize that different
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adipocyte-derived factors inhibit/reroute B lymphopoiesis by: 1.) Acting directly
on hematopoietic B lineage progenitors and/or 2.) Acting indirectly, altering BM
stromal cells or neighboring hematopoietic cells. These studies were performed
with the intention of identifying targets for therapies designed to boost B
lymphopoiesis in aged and obese individuals with fatty BM.
An additional goal is to relate the identified mechanisms to the arrest
of B cell development that occurs at 2 months of age in the BM of rabbits.
The rabbit appears to be a model of accelerated BM aging, therefore further
characterization of rabbit BM will be useful in understanding the changes that
occur later in life of humans and mice.

CHAPTER II
EXPERIMENTAL METHODS
Mice
C57BL/6 breeding pairs were purchased from the Jackson Laboratory
(Bar Harbor, ME). All mice were used in compliance with protocols approved by
the Loyola University Chicago Institutional Animal Care and Use Committee.
Rabbits
New Zealand White rabbits were maintained at Loyola University Chicago.
All rabbits were used in compliance with protocols approved by the Loyola
University Chicago Institutional Animal Care and Use Committee.
Tissue/cell culture reagents
AlphaMEM and RPMI base medium were purchased from Life
Technologies (Grand Island, NY), along with all tissue culture supplements.
Recombinant murine IL-7, SCF, Flt3L, IL-1α, IL-1β, IL-13, G-CSF, KC, MCP-1,
MIP-1α, MIP-1β, RANTES and human IL-7, SCF, Flt3L were purchased from
PeproTech (Rocky Hill, NJ). Recombinant murine S100A8 was purchased from
Abcam (Cambridge, MA) and murine S100A9 was purchased from R&D systems
(Minneapolis, MN).
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Flow cytometry
Antibodies used to stain mouse cells in this study are listed in table 2.1.
Available antibodies for staining rabbit cells are listed in table 2.2. Dead cells
were excluded from flow cytometry analyses using BD Horizon fixable viability
stain (BD Biosciences, San Jose, CA) or Fixable Viability Dye eFluor 450
(eBioscience, San Diego, CA). FACS sorting was performed using a FACSAria
cell sorter (BD Biosciences). All stained cells were analyzed by flow cytometry
using a FACSCanto II or LSRFortessa flow cytometer (BD Biosciences). Flow
cytometry data were analyzed using FlowJo software (Tree Star, Ashland, OR).
Antibody reactivity
B220
CD19
CD11b
Gr1
CD14
CD3ε
CD4
CD8a
TER-119
CD49b
CD16/32 –Fc Block
CD28
Ly6C
Ly6G
Sca1
CD117
CD127
CD135
IL-1α
IL-1β

Clone
RA3-6B2
6D5
M1/70
RB6-8C5
Sa14-2
1452C11
GK1.5
53-6.7
TER-119
DX5
93
37.51
HK1.4
1A8
D7
2B8
SB/199
A2F10
BLa-89
B122

Company
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
eBioscience
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend

Table 2.1 Mouse antibodies used in this study.
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Antibody reactivity
CD1b
CD3
CD4
CD9
CD10
CD11b
CD11b
CD11c
CD14
CD14
CD20
CD21
CD23
CD24
CD25
CD27
CD38
CD43
CD44
CD62L
CD79a
CD90
BAFF
BCL6
BR3
Complement C3
Caspase 3
Ki67
MHC II
Anti-Macrophage
IgM
IgA
IgG
Ig Light Chain
S100A8/S100A9

Clone
LAT3
PC3/188A
Ken4
MM2
CDCALLA
198
M1/70
3/22
K4
TÜK4
B9E9
BL13
9P25
M1/169
Kei-α1
LT27
IB6
L11/43
W4/86
LAM-1
HM47
5E10
Polyclonal
BL6.02
Polyclonal
Polyclonal
C92-605
B56
2C4
RAM11
367
102
359
Polyclonal
MAC387

Specificity
Rabbit
Rabbit
Rabbit
Rabbit
Human, cross reacts with rabbit
Rabbit
Human, mouse, cross reacts with rabbit
Rabbit
Rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Mouse, cross reacts with rabbit
Rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Rabbit
Rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Human, cross reacts with rabbit
Rabbit
Human, mouse, cross reacts with rabbit
Human, cross reacts with rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit, mouse, human, cow, dog, pig,
monkey

Table 2.2 Antibodies available for the detection of rabbit immune cell
antigens.
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Microscopy
Microscopy experiments were visualized on a Leica DM IRB microscope
(Leica Microsystems, Buffalo Grove, IL). Image collection was performed using a
Magnafire 2.1C camera system and software.
Preparation of bone marrow cells
Mouse. Mouse femurs and tibias were cleaned with 70% ethanol, and
then rinsed with alphaMEM medium. The bones were flushed with medium (15ml
per 2 femurs and 2 tibias) using a 27 gauge needle, followed by red blood cell
(RBC) lysis using ammonium-chloride-potassium lysis buffer. Cells were then
washed with medium and used in downstream assays.
Rabbit. Femurs and tibia were washed with 70% ethanol and rinsed with
medium. Bones were broken open and the marrow was flushed with 20-40ml of
medium using a 16 gauge needle. RBCs were lysed using 0.85% ammonium
chloride, washed in medium, and used in downstream cultures or analyses.
B lymphopoiesis assay (BM cultures)
All B lymphopoiesis culture assays were performed in alphaMEM with
supplements at the following final concentrations: 10% FCS, 0.5%
penicillin/streptomycin, 30 mg/ml gentamicin, and 0.5 mg/ml fungizone.
Mouse. On day 0, 1,000 OP9 BM stromal cells were plated per well in 96
well plates. Day 1, mouse BM cells were depleted of B220+ B lineage cells by
magnetic bead separation using an autoMACS Pro separator (Miltenyi Biotec,
Auburn, CA). Then, 40,000 B220- BM cells were plated in 96 well plates
(containing OP9 cells) in the presence of murine IL-7 (10ng/ml), SCF (10ng/ml),
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and Flt3L (10ng/ml). Cultures were performed with or without the indicated
treatments. ACM treatment was typically performed at a 1:6 dilution and MDSCCM was typically used at a 1:3 dilution. Four days later fresh cytokines were
added to BM cultures, followed by termination of cultures between day 7 and day
10. At the end of culture, cells were collected, counted, and prepared for flow
cytometry analysis.
Arginase and iNos studies. For experiments assessing the contribution
of arginase and iNos, 0.3mM Nω-hydroxy-nor-arginine (Nor-NOHA) and/or 0.3mM
NG-monomethyl-L-arginine (L-NMMA) were used to block arginase and iNos,
respectively. Additionally, the control compound NG-monomethyl-D-arginine (DNMMA) was used to assess off-target effects of L-NMMA.
IL-1 studies. For experiments assessing IL-1, 1µg/ml anti-IL-1α and
1µg/ml anti-IL-1β antibodies (or isotype control antibodies) were added at the
initiation of BM cultures. Similar results were obtained using these antibodies in
combination with 1µg/ml human IL-1R antagonist.
Hematopoietic progenitor studies. For experiments with purified
progenitor cells, 500-1,000 HSCs, MPPs, or CLPs were seeded onto OP9 cells in
the presence of murine IL-7 (10ng/ml), SCF (10ng/ml), Flt3L (10ng/ml), and the
indicated treatment. Cultures were given fresh cytokines (as described
previously), followed by flow cytometry analysis 5-10 days after the cultures were
initiated. Lineage negative cells (Lin-) were defined as B220-CD3ε-CD8a-CD11bTER-119-Gr1-CD49b-.
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Inflammasome inhibitor studies. The NLRP3 inflammasome inhibitor
glybenclamide was purchased from Invivogen (San Diego, CA). Glybenclamide
was added at the start of cultures at the concentrations indicated in the figure.
24 well plate format. For assays performed in 24 well plates, 5,000 OP9
cells were plated. 24 hours later 120,000-500,000 B220- BM cells were used as a
source of progenitor cells.
Transwell cultures. Transwell cultures were performed in the 24 well
plate format, where ACM-derived MDSCs were cultured in contact (below
transwell insert) with BM progenitors or separated by transwell (cultured above
transwell insert).
Rabbit. 1,000 OP9 cells per well were plated in 96 well plates on day 0.
On day 1, 20,000 total BM cells/well (isolated from >2 month old rabbits) were
used as a source of BM progenitors. These cultures were performed in the
presence of rabbit IL-7 (10ng/ml), SCF (10ng/ml), and Flt3L (10ng/ml). Fresh
cytokines were added to cultures 4 days after culture start, followed by
termination of the cultures between day 7 and day 10.
T cell proliferation assays
96 well plates were coated with anti-CD3 and anti-CD28 antibodies in
0.1M borate buffer pH 8.0. The next day, mouse splenocytes were stained with
5µM CellTrace violet or Carboxyfluorescein succinimidyl ester (CFSE)
(ThermoFisher Scientific, Waltham, MA), followed by resuspension in modified
RPMI 1640 containing 10% FCS. Labeled solenocytes were plated in anti-CD3
and anti-CD28 coated wells at the concentrations of 250,000 cells/well or
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300,000 cells/well with or without effector cells (ACM-generated

CD11bhiGr1+

cells or CD19+ control cells) ranging from 12,500-100,000 cells/well. Four days
later, cultures were stained for flow cytometry analysis with anti-CD4 and antiCD8 antibodies and the dilution of CFSE was assessed.
For experiments assessing arginase and iNos activity, 0.3mM Nor-NOHA
(arginase inhibitor) and 0.3mM L-NMMA (iNos inhibitor) were added to cultures.
Adipocyte differentiation and conditioned medium generation
Mouse Adipocytes. 3T3.L1 pre-adipocytes were used to generate
adipocytes (provided by Dr. Neil Clipstone – Loyola University Chicago). 80,000
pre-adipocytes were plated per well in a 6 well plate. Cells were cultured until
reaching confluency (designated as Day 0). On day 2, MDI adipocyte
differentiation medium was added. MDI medium consists of Dublecco’s Modified
Eagle Medium (DMEM) containing 10% FCS, dexamethasone (1µM), insulin
(10µg/ml), and 3-isobutyl-1-methylxanthine (0.5mM). After 48 hours of culture in
MDI (Day 4), the medium was aspirated and replaced with DMEM 10% FCS
containing insulin (10µg/ml). On day 6, the medium was again aspirated and
replaced with DMEM 10% FCS only. At this point, the cells were cultured four
more days, replacing with fresh DMEM 10% FCS every two days until the
adipocytes were fully differentiated.
To generate conditioned medium, the adipocytes were washed with serum
free DMEM (to remove trace amounts of differentiation supplements), and then
cultured for 3 days in 1ml of serum free DMEM. Adipocyte conditioned medium
(ACM) was then collected and any cell debris was removed.
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Rabbit Adipocytes. To generate rabbit adipocytes, total BM was isolated
from rabbits of any age and RBCs were lysed. For BM from rabbits <2 months of
age, 380,000 BM cells were plated per well in 12 well plates. When using BM
from >2 month old rabbits for adipocyte generation 3,800,000 cells were plated
per well in 12 well plates. BM cells were cultured for two days in alphaMEM
containing 20% FCS and supplemented with penicillin (100 units/L)/streptomycin
(100µg/L), and fungizone (250µg/L). On day 2, non-adherent cells were removed
and fresh medium was added. On day 3, the medium was replaced with
adipocyte differentiation medium (ADI) consisting of alphaMEM with 15% FCS, Lglutamine (2mM), penicillin (200 units/L)/streptomycin (200µg/L), dexamethasone
(0.4µM), indomethacin (40µM), and 3-isobutyl-1-methylxanthine (0.4µM). Every
three to four days, the medium was replaced with fresh ADI, aspirating and
replacing only half the medium in the well. On day 20, cultures were screened for
wells containing 85-100% mature adipocytes. Wells containing a high percentage
of adipocytes were then washed with serum free alphaMEM (to remove
differentiation supplements), and then ACM was generated by culturing for three
days in 700µl-1ml of serum free of alphaMEM. Finally, the supernatant was
collected, cell debris was removed, and ACM was then used in downstream
assays.
MDSC generation
MDSCs were generated in 24 well plates. 5,000 OP9 BM stromal cells
were plated in each well. The next day, 120,000-500,000 B220- mouse BM cells
were plated in OP9 containing wells in the presence of murine IL-7, SCF, and
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Flt3L. Key to generating MDSCs is the addition of mouse ACM at the start of
cultures (typically at a 1:6 dilution). On day 4, the cultures were given fresh
cytokines, and on day 7 the cultures were collected for MDSC isolation. Cells
resulting from ACM-treated cultures were pooled and stained with anti-B220,
anti-CD19, anti-CD11b, and anti-Gr1 and sorted for B220-CD19-CD11b+Gr1+
cells by flow cytometry. Sorted cells were then used for downstream culture or
analysis.
MDSC-CM
MDSC-CM was generated by culturing 100,000 purified MDSCs per well
in 48 well plates. MDSCs were cultured in serum free alphaMEM for 3 days, and
then collected for downstream assays.
BM fat conditioned medium
BM fat conditioned medium (BM fat-CM) was generated in two steps;
isolation of BM fat from >2 month old rabbits, followed by conditioned medium
generation.
Isolation of BM fat. Greater than 2 month old rabbits were used to isolate
BM fat because younger rabbits do not have enough BM fat to isolate by this
method. BM was flushed from rabbit femurs and/or tibia as described previously.
Next, cells were spun down at 1,200RPM for 5-10min at 4 degrees Celsius.
Spinning the BM results in two noticeable BM fractions; 1. The BM pellet at the
bottom of the tube. This fraction contains most BM cell types (eg. RBCs, white
blood cells, stromal cells), but is largely depleted of mature adipocytes. This
fraction is also referred to as the stromal vascular fraction (SVF). In this
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dissertation, we refer to the pellet that forms after spinning down total BM as total
BM or the SVF. In either terminology, these are depleted of mature adipocytes by
spinning total BM; 2. In addition to the BM pellet, this method also results in the
formation of a mature adipocyte fraction at the top of the tube of cells. In this
dissertation, we refer to this floating fraction as the adipocyte layer or as the BM
fat layer. The BM fat layer contains mature adipocytes, but we have also isolated
hematopoietic lineage cells (many CD11b+ cells) that are tightly associated with
adipocytes in this fraction. Therefore, conditioned medium from BM fat contains
molecules derived from adipocytes and tightly associated hematopoietic cells.
Generation of conditioned medium. BM fat-CM was generated upon
isolation of the adipocyte layer/BM fat layer from >2 month old rabbits. BM fat
was cultured in serum free alphaMEM for 16-24 hours, supernatant was collected
(no adipocytes or other cells were taken), followed by the removal of any debris.
BM fat-CM was then used in downstream assays.
Isolation of cells from BM fat
BM fat was isolated from femurs and/or tibias of >2 month old rabbits, then
cultured overnight in wells of a 12 well plate. By the next day, many cells will
have fallen out of the BM fat fraction to the bottom of each well. The cells at the
bottom of each well were collected and combined with cells isolated through
disruption of the BM fat fraction (pipetting up and down the BM fat). This is the
gentlest way to isolate cells from BM fat. Alternatively, cells were isolated from
BM fat after it was digested with 4mg/ml collagenase II in PBS supplemented
with 0.5% BSA and 10 mM CaCl2, which releases cells from the tissue. Both
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methods appeared to work well for isolating hematopoietic cells from this fat
fraction.
After isolation of cells from BM fat, CD11b+ and CD11b- cells were
separated by magnetic bead sorting using an autoMACS Pro separator. These
cell populations were then used in rabbit BM cultures.
Bone marrow sections
BM sections were performed on femurs and/or tibias taken from rabbits of
various age. The upper bone surface was removed very carefully using a new
surgical blade (many gentle strokes of the blade on the desired area of bone
surface until the surface is breached). Upon removal of the bone surface, the
bone looked like a “half-pipe” (Figure 2.1). Although the surface was removed,
care was taken so the BM was not disturbed. If BM was disturbed, it was not
used for sectioning. Multiple slices of BM were taken from opened bones (with
undisturbed BM) and prepared for cryosectioning sectioning. BM was embedded
in optimal cutting temperature (OCT) support medium and frozen. Frozen BM
was then used for sectioning. After sectioning, BM sections were stained with
Hematoxylin and Eosin, or stained for immunofluorescence analysis.

Bone Marrow
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Rabbit Bone

Bone Surface

Remove bone
surface
without
disturbing
inner BM

Rabbit Bone
(after surface removal)

Bone Marrow

Bone should
look like a
“half pipe” with
undisturbed
BM extending
out of bone

Rabbit BM
(to be sectioned)

•
•
•

Remove multiple slices of
BM.
Embed in OCT
Freeze

Figure 2.1 Preparation of rabbit bone marrow for sectioning. Rabbit BM was
prepared as described in the text and indicated in this figure.

Anion exchange chromatography
Anion exchange chromatography was performed using a 1ml volume
HiTrap Q Sepharose High Performance strong anion exchange column (GE
Healthcare Life Sciences, Pittsburgh, PA). Chromatography experiments were
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performed with an ÄKTA fast protein liquid chromatography (FPLC) system
running UNICORN control software (GE Healthcare Life Sciences, Pittsburgh,
PA).
Mouse ACM samples were prepared by filtering 8ml of total ACM through
a 10kDa filter (Amplicon ultra – EMD Millipore, Darmstadt, Germany) until 100µl
of retenate remained above the filter. Greater than 10kDa ACM was diluted 1:10
in FPLC buffer A (running buffer), to a final volume of 1ml which was then loaded
on the column. Proteins bound to the column were eluted using a linear
increasing salt concentration performed by adding increasing concentrations of
FPLC Buffer B (elution buffer).
The protein concentration of each fraction was measured by a UV reader
within the FPLC system, and was confirmed using a nanodrop 2000
spectrophotometer (Thermo Scientific, Wilmington, DE). Multiple fractions
collected from the column were pooled into the following samples and tested for
inhibitory activity in rabbit B lymphopoiesis assays.
Sample in
B
lymphopoiesi
s assay
SAMPLE 1
SAMPLE 4
SAMPLE 5
SAMPLE 6
SAMPLE 7
SAMPLE 8

Fractions in each sample

A1,A2,A3
B9,B8,B7,B6,B5,B4
B3,B2,B1,C1,C2
C3,C4,C5,C6,C7
C9,C10,C11,C12,D12,D11,D10,D9,D8,D7,D6,D5,D4,D3,D
2,D1,E1
E2,E3,E4,E5,E6,E7,E8,E9,E10,E11,E12

FPLC Buffer A (running buffer) - 10mM TRIS-HCL pH 8.2
FPLC Buffer B (elution buffer) - 10mM TRIS-HCL + 1M NaCl pH 8.2
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System/column storage buffer - 20% Ethanol in water
Quantitative RT-PCR
Cells were suspended in TRIzol reagent (Invitrogen, Carlsbad, CA), and
RNA was isolated. cDNA was made from isolated RNA and used in qPCR
reactions. PCR experiments were performed using a C1000 thermal cycler with
CFX96 real-time detection system (Bio-Rad, Hercules, CA). Expression of target
genes was normalized to β-actin (mouse experiments) or HGPRT (rabbit
experiments). Tables 2.3 and 2.4 display the primer sets used in qPCR
experiments.

Gene

Forward Primer (5’-3’)

(Reverse Primer 5’-3’)

GGCTGTATTCCCCTCCATCG

CCAGTTGGTAACAATGCCATGT

Arg1

AGACCACAGTCTGGCAGTTG

CCACCCAAATGACACATAGG

Nos2

CAGCTGGGCTGTACAAACCTT

CATTGGAAGTGAAGCGTTTCG

Actb
(βactin)

Table 2.3 Mouse qPCR primers.
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Gene

Forward Primer (5’-3’)

(Reverse Primer 5’-3’)

HGPRT

AGCCCCAGCGTTGTGATTAGT

CATCTCGAGCAAGCCTTTCAG

IL-1β

AGGTCTTGTCAGTCGTTGTG

GTAGTCATCCCAGTGTGCAG

S100A8

TCTACCACAAGTACTCCCTGG

TCCAGCTCTTTGAACCAAGTG

S100A9

ATCATCAACGTCTTCCACCAG

TTATGGCTTTCTCATCCCTCG

Table 2.4 Rabbit qPCR primers.
Cytokine array
The concentration of 23 cytokines was assessed in ACM, MDSC-CM, and
control CD11b+Gr1+ conditioned medium (control-CM) samples using a Bio-Plex
Pro mouse cytokine 23-plex (Bio-Rad, Hercules, CA). The cytokines analyzed
are as follows: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL12(p70), IL-13, IL-17A, G-CSF, GM-CSF, IFN-γ, KC, MCP, MIP-1α, MIP-1β,
RANTES, eotaxin, TNF-α. Three ACMs, three MDSC-CMs, and two control-CMs
were all generated in independent experiments before being analyzed by
cytokine array.
Statistical analysis
Data were obtained and displayed as indicated in the figure legends.
Statistical analysis of all experiments was performed using Prism software
(GraphPad Software; La Jolla, Ca). Statistical tests used in this dissertation are
indicated in the figure legends, and include unpaired two-tailed Student’s t test or
analysis of variance (ANOVA) in combination with Dunnet’s or Bonferroni’s test
for multiple comparisons. * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001

CHAPTER III
RESULTS
SECTION 1: ADIPOCYTES AND THE INHIBITION OF B LYMPHOPOIESIS
In aging and obesity, declining B lymphopoiesis correlates with an
accumulation of adipocytes in the BM. Adipocytes were once thought to be inert,
simply filling empty BM space. However, recent evidence suggests that
adipocytes can regulate multiple aspects of the immune system, including
hematopoiesis (Bilwani and Knight, 2012, Naveiras et al., 2009). Therefore, a
detailed understanding of how adipocytes influence immune cell development will
prove beneficial in developing therapeutics to restore healthy hematopoiesis in
scenarios where adipocytes accumulate in the BM, such as aging and obesity.
Bilwani and Knight found that adipocyte-derived factors inhibit human and
rabbit B cell development in BM cultures (Bilwani and Knight, 2012), but the
mechanism by which this occurs is unknown. Due to a greater abundance of
reagents available to study mice than rabbits, and increased access to BM from
mice than humans; it would be ideal to tease out the mechanism by which
adipocyte factors inhibit B cell development in mice. Therefore, we first needed to
establish whether or not adipocyte factors inhibit B lymphopoiesis in mice.
To test if adipocyte factors inhibit mouse B cell development, we needed
to generate mouse adipocyte factors, and develop an approach to study the
68

69

effect of these factors on B lymphopoiesis. Mouse adipocyte factors were
generated using the pre-adipocyte cell line, 3T3.L1. Pre-adipocytes were
differentiated into mature adipocytes with insulin, isobutylmethylxanthine, and
dexamethasone. Upon differentiation into mature adipocytes, the cells were
washed to remove trace amounts of differentiation factors, followed by three days
of culture and the collection of adipocyte conditioned medium (ACM). ACM was
then used to assess the effect of adipocyte-derived factors on mouse B
lymphopoiesis.
B lymphopoiesis was studied using the OP9 stromal cell line, originally
isolated from mouse BM. OP9 cells are commonly used to study B
lymphopoiesis, as they have been found to support the differentiation of BM
progenitors into B lineage cells (Holmes and Zuniga-Pflucker, 2009). In this
study, we cultured various subsets of hematopoietic progenitors with OP9 cells to
answer different questions using this system.
To determine if adipocyte-derived soluble factors inhibit B lymphopoiesis,
mouse BM cells were depleted of B220+ B lineage cells. We cultured these B220BM cells with OP9 BM stromal cells in the presence of IL-7, SCF, and Flt3L,
cytokines that support B lineage development. We expected that if adipocyte
factors inhibit mouse B lymphopoiesis, then treatment of B lymphopoiesis
cultures with ACM would result in a decreased frequency of B lineage cells (as
evidenced by fewer B220+ cells) observed at the end of cultures. As expected,
cultures treated with ACM contained fewer B220+ B lineage cells compared to
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untreated cultures (Figure 3.1 A & B ), suggesting that adipocyte factors inhibit
mouse B cell development.
If the adipocyte-mediated inhibition of B lymphopoiesis is conserved
among mammals, we also expected that mouse adipocyte factors would inhibit
rabbit B lymphopoiesis. To study rabbit B lymphopoiesis we modified the above
described culture system. Total BM cells from >2 month old rabbits was used as
a source of BM progenitors and cultured with OP9 cells in the presence of IL-7,
SCF, and Flt3L. BM cells from rabbits >2 months old was used as a source of
early hematopoietic progenitors because B lymphopoiesis has arrested in rabbit
BM by this time, and the cultures are not “contaminated” with proB and preB
cells.
To understand if mouse adipocyte factors have the potential to inhibit
rabbit B cell development, we cultured BM cells from >2 month old rabbits with
OP9 cells in the presence or absence of mouse ACM. We expected that if mouse
adipocyte factors inhibit rabbit B lymphopoiesis, then ACM-treated cultures will
result in the development of fewer B lineage cells. Reagents are not available to
detect the B cell marker B220, therefore we identified the development of new
rabbit B lineage cells by the appearance of cells expressing the B cell receptor
(BCR) signaling component CD79a (first expressed at the proB cell stage).
Interestingly, treatment of rabbit BM cultures with mouse ACM resulted in fewer
CD79a+ B lineage cells (Figure 3.1 C & D). These data coupled with the findings
by Bilwani and Knight lead us to conclude that adipocytes negatively regulate B
lymphopoiesis in a conserved manner between multiple mammals.
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Figure 3.1 Inhibitory potential of mouse adipocyte-derived factors in mouse
and rabbit B lymphopoiesis cultures. (A-B) Mouse B220- BM cells were
cultured with OP9 stromal cells in the presence of mouse IL-7, SCF, and Flt3L.
Flow cytometric analysis at the end of (A) untreated or (B) msACM-treated
cultures for the expression of B220 and CD14 on resulting cells. (C-D) BM cells
from a >2 month old rabbit were cultured with OP9 stromal cells in the presence
of human IL-7, SCF, and Flt3L. Flow cytometric analysis at the end of (C)
untreated or (D) msACM-treated cultures for CD79a and CD14 expression on
resulting cells. (A-D) Data are representative of at least 3 independent
experiments.
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Mechanism of adipocyte-mediated inhibition
Adipocyte factors inhibit B lymphopoiesis; although the mechanism by
which this occurs is unknown. Because the inhibition of B lymphopoiesis by
adipocytes appears conserved among mammals, we expect using mice to
understand the mechanism of inhibition will allow us to gain insights applicable to
humans, mice, and rabbits.
There are two ways in which adipocyte molecules could inhibit B cell
development; directly acting on a B lineage progenitor or indirectly through
another cell (such as OP9 stromal cells) in BM cultures. While ACM treatment of
cultures containing mouse B220- BM cells and OP9 stromal cells resulted in the
development of very few B220+ B lineage cells (Figure 3.2 A, B&E), these
cultures contained a large population of cells that do not express B220. We
became interested in identifying which cell type develops after treatment of BM
cultures with adipocyte factors. To characterize these B220- cells, we stained the
cells with a panel of lineage specific antibodies (including myeloid [eg. antiCD11b], NK [eg. anti-NK1.1], T lineage [eg. anti-CD3] specific antibodies) and
analyzed the cells by flow cytometry. We expected that if ACM promoted the
development of another hematopoietic lineage, then we would visualize the
resulting lineage with our panel of antibodies. Alternatively, if adipocyte factors
directly block B cell development and hematopoietic progenitors accumulate in
ACM-treated cultures, then we would not see staining with our lineage panel. In
the latter scenario, additional staining would be needed to identify hematopoietic
progenitors. As evidenced by flow cytometric analysis of cells resulting from ACM
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treatment, the vast majority of

B220-

cells were identified with the myeloid

markers CD11b and Gr1 (Figure 3.2 C, D, &F), suggesting that adipocyte factors
promote the accumulation of myeloid lineage cells.
In addition to increased quantity of CD11b+Gr1+ myeloid cells after ACM
treatment (Figure 3.2 C, D, &F), the quality also appeared to differ from the
CD11b+Gr1+ cells generated in untreated cultures. Flow cytometric analysis
showed that CD11b+Gr1+ cells from ACM-treated cultures had higher expression
of CD11b, were larger (FSC), and more granular (SSC) than myeloid cells from
untreated cultures (Figure 3.3). Although yet to be determined, these phenotypic
differences suggest CD11bhiGr1+ cells generated in the presence of adipocyte
factors might also have different functional properties as compared to
CD11b+Gr1+ cells from untreated cultures.
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Figure 3.2 Characterization of cells resulting after treatment with adipocyte
factors. Flow cytometric analysis and absolute cell numbers after mouse B
lymphopoiesis cultures were treated with ACM or left untreated. Cells were
stained and analyzed for (A&B) B220 and CD14 expression, followed by (C&D)
CD11b and Gr1 expression in the B220- gate (C&D). Number of (E) B220+ and
(F) CD11b+Gr1+ cells present after culture. Data are representative of 3
independent experiments. For (E&F), Student’s t test was used to determine
significance. Error bars represent the average of triplicate wells +/- SD.

Figure 3.3 Phenotypic analysis of myeloid populations in ACM-treated and
untreated cultures. Flow cytometric analysis of mouse B lymphopoiesis cultures
7 days post initiation. Cells were stained for B220, CD14, CD11b, and Gr1
expression to identify B220-CD11b+Gr1+ cells. CD11b+Gr1+ cells resulting from
ACM-treated or untreated (NT) cultures were analyzed for mean fluorescence
intensity (MFI) of (left) CD11b, (middle) forward scatter (FSC), and (right) side
scatter (SSC). Data are representative of at least 3 independent expedriments.
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In young healthy BM, cells defined as

CD11b+Gr1+

are considered

myeloid progenitors, which will quickly differentiate into cells such as monocytes,
macrophages, and neutrophils. Although in pathologies such as cancer, MDSCs
(also defined as CD11b+Gr1+) accumulate (Gabrilovich and Nagaraj, 2009). To
test if the CD11bhiGr1+ cells that develop in the presence of ACM are MDSCs,
we asked if they possess classical characteristics of MDSCs. We assessed if
ACM-derived CD11bhiGr1+ cells have the functional ability to suppress T cell
proliferation, as well as co-express Arg1 and Nos2 which encode for the
enzymes arginase and iNos; important effector molecules for MDSC-mediated
suppression of T cell responses.
To understand whether ACM-generated CD11bhiGr1+ cells express Arg1
and Nos2, we FACS-sorted CD11bhiGr1+ cells resulting from ACM-treated BM
cultures and performed qPCR. We expected if ACM-generated CD11bhiGr1+ cells
are MDSCs, they should co-express higher levels of Arg1 and Nos2 compared to
CD11b+Gr+ myeloid cells isolated from control untreated cultures and CD19+ B
lineage cells. As expected, compared to CD11b+Gr+ myeloid cells (-ACM) and
CD19+ cells (CD19+) from untreated BM cultures, the myeloid cells isolated from
ACM-treated cultures (+ACM) co-expressed large amounts of Arg1 and Nos2
(Figure 3.4 A).
To determine if myeloid cells isolated from ACM-treated cultures actively
suppress T cell proliferation, we analyzed their ability to suppress in T cell
proliferation assays. In these assays, splenocytes were CFSE-labeled and
stimulated with plate-bound anti-CD3 and anti-CD28. Stimulation of splenocytes
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activates

CD4+

T cells to proliferate, which can be visualized via flow cytometry

as the dilution of CFSE in this splenocyte population. The reason this can be
visualized is because CFSE is cell permeable and covalently binds to
intracellular molecules, and as each division occurs the CFSE labeled
components of a parent cell become shared by the resulting daughter cells
(diluting the amount of stain per cell).
To assess the suppressive activity of ACM-generated CD11bhiGr1+
myeloid cells, these cells were FACS-sorted and cultured with stimulated CFSElabeled splenocytes. If ACM-generated myeloid cells suppress T cell
proliferation, then culturing CD4+ T cells with CD11bhiGr1+ myeloid cells will
prevent CFSE dilution (proliferation) in CD4+ T cells. Compared to cultures
containing an equal number of control effector cells (Figure 3.4 B dashed line),
CD4+ cells in cultures containing ACM-generated myeloid cells proliferated less
(Figure 3.4 B solid line). These data coupled with the co-expression of Arg1 and
Nos2 lead us to conclude that adipocyte soluble factors promote the
accumulation of MDSCs.
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Figure 3.4 Phenotypic and functional characterization of ACM-generated
CD11bhiGr1+ cells. (A) qPCR analysis of Arg1 and Nos2 expression comparing
CD11b+Gr1+ cells isolated by FACS from ACM-treated (+ACM), untreated (ACM) BM cultures, and CD19+ control cells . (B) Flow cytometric plot of anti-CD3
and anti-CD28 stimulated CD4+ splenocytes (CFSE-labeled) cultured with ACMgenerated CD11bhiGr1+ cells (solid line) or CD19+ control cells (dashed line).
Data in (A) are representative of two independent experiments and in (B) are
representative of three independent experiments.

There are two major subsets of MDSCs; monocytic and granulocytic.
These subsets can be differentiated based on staining for the molecules Ly6C
and Ly6G, where monocytic MDSCs are defined as Ly6C+Ly6G- and granulocytic
MDSCs are defined as Ly6C+Ly6G+ (Gabrilovich and Nagaraj, 2009, Youn et al.,
2008). While both types of MDSCs suppress T cell responses, the mechanisms

78

regulating their induction and suppressive activity can vary. Understanding the
type of MDSC induced by adipocyte factors will be help us identify critical
molecules for MDSC induction and suppressive activity.
By flow cytometric analysis of CD11b+ cells resulting from ACM-treated
BM cultures, we found that 65% of CD11b+ cells were Ly6C+Ly6G- monocytic,
while 21% exhibited the Ly6C+Ly6G+ granulocytic MDSC phenotype (Figure 3.5
A). To complement this result, we also visualized the nuclei of ACM-generated
MDSCs, as monocytic MDSCs have nuclei resembling immature monocytes and
granulocytic MDSCs have polymorphic nuclei similar to neutrophils. We FACSsorted ACM-generated CD11b+Gr1hi MDSCs, plated the MDSCs in tissue culture
wells, and then stained with Diff-QuickTM stain to visualize nuclei by light
microscopy. Based on our flow cytometry data, we expected that the majority of
the MDSCs would have nuclei that resemble monocytic MDSCs. In fact,
microscopy analysis of sorted MDSCs confirmed that this population is primarily
of the monocytic subset (Figure 3.5 B), as very few MDSCs had a
polymorphonuclear appearance similar to neutrophils. These data lead us to
conclude that adipocyte factors mainly promote the generation of monocytic
MDSCs in vitro. Further, the above experiments indicate that the use of
adipocyte factors is an efficient means to generate a pure population of MDSCs.
This culture system will be a useful tool to generate MDSCs for further study of
these cells, as well as for the use of MDSCs as a therapeutic agent.
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Figure 3.5 Ly6C vs Ly6G expression and morphology of CD11b+Gr1+ cells
isolated from ACM-treated or control BM cultures. (A) Flow cytometric
analysis of CD11b+ cells from ACM-treated or untreated cultures for the
expression of Ly6C and Ly6G. (B) FACS-sorted CD11b+Gr1+ cells were plated in
wells and stained with Diff Quick (Siemens, USA).
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SECTION 2: MDSCs AND THE INHIBITION OF B LYMPHOPOIESIS
MDSCs are well characterized for their ability to suppress T cells, but it is
not known whether these cells alter hematopoiesis. The generation of MDSCs by
adipocyte soluble factors could be the result of skewed hematopoiesis, where
MDSCs are simply bystanders. Alternatively, because MDSCs are suppressive in
nature we hypothesized that ACM-generated MDSCs might contribute to the
inhibition of B lymphopoiesis. To test if MDSCs have the functional capacity to
inhibit B cell development, we added FACS-sorted MDSCs from ACM-treated
cultures or CD11b+Gr1+ myeloid cells from untreated cultures directly to new B
lymphopoiesis cultures (no ACM added). If MDSCs contribute to the inhibition of
B lymphopoiesis, then we expect BM cultures containing MDSCs will result in a
decreased number of B220+ B lineage cells compared to control cultures.
Strikingly, wells with ACM-generated MDSCs contained very few B220+ B
lineage cells; whereas cultures treated with control myeloid cells exhibited a
similar number of B lineage cells to untreated cultures (Figure 3.6). We conclude
that MDSCs actively inhibit B lymphopoiesis.
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Figure 3.6 Effect of MDSCs on B lymphopoiesis cultures. Absolute number
of B220+ cells resulting from BM cultures treated with the following FACS isolated
effector cells: 5,000 CD11bhiGr1+ MDSCs from ACM-treated cultures (pink),
5,000 CD11b+Gr1+ control cells from untreated cultures (blue), or no effectors
(black). Data are representative of 3 independent experiments. Student’s t test
was used to determine significance. Error bars represent the average of triplicate
wells +/- SD.
Mechanism of MDSC-mediated inhibition of B lymphopoiesis
The finding that MDSCs potently inhibit B lymphopoiesis is novel.
Therefore, we asked by what mechanism these MDSCs mediate their inhibitory
effect. Further understanding how adipocyte soluble factor generated MDSCs
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inhibit B cell development will help us identify the active molecules produced by
adipocytes to trigger this MDSC-mediated inhibition.
Since MDSC effector mechanisms are well-known for the suppression of T
lymphocytes, we asked if B cell development is also sensitive to one of these
mechanisms. The most well-known way MDSCs suppress T cell responses is
through the effector molecules arginase and iNos. These enzymes both use Larginine as a substrate and can suppress through L-arginine depletion. In
addition, nitric oxide produced by iNos has suppressive activity (Gabrilovich and
Nagaraj, 2009, Rodriguez and Ochoa, 2008). The idea that these effector
molecules could alter B lymphopoiesis is plausible, as one study found arginine
deficient mice have impaired B cell development (de Jonge et al., 2002).
To test if arginase and/or iNos are responsible for MDSC-mediated
inhibition of B lymphopoiesis, we cultured BM progenitors, OP9 cells, and
MDSCs with or without nor-NOHA (arginase inhibitor) and L-NMMA (iNos
inhibitor). We expected that if arginase and/or iNos mediate the MDSC inhibitory
activity, then blocking these effectors will restore B lymphopoiesis in cultures
containing MDSCs. Surprisingly, B lymphopoiesis was not restored when
blocking arginase and iNos in cultures containing MDSCs. BM cultures with
MDSCs in the absence of any inhibitors contained significantly fewer B220+ B
lineage cells compared to control wells (Figure 3.7 A). Consistently, the number
of B lineage cells in all wells containing MDSCs was significantly lower than
untreated wells and cultures containing control cells, regardless of the addition of
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arginase and iNos inhibitors. This result suggests that MDSCs do not inhibit B
lymphopoiesis through arginase/iNos.
To ensure the nor-NOHA and L-NMMA inhibitors were active, we tested
them in the context of T cell proliferation assays. If ACM-generated MDSCs
behave like classical MDSCs, we expected they would inhibit T cell proliferation
via arginase and iNos. Therefore using these inhibitors in T cell proliferation
assays should restore T cell proliferation in wells containing MDSCs. To test this,
CFSE labeled splenocytes were stimulated with anti-CD3 and anti-CD28, and
then T cell proliferation (CD4+ and CD8+) was assessed comparing cultures with
MDSCs in the presence or absence of nor-NOHA and L-NMMA. If ACMgenerated MDSCs inhibit T cell proliferation in an arginase and iNos dependent
manner, and if the nor-NOHA and L-NMMA inhibitors are active, then T cell
(CD4+ and CD8+) proliferation will decrease in the presence of MDSCs, but will
be restored to untreated levels when arginase and iNos are inhibited. Flow
cytometric analysis of the CD4+ and CD8+ splenocyte populations showed similar
results. CD4+ and CD8+ splenocytes from cultures containing MDSCs exhibited
decreased CFSE dilution (proliferation) compared to when no effector cells were
added. Further, CFSE dilution (proliferation) was significantly increased in
cultures with MDSCs in which arginase and iNos were blocked (Figure 3.7 B &
C). We conclude that ACM-generated MDSCs inhibit T cell proliferation in an
arginase and iNos dependent manner, although this is not the primary
mechanism by which MDSCs inhibit B cell development.
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Figure 3.7 MDSC-mediated inhibition of B lymphopoiesis in the absence of
arginase and iNos. (A) Number of B220+ cells resulting from B lymphopoiesis
cultures containing no effector cells, ACM-generated MDSCs, or non-inhibitory
CD11b+Gr1+ control cells. The indicated wells were treated with 0.3mM L-NMMA
(iNos inhibitor), 0.3mM D-NMMA (control compound), and/or 0.3mM nor-NOHA
(arginase inhibitor). (B-C) Proliferation of (B) CD4+ or (C) CD8+ splenocytes after
anti-CD3 and anti-CD28 stimulation in the presence or absence of ACMgenerated MDSCs, and treated with 0.3mM L-NMMA and nor-NOHA where
indicated. Data in (A-C) are representative of three independent experiments.
Error bars represent the average of triplicate wells +/- SD. Data in (A) were
analyzed for statistical significance by ANOVA coupled with the Dunnet multiple
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comparison test (p<0.0001). Data in (B&C) were analyzed for statistical
significance by ANOVA coupled with the Bonferroni multiple comparison test
(p=0.001 and p=0.003 respectively).

Do MDSCs require contact with target cells? MDSCs do not use
arginase and iNos to inhibit B lymphopoiesis, suggesting MDSCs inhibit via a
novel mechanism. To gain a better sense of how MDSCs negatively regulate B
cell development, we asked if inhibition required contact with BM progenitors. BM
progenitors were cultured with OP9 cells in B lymphopoiesis assays, either with
MDSCs in contact with BM progenitors or separated by transwells. We expected
that if MDSCs require contact with target cells to mediate inhibition, then MDSCs
will not inhibit B lymphopoiesis when cultured in transwells. Interestingly, the
number of B220+ B lineage cells was significantly reduced compared to no
MDSC controls regardless of whether MDSCs were cultured in contact or away
from BM progenitors (Figure 3.8 A). This result suggested that ACM-generated
MDSCs do not require contact with target cells to mediate inhibition, and likely
inhibit through the production of a soluble factor.
To complement the above finding and to test if MDSC-derived soluble
factors inhibit B lymphopoiesis, we asked if conditioned medium from MDSCs
(MDSC-CM) contained inhibitory activity. To generate conditioned medium, we
isolated MDSCs (by FACS) from ACM-treated BM cultures and plated the
isolated cells in wells of a 48 well plate. Several days later, supernatant from
MDSC cultures was collected and used as a source of MDSC-derived soluble
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factors. The inhibitory activity of MDSC factors was tested by treating mouse BM
cultures with MDSC-CM and analyzing the resulting frequency and absolute
number of B220+ B lineage cells by flow cytometry. We expected that if MDSCs
inhibit via a soluble factor(s), then MDSC-CM treated cultures would exhibit
decreased development of B lineage cells compared to untreated cultures. As
expected, MDSC-CM inhibited B cell development, where the percentage and
number of B220+ cells were significantly reduced in cultures containing MDSCCM (Figure 3.8 B, D&F). Together these data suggest MDSCs do not require
contact with target cells to negatively regulate B lymphopoiesis. We conclude
that MDSCs inhibit through the production of a soluble factor(s).
Interestingly, we noticed that BM cultures treated with MDSC-CM
exhibited an increased percentage and number of CD11b+Gr1+ myeloid lineage
cells (Figure 3.8 C, E&G). These data suggest that MDSCs either produce
multiple factors that separately inhibit B lymphopoiesis and promote
myelopoiesis, or one factor that has a dual function to inhibit B cell development
and promote myeloid cell development and/or survival. Therefore we decided to
profile MDSC-derived soluble factors to identify molecules that could recapitulate
this phenomenon.
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Figure 3.8 Effect of MDSC-derived soluble factors on B lymphopoiesis. (A)
Number of B220+ cells resulting from B lymphopoiesis cultures containing no
effector cells (no MDSC), MDSCs, or MDSCs cultured in a transwell. (B-G) B
lymphopoiesis assays were performed with or without (untreated) MDSC-CM
treatment. (B-E) Flow cytometric analysis of cells stained with antibodies to
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(B&D) B220 and CD19, or (C&E) CD11b and Gr1. Number of (F)

B220+

cells and

(G) CD11b+Gr1+cells resulting from untreated cultures or cultures treated with
MDSC-CM. Data in (A) are representative of 2 independent experiments and
were analyzed by ANOVA in combination with a Bonferroni multiple comparison
test (p<0.0001). Data in (B-G) are representative of 3 independent experiments.
Statistical significance in (F&G) was analyzed by Student’s t test. Error bars
represent the average of triplicate wells +/- SD.

Soluble factors produced by MDSCs. Since MDSCs inhibit through
soluble factors, we performed a cytokine array to profile MDSC-derived
molecules. Conditioned medium was generated from FACS isolated MDSCs
(inhibit B cell development) and control CD11b+Gr1+ myeloid cells (do not inhibit
B cell development), then profiled for the concentrations of 23 different factors.
We expected that potential inhibitory factor(s) would be present at higher
concentrations in MDSC-CM than control-CM. Cytokine array analysis showed
that MDSCs produced increased concentrations of IL-1α, IL-1β, IL-13, G-CSF,
KC, MCP, MIP-1α, MIP-1β, and RANTES (Figure 3.9), many of which are
classified as inflammatory cytokines or chemokines known to recruit
inflammatory cells. Alternatively, IL-12(p40) and IL-9 concentrations were higher
in control-CM; ruling out these molecules as the MDSC-derived inhibitory factors.
Additional proteins that were assessed but not detected in MDSC-CM include: IL2, IL-3, IL-5, and GM-CSF. Further IL-2, IL-4, IL-6, IL-10, IL-12(p70), IL-17,
TNFα, and IFNγ were present, but at levels <10pg/ml. For subsequent studies

we focused only on IL-1α, IL-1β, IL-13, G-CSF, KC, MCP, MIP-1α, MIP-1β, and
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RANTES, as these were present in MDSC-CM at higher levels than control-CM.

Figure 3.9 Profile of MDSC-derived soluble factors by cytokine array.
Protein concentrations of the indicated factors as detected by cytokine array in
MDSC-CM or control-CM. Data are from three different MDSC-CM and two
different control-CM generated in individual experiments. Error bars show the
average of the two or three different conditioned media +/- SD. ND= not
detected.
We identified nine factors that were upregulated in MDSC-CM and asked
if any of these molecules inhibit B lymphopoiesis. B lymphopoiesis cultures were
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performed in the presence or absence of each factor (recombinant) individually,
and then the number of B lineage cells was analyzed at the end of culture. We
did not think all nine identified factors would inhibit B cell development, but
perhaps one or two. We expected if any of these molecules have the potential to
inhibit B lymphopoiesis, then BM cultures containing an inhibitory molecule would
result in decreased development of B220+ B lineage cells compared to untreated
cultures. In fact this experiment drastically narrowed our search for MDSCderived inhibitory factors because, of all the molecules assessed, only cultures
containing IL-1α and IL-1β had significantly lower numbers of B220+ B lineage
cells (Figure 3.10 A); suggesting these molecules inhibit B cell development.
Only IL-1α and IL-1β could inhibit when added to B lymphopoiesis cultures
individually, but we also sought to determine if the other seven identified factors
could inhibit when in combination with the others. To test this, we compared the
inhibitory potential of adding all nine factors (IL-1α, IL-1β, IL-13, G-CSF, KC,
MCP, MIP-1α, MIP-1β, and RANTES) to BM cultures in combination or without
IL-1α/β. We know IL-1α/β can inhibit alone, therefore treatment with all nine
factors should result in reduced B lineage development. If the other seven factors
are able to inhibit B lymphopoiesis when combined, we expected adding IL-13,
G-CSF, KC, MCP, MIP-1α, MIP-1β, and RANTES would also inhibit B
lymphopoiesis. However, this did not occur. Cultures containing all nine factors
resulted in the development of significantly fewer B220+ cells compared to
untreated cultures. But treatment of BM cultures with all factors without IL-1α/β
contained a similar number of B220+ cells compared to untreated cultures (Figure

3.10 B). These data suggest that IL-1α and IL-1β are the only molecules
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identified in MDSC-CM with inhibitory activity to B lymphopoiesis.
Do MDSCs inhibit B lymphopoiesis via IL-1? MDSCs produce IL-1α/β
and these cytokines inhibit B lineage development. But is the mechanism by
which MDSCs inhibit mediated through IL-1α/β? Our approach to answer this
question was to neutralize IL-1α/β in B lymphopoiesis cultures containing
MDSCs, and then determine if B lymphopoiesis was restored to untreated levels.
We added MDSCs to B lymphopoiesis cultures in the presence or absence of
anti-IL-1α and anti-IL-1β to neutralize these cytokines. We expected that if IL1α/β were the major inhibitory factors produced by MDSCs, then blocking these
molecules would enhance B lymphopoiesis in cultures containing MDSCs.
Compared to control cultures lacking MDSCs, cultures containing MDSCs
exhibited a significant reduction in the number of B220+ B lineage cells. However
when IL-1α/β was neutralized in cultures containing MDSCs, the number of
B220+ B lineage cells was restored to control levels (Figure 3.10 C). These data
lead us to conclude that MDSCs inhibit B lymphopoiesis via IL-1α/β.
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Figure 3.10 Identification of MDSC-derived inhibitory factors. (A&B) Number
of B220+ cells resulting from B lymphopoiesis cultures treated with the indicated
recombinant cytokine(s) (1ng/ml). (C) Number of B220+ cells resulting from B
lymphopoiesis cultures with or without MDSCs and treated with anti-IL-1α
(1µg/ml) and anti-IL-1β (1µg/ml), or isotype control antibodies where indicated.
Data in (A-C) are representative of three independent experiments. Statistical
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significance in (A) was determined using ANOVA coupled with a Dunnet multiple
comparison test (p<0.0001). Statistical significance in (B & C) were determined
using ANOVA coupled with a Bonferroni multiple comparison test (p<0.0001 and
p=0.001 respectively). Error bars represent the average of triplicate wells +/- SD.

Hematopoietic target of IL-1. The identification that MDSCs inhibit B cell
development via IL-1 has uncovered a novel interaction between MDSCs and
hematopoiesis. But how does IL-1act to inhibit B cell development? We know
that IL-1 treatment of BM cultures results in the development of very few (if any)
B220+ cells. Because B220 is first expressed at the pre-proB cell stage, we
hypothesized that the hematopoietic target of IL-1 treatment is a progenitor prior
to the pre-proB cell stage. Therefore IL-1 must act at the HSC to MPP, MPP to
CLP, or CLP to pre-proB transition. To identify the hematopoietic target of IL-1
we FACS-sorted either HSCs (Lin-Sca1+c-kit+Flt3-), MPPs (Lin-Sca1+c-kit+Flt3+),
or CLPs (Lin-Sca1loc-kitloFlt3+IL-7R+) (Figure 3.11 A) and assessed the ability of
these progenitors to differentiate into B lineage cells on OP9 stromal cells when
treated with IL-1β. We expected that if IL-1β targets CLPs to inhibit B cell
development, for example, then B lymphopoiesis assays seeded with CLPs will
have fewer B220+ B lineage cells develop in IL-1β treated cultures. Interestingly,
IL-1β treatment did not affect the ability of CLPs to differentiate into B220+ B
lineage cells. Flow cytometric analysis of cultures starting with CLPs showed no
difference in the frequency of B lineage cells comparing untreated and IL-1β
treated wells (Figure 3.11 B). Similarly, there was no significant difference in the
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number of

B220+

cells resulting from these cultures (Figure 3.11 C). Alternatively,

analysis of cultures seeded with MPPs resulted in a large reduction in B220+ B
lineage cell frequency (Figure 3.11 D) coupled with a significant decrease in the
number of B220+ B lineage cells in IL-1β treated cultures (Figure 3.11 E). Flow
cytometric analysis of cultures beginning with purified HSCs showed a similar
result to cultures seeded with MPPs upon IL-1β treatment (Figure 3.11 F & G).
Because IL-1β inhibited B lymphopoiesis in both cultures seeded with purified
HSCs and MPPs, this could suggest that IL-1β targets both the HSC and the
MPP. Alternatively, the inhibitory effect observed in cultures of HSCs could be
mediated once HSCs differentiate into MPPs. We conclude that IL-1β treatment
targets early hematopoietic progenitors, likely the MPP, to inhibit B cell
development. IL-1α treatment showed similar results, suggesting these MDSCderived molecules inhibit through the same mechanism. This was also expected
as IL-1α and IL-1β both act through the same receptor on target cells.
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Figure 3.11 Identification of hematopoietic progenitors targeted by IL-1. (A)
B lineage developmental stages and key markers for identification. (B, D&F) Flow
cytometric analysis of cells resulting from B lymphopoiesis cultures starting with
purified (B) CLPs, (D) MPPs, or (F) HSCs. Cultures were performed in the
presence or absence (untreated) of IL-1β and stained with anti-B220 and antiCD19. (C, E, &G) Number of B220+ cells or CD11b+Gr1+ cells resulting from B
lymphopoiesis cultures seeded with (C) CLPs, (E) MPPs, or (G) HSCs and
treated with or without (untreated) IL-1β. Data in (B-G) are representative of three
independent experiments. Statistical significance in (C, E, &G) was determined
by Student’s t test. Error bars represent the average of triplicate wells +/- SD.
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IL-1 treatment acts at the MPP stage to inhibit B lymphopoiesis. But is B
cell development blocked at the MPP stage, or is hematopoiesis re-routed? The
answer to this question came from flow cytometric analysis of myeloid lineage
cells resulting from cultures seeded with HSCs, MPPs, or CLPs (Figure 3.11 C,
E&G). If B lymphopoiesis is blocked at the MPP stage, we expected to find an
accumulation of MPPs in IL-1 treated cultures seeded with HSCs and MPPs.
Alternatively, if IL-1 treatment re-routes hematopoiesis to another lineage, then
we expected to find the accumulation of cells of another hematopoietic lineage
(eg. myeloid lineage) in IL-1 treated cultures. Interestingly, IL-1 treatment of
cultures seeded with HSCs or MPPs resulted in a large significant increase in the
development of CD11b+Gr1+ myeloid cell number. While IL-1 treatment of CLPs
also resulted in an increase in myeloid cells, this increase was small compared to
the number observed in HSC and MPP cultures. Overall, these data suggest that
IL-1 treatment acts at the MPP stage to promote myelopoiesis at the expense of
B lymphopoiesis. Further, we conclude that IL-1 does not block B cell
development, but instead skews hematopoiesis to the myeloid lineage.
In summary, our data suggest that adipocytes inhibit B lymphopoiesis in
vitro by promoting the accumulation of MDSCs. These MDSCs produce IL-1,
which then skews hematopoiesis to the myeloid lineage. While we know that
MDSCs produce IL-1, we do not know what adipocyte factor(s) promote MDSCs.
We also do not know if adipocytes produce only one factor or many factors that
contribute to the loss of B lymphopoiesis, as adipocytes are known to produce
many immunomodulatory factors, such as adiponectin and leptin. Further
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characterization of ACM is needed to understand if adipocytes produce multiple
inhibitory factors and to identify the most critical factors that induce MDSCs.

SECTION 3: CHARACTERIZATION OF ADIPOCYTE-DERIVED MOLECULES
IN THE NEGATIVE REGULATION OF B LYMPHOPOIESIS
The mechanism of MDSC-mediated inhibition of B lymphopoiesis,
elucidated above, is initiated by adipocyte-derived soluble factors. This made us
interested in understanding how adipocyte factors promote MDSC accumulation
and ultimately lead to the loss of B lymphopoiesis. We asked; 1. Do multiple
adipocyte factors contribute to the inhibition of B lymphopoiesis; 2. What
adipocyte-derived molecules are most critical for generating MDSCs; and 3. Can
we target adipocyte factors to prevent MDSC accumulation?
Do multiple adipocyte factors contribute to the inhibition of B
lymphopoiesis?
Adipocytes are capable of producing many factors that modulate the
immune system and other processes throughout the body. Adiponectin is one
adipocyte-derived product known to influence hematopoiesis (Yokota et al.,
2003), but we hypothesized that adipocytes produce additional molecules that
can affect immune cell development. To understand how adipocyte-derived
soluble products negatively regulate B lymphopoiesis as a whole, we decided to
characterize different fractions (based on molecular weight) of ACM. We
expected this would give us a better understanding of how adipocyte products
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lead to the inhibition of B lymphopoiesis and how they lead to the accumulation
of IL-1 producing MDSCs.
To assess the type of inhibitory molecule(s) produced by adipocytes, we
fractionated mouse ACM by size and assessed the inhibitory potential of each
fraction on B lymphopoiesis. ACM was fractionated using a 10kDa filter to
generate ACM <10kDa molecules and ACM >10kD molecules. We reasoned that
if ACM contains multiple inhibitory molecules, then we expect that treatment of B
lymphopoiesis cultures with ACM <10kDa and ACM >10kDa would result in
reduced B lineage development compared to untreated cultures. As expected
total ACM-treated BM cultures resulted in a decreased percentage of B220+ B
lineage cells compared to untreated cultures (Figure 3.12 A). In separate
experiments, treatment with ACM <10kDa (Figure 3.12 B) and ACM >10kDa
(Figure 3.12 C) also resulted in a decreased percentage of B220+ B lineage cells
compared to their respective medium controls. Similar results were obtained
when studying the >10kDa and <10kDa fractions of rabbit ACM (data not shown),
suggesting that ACM contains multiple inhibitory factors of different size.
The above result only indicates that there is more than one inhibitory
factor produced by adipocytes. Naturally, there could be more than one inhibitory
factor in the ACM <10kDa, as well as the ACM >10kDa. Our subsequent
experiments were aimed to further characterize inhibitory molecules in ACM, to
address whether or not they are protein in nature; as this information will guide
attempts to identify ACM-derived molecules.
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Figure 3.12 Effect of <10kDa and >10kDa adipocyte molecules on B
lymphopoiesis. Flow cytometric analysis of B lymphopoiesis cultures performed
in the presence or absence (untreated) of (A) total ACM, (B) ACM <10kDa, or (C)
ACM >10kDa. (A&B) Flow cytometry plots displaying cells stained with anti-B220
and anti-CD14. (C) Flow cytometry plots displaying cells stained with anti-B220
and anti-CD19. Note the different staining scheme in panel (C). For all panels,
total B220+ cells are considered B lineage (49% untreated vs 6% ACM >10kDa in
panel C). Data are representative of at least two or three independent
experiments per fraction.

Are the inhibitory molecules in ACM protein in nature?
Adipocytes can produce both protein and lipid products. To understand
the contribution of these major classes of molecules to the inhibitory effect, we
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proteinase K treated the >10kDa and <10kDa fractions of ACM. We expected
that if proteins are responsible for the inhibitory effect in either of these fractions,
then proteinase K treatment would remove the inhibitory activity of ACM >10kDa
or <10kDa. B lymphopoiesis assays performed with mouse ACM and rabbit ACM
both suggest that adipocytes produce inhibitory factors both protein and nonprotein (likely lipid) in nature (data not shown), as proteinase K treatment
removed the inhibitory activity of >10kDa ACM but not smaller molecule fractions.
This information is critical for developing strategies to purify the inhibitory activity
in ACM. Now that we know the active molecules in ACM <10kDa and ACM
>10kDa have different biochemical make up, we tried to exploit this information to
purify inhibitory molecules.
Purification of adipocyte derived-inhibitory factors
Since ACM >10kDa is protein in nature, we asked if we could purify the
inhibitory molecule(s) via anion exchange chromatography. We used mouse
ACM to purify ACM >10kDa molecules because mouse ACM can be generated
in greater abundance and in less time than rabbit and human ACM. By fast
protein liquid chromatography (FPLC), using a strong anion exchange column
and increasing salt concentration to elute, we separated ACM >10kDa based on
charge (Figure 3.13 A). There was a large protein peak in the column flow
through, suggesting not all ACM proteins bound to the column, and two defined
peaks were observed after elution was started. We collected and concentrated
the effluent into five fractions (4-8) as seen in Figure 3.13 A.
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To assess whether any of the peaks contained inhibitory activity, we
added various column fractions/samples to rabbit B lymphopoiesis assays and
analyzed the percentage of CD79a+ B lineage cells resulting after treatment. If
this strategy was effective in purifying inhibitory molecules, we expect to find
some column samples that contain inhibitory activity and some that do not.
Although the flow through contained a large protein concentration peak, this
fraction did not contain significant inhibitory activity (Figure 3.13 A&B). In
contrast, treatment with samples 6 and 7 resulted in decreased B lineage
development similar to unfractionated ACM treatment (positive control for
inhibition). Therefore the inhibitory activity was in part purified through this
method and could be found in samples 6 and 7.
To see how effective this purification strategy was, we assessed the purity
of the inhibitory fractions. We performed SDS PAGE to separate proteins within
each column sample and visualized the proteins in each fraction after silver
staining. If this strategy effectively purified ACM inhibitory proteins, we expected
samples 6 and 7 would only contain several stained protein bands. As expected,
unfractionated ACM >10kDa contained many protein bands of various sizes
(Figure 3.13 C ACM lane). Although the inhibitory fractions 6 and 7 contained
fewer protein bands, there were still many, suggesting that additional purification
methods will be needed to purify single protein bands (Figure 3.13 C Sample 6,
Sample 7a, 7b, 7c lanes). In sample 6 there was a prominent protein band
between the 75kDa and 50kDa size markers, which was less concentrated in the
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other samples. Additional experiments will be needed to determine the identity of
the corresponding protein and its inhibitory potential.
As seen in Figure 3.13 C, we further divided sample 7 into 3 smaller
fractions (Sample 7a, 7b, and 7c) and found two of the three fractions contained
an inhibitory factor(s) (as indicated with +). Inhibitory activity was determined
similar to that seen in Figure 3.13 B, where each fraction was dialyzed against
cell culture medium then added to rabbit B lymphopoiesis assays at a 1:2
dilution. Further division of sample 7 did not substantially change the number of
protein bands observed after silver staining (Figure 3.13 C sample 7a, 7b, and 7c
lanes), therefore future studies will be needed to obtain more pure samples to
identify single inhibitory factors.
Our attempts to characterize and purify ACM molecules with inhibitory
activity have focused on the overall inhibition of B lymphopoiesis. Because we
found that adipocyte factors induce inhibitory MDSCs, we focused our search to
identify ACM molecules that promote the accumulation of MDSCs.
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Figure 3.13 Purification of inhibitory molecules in ACM >10kDa. Anion
exchange chromatography was performed on msACM >10kDa with increasing
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salt concentration used to elute material from the column. (A) Protein
concentration profile corresponding to fractions collected from the column. Green
arrow marks when linear increasing salt elution (0-1M NaCl) was started.
Collected fractions/samples tested for inhibitory activity in (B) are indicated on
the profile in (A). (B) Percent of maximum B lymphopoiesis resulting from rabbit
BM cultures treated with the indicated samples taken after anion exchange
chromatography of msACM >10kDa. Percent of maximum was calculated by
setting the percentage of CD79a+ cells from “no treatment” cultures to 100%. (C)
Silver stained SDS PAGE gel loaded with the indicated samples. Samples 6, 7a,
7b, and 7c were loaded in anion exchange running buffer. Samples 7a Med, 7b
Med, and 7c Med were dialyzed in alpha mem culture medium, and then loaded
(contain additional medium derived proteins). Inhibitory activity on B
lymphopoiesis is summarized as + (inhibits B lymphopoiesis) or – (does not
inhibit). Precision plus protein standard (BioRad) was used as a size reference
(250kDa, 150kDa, 100kDa, 75kDa (most prominent band mid gel), 50kDa,
37kDa, 25kDa, and 10kDa). Data were obtained only in one experiment but will
provide the basis for future purification strategies.

Which adipocyte-derived soluble factors induce MDSCs?
The above results suggest that adipocytes produce multiple molecules
that negatively regulate B lymphopoiesis. Because ACM promotes the
accumulation of MDSCs that in turn inhibit B lymphopoiesis, we sought to identify
and neutralize the adipocyte-derived molecules responsible for inducing
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inhibitory MDSCs. We hypothesized that preventing the accumulation of MDSC,
would result in enhanced B lymphopoiesis.
To characterize which ACM molecules promote the accumulation of
MDSCs, we used a similar approach as before. We generated ACM <10kDa and
>10kDa fractions, and then compared total ACM, ACM <10kDa, and ACM
>10kDa for the ability to promote CD11b+Gr1+ MDSCs in vitro. Mouse BM
progenitors were cultured with OP9 stromal cells and treated with each ACM
fraction individually, followed by flow cytometric analysis to determine the number
of CD11b+Gr1+ cells resulting after treatment. For example, if ACM >10kDa
molecules are sufficient to promote MDSC accumulation, then we expected that
treatment with total ACM and ACM >10kDa would result in an increased number
of MDSCs compared to untreated cultures. As expected for total ACM-treated
cultures, there was a significant increase in the number of CD11b+Gr1+ cells
compared to untreated cultures (Figure 3.14). ACM >10kDa treatment also
resulted in significantly more CD11b+Gr1+ cells compared to control cultures
(Figure 3.14), while ACM <10kDa treatment contained a similar number of
CD11b+Gr1+ cells compared to untreated controls (Figure 3.14). These results
suggest that an adipocyte factor(s) >10kDa is responsible for generating MDSCs.
For the remainder of studies, we focused on adipocyte factors >10kDa.
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Figure 3.14 Characterization of adipocyte factors for the capacity to induce
CD11b+Gr1+ myeloid cells. Number of CD11b+Gr1+ cells resulting from B220BM cells cultured with OP9 stromal cells in the presence or absence of total ACM
(left), ACM <10kDa (middle), or ACM >10kDa (right). Data are representative of
three independent experiments. Statistical significance was determined using
Students t test. Error bars represent the average of triplicate wells +/- SD.

To identify potential MDSC-promoting adipocyte molecules, we performed
a cytokine array focused on 23 cytokines/chemokines. In this experiment ACM
(inhibits B lymphopoiesis/induces MDSCs) was compared to MDSC-CM (inhibits
B lymphopoiesis) and CD11b+Gr1+ control-CM (does not inhibit B
lymphopoiesis). We expected that MDSC promoting factors would be increased
in ACM as compared to control-CM, because CD11b+Gr1+ control cells do not
induce MDSCs in BM cultures. Interestingly, ACM contained IL-6, IL-12(p40), IL12(p70), IL-13, G-CSF, KC, MCP, TNFα, Eotaxin, MIP-1α, and RANTES (Figure
3.15). Many of these factors are inflammatory in nature, suggesting that
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adipocyte factors produce an inflammatory environment. Additionally, multiple
factors in ACM identified by us (eg. IL-6, IL-13, G-CSF, TNFα, MCP1,
complement C3 [data not shown]) and reported by others to be produced by
adipocytes (eg. S100A8) (Hiuge-Shimizu et al., 2011, Sekimoto et al., 2012) are
known to induce MDSCs (Bunt et al., 2007, Cheng et al., 2008, Drevets et al.,
2004, Gabrilovich and Nagaraj, 2009, Gallina et al., 2006, Hsieh et al., 2013,
Huang et al., 2007, Movahedi et al., 2008, Sawanobori et al., 2008, Sinha et al.,
2008, Terabe et al., 2003, Zhao et al., 2012). Upon identifying that ACM contains
multiple factors known to induce MDSCs, we suggest a combination of these
molecules (rather than one) are likely responsible for the generation of MDSCs
by ACM. This finding is important to consider when developing strategies to
target adipocyte factors.
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Figure 3.15 Profile of adipocyte-derived soluble factors by cytokine array.
Protein concentrations of the indicated factors as detected by cytokine array in
ACM, MDSC-CM, or control-CM. Data are from three different ACM, three
different MDSC-CM and two different control-CM generated in individual
experiments. Error bars show the average of the two or three different
conditioned media +/- SD.
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Can adipocyte factors be targeted to prevent MDSC accumulation?
To develop therapeutics aimed at blocking adipocyte-mediated generation
of MDSCs, we must devise a strategy to target the adipocyte, the MDSC, or
neutralize adipocyte factors. Since ACM is a source of multiple factors able to
induce MDSCs, it would be difficult to identify and block all potential MDSC
promoting factors. An approach to identify and block a common pathway used by
adipocyte-factors to induce MDSCs might be more successful. Cytokine array
analysis of ACM showed that while ACM induces IL-1 producing MDSCs, IL-1
was not detected in the ACM (Figure 3.15), suggesting that a factor (or
combination of factors) in ACM other than IL-1, induces this inflammatory
molecule. Because IL-1 production is induced through inflammasome activation
(Garlanda et al., 2013, Latz et al., 2013) and adipocytes produce NLRP3
inflammasome activators (eg. S100A8, DAMPs) (Coppack, 2001, Nagareddy et
al., 2014, Wen et al., 2011, Youm et al., 2012, Youm et al., 2013), we
hypothesized that blocking the NLRP3 inflammasome would prevent adipocyte
induced MDSC activation/accumulation. To test this we performed BM cultures
treated with ACM >10kDa in the presence or absence of glybenclamide, which
reportedly blocks NLRP3 inflammasome activation and downstream IL-1
production in myeloid cells (Lamkanfi et al., 2009, Henriksbo et al., 2014,
Laliberte et al., 1999, Dostert et al., 2009, Chen et al., 2012, Tavares et al.,
2013). We expected that if ACM induces MDSCs through NLRP3 inflammasome
activation, then blocking this pathway would prevent MDSC accumulation. As
predicted, glybenclamide treatment significantly reduced CD11b+Gr1+ MDSC
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generation compared to cultures containing only ACM >10kDa (Figure 3.16 A
and C). Additionally, because MDSCs negatively regulate B lineage
development, we expected that blocking MDSC accumulation would enhance B
lymphopoiesis in cultures containing ACM >10kDa. Strikingly, as seen in Figure
3.16 B and D, blocking MDSC accumulation did increase B cell development as
evidenced by an increase in B220+ cells. These data suggest that blocking the
NLRP3 inflammasome is potentially an effective strategy to prevent MDSC
accumulation and boost B lymphopoiesis in fatty BM.
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Figure 3.16 Effect of glybenclamide treatment on MDSC accumulation. BM
cultures were performed in the presence of ACM >10kDa with or without
glybenclamide (NLRP3 inflammasome inhibitor). (A&B) Representative flow
cytometric profiles displaying (A) CD11b and Gr1, or (B) B220 and CD19
expression at the end of culture. Percent of (C) CD11b+Gr1+ or (D) B220+ cells
resulting after culture with the indicated treatments. Data are representative of
three to four individual experiments per condition. Significance was determined
by ANOVA in combination with a Bonferroni multiple comparison test (p=0.0005
and p=0.0001 for (C) and (D) respectively). Error bars represent the average of
individual experiments +/- SD.

SECTION 4: CHARACTERIZATION OF RABBIT HEMATOPOIESIS
Through mouse BM cultures, we have uncovered a mechanism where
adipocytes induce inflammatory myeloid cells which inhibit B cell development
through IL-1. This inhibition does not lead to a direct block of B cell development;
rather IL-1 promotes myelopoiesis at the expense of B lymphopoiesis. Because
large amounts of BM fat have been observed in adult rabbit BM, we asked if this
mechanism could be occurring in vivo in rabbits at two to four months of age,
when B lymphopoiesis is lost. If true, we expected to find an accumulation of
adipocytes, increased BM myeloid cell compartment, and increased expression
of IL-1 in the BM of rabbits >2 months of age.
In addition to testing whether or not the mechanism of adipocyte-mediated
inhibition of B lymphopoiesis could be occurring in rabbit BM, we also sought to
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determine if rabbit BM could be studied as an accelerated model of BM aging.
Our laboratory has established that rabbit B lymphopoiesis arrests early in life,
compared to humans and mice. In this study, we characterized rabbit BM to see
if additional changes occurring at two months of age resemble the BM of two
year old mice; the time when B lymphopoiesis declines (Kirman et al., 1998,
Miller and Allman, 2003, Riley et al., 1991, Sherwood et al., 1998, Stephan et al.,
1996). If the BM of >2 month old rabbits resembles that of aged mice, we would
expect to find increased BM fat and an increase in BM myeloid cells at the time B
lymphopoiesis declines; as mentioned in the previous paragraph, these
characteristics would also be consistent with the elucidated mechanism of
adipocyte-mediated inhibition of B lymphopoiesis.
Several studies allude to the abundance of fat in the BM of adult rabbits
(Bigelow and Tavassoli, 1984, Bilwani and Knight, 2012); however, B
lymphopoiesis arrests in rabbits prior to adulthood. It is unknown if adipocytes
accumulate in the BM at the exact timing B lineage development is lost. Jasper et
al. found that rabbit B lymphopoiesis peaks in the first few weeks of life and
arrests by two to four months of age (Jasper et al., 2003). To visualize the
appearance of BM fat at the time B cell development arrests in rabbits, we
sectioned BM from rabbits of various ages followed by H&E staining. If increased
BM fat correlates with the timing B lymphopoiesis is lost in rabbits, then we
expected to find an increase in fat spaces observed in BM sections taken from
>2-4 month old rabbits compared to <2 month old rabbits. As expected,
representative BM from a 3 month old rabbit (a time after B cell development is
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arrested) exhibited an increased number and size of fat spaces compared to
representative BM from a 3 week old rabbit (active B cell development) (Figure
3.17). Interestingly, rabbits older than two to three months (ranging to 13 months
old) also had increased BM fat that appeared similar to that of a two to three
month old rabbit (data not shown). These data suggest that adipocytes
accumulate in rabbit BM at the time B lineage development is arrested. These
data are consistent with increased BM fat found in aged mice (Krings et al.,
2012).
3 week rabbit

3 month rabbit

10x

Figure 3.17 Characterization of bone marrow fat in rabbits. Representative
BM sections generated from femurs of a 3 week old rabbit (left) and a 3 month
old rabbit (right). Sections were H&E stained and visualized for the proportion of
fat (white spaces) vs red marrow (pink and purple staining). Multiple sections and
multiple fields of each section were visualized from each rabbit to obtain
representative images. BM sections analyzed from rabbits >3 months of age had
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a profile similar to the 3 month (right) section shown above. The displayed
images were taken at 10x magnification.

If the mechanism of adipocyte-induced inhibition of B cell development
(elucidated in this dissertation) occurs in the BM of >2 month old rabbits, we
expect this BM would exhibit a myeloid skew. This would also be consistent with
the myeloid skew observed in two year old mice (Enioutina et al., 2011), when B
lymphopoiesis is declining. To test this, we performed flow cytometric analysis on
BM isolated from rabbits of various ages. If hematopoiesis is skewed toward
myelopoiesis in BM of >2 month old rabbits, we expected to find a greater
frequency of CD11b+ myeloid cells in the BM of >2 month old rabbits as
compared to younger rabbits. Interestingly, the percentage of CD11b+ myeloid
cells was increased in the BM of rabbits >2 months old as seen by flow cytometry
(Figure 3.18 A-C). These data suggest that rabbit BM exhibits a myeloid skew at
2 months of age similar to that seen in two year old mice.
Further flow cytometric analysis of the CD11b+ cells from >2 month old
and <2 month old rabbits showed that myeloid cells from >2 month old rabbits
have higher CD11b expression (Figure 3.18 D). This phenotype is similar to
CD11bhiGr1+ ACM-generated MDSCs (Figure 3.3), suggesting these cells may
be similar. If CD11b+ cells from aged BM are similar to ACM-generated MDSCs,
we expect they would be influenced by adipocyte-derived molecules. To
characterize the localization of CD11b+ cells relative to BM adipocytes, we
generated frozen OCT embedded BM sections from <2 month old and >2 month
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old rabbits, stained for

CD11b+

cells and analyzed them by fluorescence

microscopy. If BM CD11b+ cells are influenced by BM adipocytes, we expected
to find CD11b+ cells near BM adipocytes. Consistent with our flow cytometry
data, BM of >2 month old rabbits contained many more cells staining for CD11b
expression, compared to BM of <2 month old rabbits (Figure 3.18 E). Further,
immunofluorescence analysis of BM sections from >2 month old rabbits sections
showed a large proportion of BM CD11b+ cells (Figure 3.18E- green) near large
fat spaces (Figure 3.18E- black). These data suggest that CD11bhi rabbit BM
cells are likely influenced by adipocyte products.
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CD11b

E.

3 week rabbit

3 month rabbit

Figure 3.18 Characterization of rabbit bone marrow before and after two
months of age. (A&B) Flow cytometry profiles of nucleated cells from (A) BM of
<2 month old or (B) >2 month old rabbits. BM cells were analyzed for FSC vs
SSC (left), then for CD11b and CD14 (right) staining. (C) Percentage of BM
CD11b+ cells in <2 month old (circles) and >2 month old rabbits (squares) (total
n=11). (D) Representative flow cytometry profile of CD11b expression in the BM
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CD11b+

cell gate comparing a <2 month old rabbit (young) and a >2 month old

rabbit (old). (E) Fluorescence microscopy analysis of BM sections stained with
Hoechst (blue), anti-CD11b (green), and anti-kappa light chain (red) – very few
cells stained with anti-kappa. (A&B) Data are representative of a panel of 11
rabbits. Data in (E) are representative of a panel of 7 rabbits. Significance in (C)
was determined by Student’s t test. Error bars represent the average percentage
over multiple rabbits per group +/- SD.

We found that ACM-induced MDSCs inhibit B lymphopoiesis through IL-1
production. To further compare BM of >2 month old rabbits to the mechanism of
adipocyte-mediated inhibition of B cell development, we performed qPCR
analysis on rabbit BM cells to assess IL-1 expression. BM was isolated from
rabbits <2 months of age and >2 months of age, followed by qPCR analysis for
IL-1β expression. If IL-1β contributes to the loss of B lymphopoiesis in rabbit BM,
we expected to find increased expression of IL-1β in BM cells isolated from >2
month old rabbits. In fact, qPCR analysis of total rabbit BM showed that IL-1β
expression increased with age (Figure 3.19 A).
If IL-1β is produced by an MDSC-like cell in BM of >2 month old rabbits,
we expected to find IL-1β expression localized to BM myeloid cells. As antiCD11b is the best reagent available to identify myeloid cells in rabbits, we used
this reagent to isolate CD11b+ and CD11b- cells from BM of >2 month old rabbits
by FACS, then performed qPCR analysis for the expression of IL-1β. If IL-1β is
expressed by BM myeloid cells, then we expected CD11b+ cells to express
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higher amounts of IL-1β compared to

CD11b-

cells. As expected, we found IL-1β

was expressed at much higher levels (~30x) in CD11b+ cells (Figure 3.19 B).
Together, these data suggest that BM of >2 month old rabbits exhibits a larger
myeloid compartment compared to younger rabbits, and that these myeloid cells
resemble ACM-generated MDSCs based on CD11b and IL-1β expression.

Figure 3.19 Quantitative PCR anaysis of IL-1β expression in rabbit bone
marrow. (A) Total BM cells from rabbits <2 months and >2months of age. (B)
FACS-sorted CD11b- and CD11b+ populations from BM of >2 month old rabbits.
Each sample was normalized to HGPRT housekeeping gene to determine
relative expression. Data in (A) are calculated from a panel of 7 rabbits. Data in
(B) display the average of 3 independent experiments. Statistical significance in
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(A) was determined by Student’s t test. Error bars represent the average
expression of multiple rabbits per group +/- SD.
SECTION 5: CONTRIBUTION OF THE BONE MARROW
MICROENVIRONMENT TO ALTERED HEMATOPOIESIS IN RABBITS
The arrest of B lymphopoiesis and the myeloid skew seen at 2 months of
age in rabbits could be due to intrinsic changes to hematopoietic progenitors or
due to changes in the BM microenvironment. Due to the large increase in BM fat
and our findings linking adipocytes to the generation of inhibitory myeloid cells,
we hypothesized that the BM microenvironment of >2 month old rabbits
recapitulates the myeloid skew seen in BM of >2 month old rabbits. To test this,
we isolated the adipocyte layer that forms when preparing BM from >2 month old
rabbits and generated conditioned medium from these fat explants (BM fat-CM)
(Figure 3.20 A). We know that the adipocyte layer also contains CD11b+ myeloid
cells that are tightly associated with adipocytes (data not shown); therefore the
factors in BM fat-CM are the combination of adipocyte factors and myeloidderived factors. We expected if this combination of factors is responsible for
decreased B lymphopoiesis and increased myelopoiesis, then rabbit BM cultures
treated with BM fat-CM will have decreased CD79a+ cells and increased CD11b+
cells. As seen in untreated cultures, BM progenitors from >2 month old rabbits
are able to differentiate to the B lineage (Figure 3.20 B), suggesting the
progenitors do not have intrinsic defects. Alternatively, cultures treated with BM
fat-CM had significantly fewer CD79+ B lineage cells and an increase in CD11b+
myeloid cells (Figure 3.20 C-E). These data suggest that the BM
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microenvironment, made up of adipocytes and myeloid cells, is a major
contributor to decreased B cell development and increased myeloid development

-4

+

CD11b cells per wellx10

-4

CD79a cells per wellx10

+

as seen in BM of >2 month old rabbits.

Figure 3.20 Effect of BM fat-CM on rabbit B lymphopoiesis cultures. (A)
Schematic diagram: The adipocyte layer from >2 month old rabbits was isolated
and then cultured 16-24 hours to generate BM fat-CM. BM fat-CM was added to
rabbit B lymphopoiesis cultures and the development of B lineage cells was
assessed. (B&C) Flow cytometry profiles of cells resulting from B lymphopoiesis
cultures with or without (no treatment) BM fat-CM, and analyzed for CD79a and
CD11b expression. (D&E) Number of (D) CD79a+ or (E) CD11b+ cells resulting
from no treatment or BM fat-CM treated cultures. Data are representative of four
independent experiments. Statistical significance in (D&E) was determined using
Student’s t test. Error bars represent the average of triplicate wells +/- SD.
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Do rabbit bone marrow myeloid cells inhibit B cell development?
Through mouse BM cultures treated with ACM, we learned that adipocyte
factors activate myeloid cells to inhibit B lymphopoiesis. The previous experiment
suggests the combination of adipocyte and myeloid-derived factors also
negatively impact B lymphopoiesis in rabbits. We asked if inhibitory myeloid cells
could be isolated directly from BM of >2 month old rabbits. We tested this by
using magnetic beads to isolate CD11b+ myeloid cells from both the BM
adipocyte layer, as well as the adipocyte free BM pellet. The adipocyte-free BM
pellet is called the SFV (stromal vascular fraction) and contains all BM cells that
are not in the adipocyte layer (corresponds to red BM pellet displayed in Figure
3.20 A). These are the BM cells prepared in previous experiments, referred to as
“total BM”, and are the only cells isolated from <2 month old rabbits; as an
adipocyte layer does not form when preparing younger rabbit BM.
While isolation of CD11b+ cells from the SVF pellet can be performed
easily, isolation of hematopoietic cells from the adipocyte layer requires more
effort. This was typically done in one of two ways. The first approach is to culture
BM fat overnight to allow hematopoietic cells to fall out of the floating adipocyte
layer. These hematopoietic cells can then be isolated along with additional cells
that are released from the adipocyte layer after repetitive pipetting. The second
approach is to digest the adipocyte layer with collagenase, which will release
cells that can then be isolated. Both approaches showed similar results in our
hands.
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Reagents to detect Gr1 in mice, are unavailable for rabbits. Therefore we
used CD11b to isolate general BM myeloid cells, reasoning that an inhibitory
population would be contained in a smaller percentage of these cells. We
isolated CD11b+ cells from the BM adipocyte layer and the BM SVF pellet, then
added them to B lymphopoiesis cultures, and assessed the number of B lineage
cells that developed. If BM of >2 month rabbits contains an inhibitory myeloid
population, we expected treatment of BM cultures with CD11b+ cells isolated
from both the BM adipocyte layer and SVF pellet would result in fewer CD79a+ B
lineage cells compared to control cultures. In fact, cultures containing CD11b+
cells isolated from the BM fat layer and SVF pellet had a decreased number of B
lineage cells develop compared to untreated cultures, and cultures containing an
equal number of CD11b- cells isolated from BM fat (Figure 3.21). These results
suggest that a suppressive population within the CD11b+ BM myeloid
compartment is capable of inhibiting rabbit B lymphopoiesis in vitro. We
hypothesize the inhibitory activity in this myeloid population is activated by
adipocyte products in the BM of >2 month old rabbits. Generation of additional
reagents to study rabbit myeloid cells will be critical to characterizing specific
myeloid lineage suppressor cells in BM.
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Figure 3.21 Effect of BM myeloid cells from >2 month rabbits on B
lymphopoiesis in vitro. Rabbit B lymphopoiesis cultures were performed
starting with 10,000 BM progenitors with no effectors (no treatment) or the
indicated number of CD11b- cells from BM fat, CD11b+ cells from BM fat, or
CD11b+ cells from the SVF fraction of BM. Error bars represent the average of
triplicate wells +/- SD. Data were analyzed for statistical significance by ANOVA
coupled with the Dunnet multiple comparison test (p<0.0001). Data are
representative of 3 independent experiments.

Characterization of inflammatory myeloid cells in bone the marrow of >2
month old rabbits
Inflammatory cells that accumulate with age, such as aged B cells, have
been shown to negatively regulate B lymphopoiesis (Ratliff et al., 2013).
Activation of an inflammatory profile in myeloid cells by adipocytes in adipose
tissue has also been reported (Nagareddy et al., 2014, Vandanmagsar et al.,
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2011, Wen et al., 2011, Youm et al., 2012). Because BM of >2 month old rabbits
has increases in adipocytes and myeloid cells, we looked for the presence of
additional inflammatory factors in rabbit BM with age.
Expression of the inflammatory proteins S100A8 and S100A9 is
upregulated in many tissues, including adipose tissue during aging and obesity
(Schiopu and Cotoi, 2013, Sekimoto et al., 2012, Swindell et al., 2013).
Additionally, these factors induce inflammasome activation (Nagareddy et al.,
2014, Simard et al., 2013) and promote MDSCs, which can in turn produce more
inflammatory S100A8 and/or S100A9 (Sinha et al., 2008). We profiled rabbit BM
by flow cytometry using an antibody that recognizes S100A8 and S100A9, to
determine if these proteins are increased in the BM of >2 month old rabbits.
Interestingly, by flow cytometry, we found a population of S100A8/S100A9
expressing myeloid cells that was increased in the BM of older rabbits (Figure
3.22 A&B), suggesting that inflammatory myeloid cells accumulate in rabbit BM
at the time B lymphopoiesis is lost.
The anti-S100A8/S100A9 antibody used to profile rabbit BM by flow
cytometry (described above) does not discriminate between S100A8 and
S100A9, therefore we do not know if the expression of just one or both S100A8
and S100A9 is increased with age. To determine if the expression of S100A8
and/or S100A9 is increased in the BM of >2 month old rabbits we performed
qPCR analysis on rabbit BM cells (BM SVF pellet – without the adipocyte layer).
We expected that both S100A8 and S100A9 expression would be increased in
the BM of >2 month old rabbits. To our surprise, analysis of S100A8 expression
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was similar between young and older rabbits (Figure 3.22 C), whereas S100A9
expression was increased in the BM of rabbits >2 months of age (Figure 3.22 D).
We conclude that S100A9 expressing myeloid cells are increased in the BM of
>2 month old rabbits.

Figure 3.22 Characterization of S100A9+ myeloid cells in rabbit bone
marrow. (A) Flow cytometry profile of rabbit BM nucleated cells stained with antiCD11b (surface) and anti-S100A8/A9 (intracellular). (B) Percent of
CD11b+S100A8/A9+ cells in nucleated BM cells from <2 month (circles) and >2
month (squares) old rabbits. (C&D) qPCR analysis of total BM nucleated cells
from <2 month and >2 month old rabbits analyzed for the expression of (C)
S100A8 and (D) S100A9. Expression was normalized to HGPRT housekeeping
gene. For data in (B) n=12 rabbits total. Error bars represent the average of each
population of rabbits +/- SD. (C-D) Data are the average of three independent
experiments. Error bars represent the average of three experiments +/- SD. (B-D)
Statistical significance was determined by Student’s t test.
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S100A9 and the inhibition of B lymphopoiesis
S100A9 is known for its potent inflammatory properties, but it is unknown
if this molecule negatively regulates B lymphopoiesis. Because expression of this
molecule is increased in BM of >2 month old rabbits (when B lymphopoiesis is
arrested), we hypothesized that S100A9 negatively regulates B lymphopoiesis.
To test this, we treated mouse B lymphopoiesis cultures with recombinant
S100A9, and then assessed the number of B220+ B lineage cells resulting from
these cultures. We expected that if S100A9 inhibits B cell development, then
cultures containing S100A9 will have fewer B220+ cells develop compared to
controls. Flow cytometric analysis of cultures treated with S100A9 exhibited a
decreased percentage and number of B220+ B lineage cells compared to
untreated cultures (Figure 3.23 A-C). In addition to decreased B lineage
development, S100A9 treatment resulted in significantly more CD11b+Gr1+
myeloid cells (Figure 3.23 D-F), reminiscent of cultures treated with IL-1. We
conclude that S100A9 inhibits B lymphopoiesis and promotes myeloid cell
development/survival.
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Figure 3.23 Effect of S100A9 on B lymphopoiesis in vitro. Mouse B
lymphopoiesis cultures of B220- BM progenitors with OP9 cells were performed
in the presence or absence (no treatment) of recombinant S100A9. Flow
cytometry profiles displaying (A&B) B220 and CD19, (D&E) CD11b and Gr1.
(C&F) Number of (C) B220+ cells or (F) CD11b+Gr1+ cells resulting from cultures
treated with the indicated amount (bar graphs) or 5µg/ml (flow cytometry plots) of
S100A9. Data are representative of 3 independent experiments. Statistical
significance in (C&F) was analyzed by ANOVA coupled with the Dunnet multiple
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comparison test (p<0.0001 and p<0.0001 respectively). Error bars represent the
average of triplicate wells +/- SD.
Hematopoietic target of S100A9
We showed for the first time that S100A9 negatively regulates B
lymphopoiesis. Because S100A9 is an inflammatory molecule, like IL-1, we
asked if S100A9 inhibits in a similar manner. We set out to identify the
hematopoietic target of S100A9 treatment. If the mechanism of inhibition mirrors
that of IL-1 mediated inhibition, we expect S100A9 alters the differentiation
potential of MPPs. To test this, we cultured FACS-sorted HSCs, MPPs, or CLPs
(Figure 3.24 A) with OP9 cells in the presence or absence of S100A9 treatment.
To our surprise, the number of B220+ B lineage cells resulting after S100A9
treatment did not differ from untreated cultures seeded with HSCs, MPPs, or
CLPs (Figure 3.24 B). We conclude that neither HSCs, MPPs, nor CLPs are the
the direct target of S100A9 treatment.
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Figure 3.24 Impact of S100A9 treatment on hematopoietic progenitors. (A) B
lineage developmental stages and key markers for identification. (B) Number of
B220+ cells resulting from B lymphopoiesis cultures seeded with HSCs, MPPs, or
CLPs and treated with or without (untreated) S100A9. Data are representative of
three independent experiments. Statistical significance was determined by
Student’s t test. Error bars represent the average of triplicate wells +/- SD.

The finding that S100A9 treatment does not act on HSCs, MPPs, or CLPs
raised several questions. If early hematopoietic progenitors (with B lineage
potential) are not the target of S100A9 mediated inhibition, what cell type is?
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Also, if S100A9 does not inhibit B lymphopoiesis in cultures of purified HSCs,
how did inhibition occur in previous B lymphopoiesis assays? We were able to
answer these questions after comparing the methodology used in the experiment
shown in Figure 3.23, and in S100A9 treatment of individually purified
hematopoietic progenitors (Figure 3.24).
In B lymphopoiesis cultures that were inhibited by S100A9 (Figure 3.23),
the starting population of cells was B220- BM, which contains a mix of non-B
lineage BM progenitors including HSCs, MPPs, etc. In addition to early
progenitors, B220- BM also contains a population of CD11b+Gr1+ myeloid
progenitors (without suppressive activity) that either do not survive in B
lymphopoiesis promoting conditions or differentiate into normal mature myeloid
lineage cells. This information coupled with a study that found S100A9 treatment
induces pro-inflammatory cytokine production from mature myeloid cells in
human peripheral blood (Simard et al., 2013), led us to ask whether immature
myeloid cells could also respond in a similar manner. To test this, we isolated
CD11b+Gr1+ myeloid cells from healthy mouse BM using magnetic beads (Figure
3.25 A), treated these cells with S100A9 and used qPCR to analyze the
expression of inflammatory mediators known to inhibit B lymphopoiesis (IL-1β,
NLRP3, IL-6, and TNFα) at various time points after treatment. If S100A9 inhibits
B lymphopoiesis by inducing the production of inhibitory molecules from
otherwise normal CD11b+Gr1+ BM myeloid progenitors, we expected S100A9
treatment would induce increased expression of IL-1β, NLRP3, IL-6, and TNFα in
these cells. Interestingly, S100A9 treatment induced an early burst in expression
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of IL-1β, NLRP3, IL-6, and TNFα. Increases were observed as early as 2 hours
after treatment, peaking at the 4 hour time point for most of these molecules.
Several novel conclusions can be drawn from this experiment. First, BM
CD11b+Gr1+ myeloid progenitors have the appropriate machinery to respond to

S100A9 treatment, similar to that seen in mature human peripheral blood myeloid
lineage cells. Second, S100A9 treatment induces otherwise normal myeloid
progenitors to express inflammatory mediators known to negatively regulate B
lymphopoiesis. Finally, this result (induction of IL-1) suggests that S100A9mediated inhibition also feeds into the mechanism previously described for IL-1.
This explains why S100A9 treatment (similar to IL-1 treatment) induces
myelopoiesis and the loss of B lymphopoiesis.
Overall, our analysis of rabbit BM led/leads us to: 1. Suggest the
mechanism of adipocyte-mediated inhibition of B lymphopoiesis (elucidated in
mouse BM cultures) contributes to the arrest of B cell development in rabbits; 2.
Identify similarities between BM of >2 month old rabbits and two year old mouse
BM (to be discussed further); and 3. Identify S100A9 as a negative regulator of B
lineage development.
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Figure 3.25 Effect of S100A9 treatment on bone marrow myeloid cells. (A)
Flow cytometry profile of mouse BM CD11b+Gr1+ myeloid cells after anti-CD11b
magnetic bead isolation, and prior to treatment with S100A9 (5µg/ml). (B-E)
qPCR analysis of CD11b+Gr1+ BM cells either no treatment, or treated with
S100A9 for the indicated amount of time. Following treatment the resulting cells
were analyzed for the expression of (B) IL-1β, (C) NLRP3, (D) TNFα, and (E) IL6. Data are representative of three independent experiments.

CHAPTER IV
DISCUSSION
The findings in this study provide mechanistic insight into the negative
regulation of B lymphopoiesis by adipocytes. We have found that adipocytes
produce soluble factors that promote the accumulation of MDSCs (Figure 4.1).
As described for the first time, these MDSCs have the ability to potently inhibit B
lymphopoiesis. B cell development does not appear to be directly blocked by
MDSCs, instead MDSC-derived IL-1 acts at the MPP stage in development
driving myelopoiesis at the expense of B lymphopoiesis.
Our characterization of rabbit BM suggests the above mechanism could
contribute to the loss of B lymphopoiesis that occurs at two to four months of
age. These findings also lead us to propose the rabbit as an accelerated model
to study changes in the BM that result in the decline of B lymphopoiesis occurring
in mid to late life in humans and mice. We propose that our observations can be
applied to situations that result in adipocyte accumulation in the BM, such as
aging and obesity (Adler et al., 2014, Chinn et al., 2012, Justesen et al., 2001,
Lecka-Czernik et al., 2010, Luo et al., 2015, Rosen et al., 2009, Tuljapurkar et
al., 2011), and will provide the basis for therapeutics aimed at boosting B
lymphopoiesis in these scenarios.
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Figure 4.1 Model of Adipocyte-mediated inhibition of B lymphopoiesis.
Hematopoiesis in healthy BM is characterized by a balance of lymphoid and
myeloid cell production. This balance is lost with an increased number of
adipocytes in the BM. Adipocytes secrete inflammasome activators leading to the
accumulation of MDSCs. Adipocyte factor induced-MDSCs produce IL-1, which
acts at the MPP stage to promote myelopoiesis resulting in the loss of B
lymphopoiesis. Adapted from Kennedy and Knight, 2015.

The bone marrow microenvironment and the arrest of rabbit B
lymphopoiesis
The decline of B lymphopoiesis in aging mice has been attributed to both
intrinsic changes in hematopoietic progenitors and extrinsic changes to the BM
microenvironment (reviewed in chapter I). Our study suggests that the arrest of B
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lymphopoiesis in rabbits is primarily mediated through extrinsic changes to the
BM microenvironment. Through analysis of BM sections from rabbits of various
age, we found that adipocytes accumulate by 3 months of age (Figure 3.17).
While it was known that adult rabbits contain significant amounts of BM
adipocytes (Bigelow and Tavassoli, 1984), B lymphopoiesis is lost before
adulthood. Our observation is the first to suggest that the accumulation of BM
adipocytes occurs in the same time frame that B lymphopoiesis arrests in rabbits
(by two to four months of age) (Jasper et al., 2003); suggesting adipocyte factors
could negatively regulate B lymphopoiesis.
Isolation of BM fat from >2 month old rabbits and the observation that BM
fat-CM inhibits B lymphopoiesis in rabbit B lymphopoiesis assays (Figure 3.20)
further implicates that the microenvironment negatively regulates B
lymphopoiesis in >2 month old rabbits. In fact, adipocyte layers are not found in
the BM of <2 month old rabbits (Figure 3.20 A), suggesting the inhibitory
component of the microenvironment is only found in older rabbits. Additionally,
hematopoietic progenitors from >2 month old rabbits robustly differentiate into B
lineage cells in BM cultures, suggesting they are normal. Complementary to our
findings, Kalis et al. performed an adoptive transfer study in rabbits to understand
if intrinsic or extrinsic mechanisms regulate the loss of B lymphopoiesis. BM from
>2 month old GFP+ rabbits was transferred into young irradiated recipients, and
then the generation of B lineage cells from GFP+ BM was assessed. Consistent
with our results, GFP+ hematopoietic cells from the BM of older rabbits were able
to differentiate into B lineage cells after transfer into young recipients (Kalis et al.,
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2007), suggesting that BM progenitors from >2 month old rabbits retain the
potential to differentiate to the B lineage. These data lead us to conclude that B
cell development is inhibited by the BM microenvironment of >2 month old
rabbits.
We described a mechanism in which adipocytes produce negative
regulators to inhibit B lymphopoiesis. But the accumulation of BM adipocytes can
lead to decreased B cell development via other means as well. In addition to
producing negative regulators, the accumulation of adipocytes in the BM of
humans, mice, and rabbits during aging and obesity could impair B
lymphopoiesis by disrupting the normal supportive capacity of the
microenvironment. For example, MSCs from rabbit BM were found to have a
decreased propensity to differentiate into osteoblasts (actively support B cell
development) and increased ability to differentiate into adipocytes (actively inhibit
B cell development) starting at two months of age (Bilwani and Knight, 2012).
While we showed the increase in adipocytes adds negative regulators to the BM
environment, the loss of osteoblasts alone would result in decreased support for
B cell development. Further evidence for this notion comes from a study of mice
fed a high fat diet. These mice exhibited increased BM adipocytes and reduced B
cell development (Adler et al., 2014). Molecules produced by adipocytes were
not addressed in this study, but the authors suggested that an increased number
adipocytes in the BM physically disrupted the normal supportive niche. While the
loss of supportive cells in the BM microenvironment contributes to the loss of B
cell development, this dissertation focused on adipocyte-derived negative
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regulators that actively inhibit B cell development, as adipocytes have only
recently been appreciated for their ability to modulate the immune system.
Adipocytes and the accumulation of inhibitory myeloid-derived suppressor
cells
Through mouse BM cultures, we found that adipocytes produce a
combination of molecules that induce MDSC generation. MDSCs are a
population of immature myeloid cells identified by the markers CD11b and Gr1,
and commonly found to accumulate in cancers (Gabrilovich and Nagaraj, 2009).
Most studies of MDSCs highlight their well-known ability to suppress T cell
responses (Gabrilovich and Nagaraj, 2009, Talmadge and Gabrilovich, 2013).
Important for this suppression, MDSCs co-express the effector molecules
arginase and iNos. Expression of these enzymes can be used to differentiate
MDSCs from mature inflammatory M1 macrophages and anti-inflammatory M2
macrophages, as M1 macrophages only express iNos and M2 macrophages only
express arginase (Gabrilovich and Nagaraj, 2009).
MDSCs come in two varieties; monocytic MDSCs (CD11b+Ly6C+y6G-)
and granulocytic (CD11b+Ly6Cloy6G+) MDSCs (Gabrilovich and Nagaraj, 2009,
Youn et al., 2008). By flow cytometric and microscopy analysis we found that
adipocyte factors primarily promote the accumulation of monocytic MDSCs
(Figure 3.5).
The majority of MDSC studies focus on MDSCs in the context of T cell
responses. While a few studies of MDSCs interacting with other cell types exist
(Green et al., 2013, Green et al., 2015, O'Connor et al., 2015, Zhu et al., 2012), a
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thorough understanding of these interactions is lacking. Therefore our finding that
MDSCs inhibit B lymphopoiesis is novel (Figure 3.6). Even more interesting is the
mechanism by which they inhibit B cell development. ACM-generated MDSCs
co-express large levels of arginase and iNos (Figure 3.4) and, similarly to classic
MDSCs, utilize these enzymes to suppress CD4+ and CD8+ T cell proliferation
(Figure 3.7 B&C). Arginase and iNos use L-arginine as a substrate, and as T
cells need L-arginine to proliferate, depletion of this amino acid is one way in
which MDSCs suppress through these enzymes (Gabrilovich and Nagaraj,
2009). Further, over expression of arginase in transgenic mice resulted in
arginine deficiency and impaired B cell development (de Jonge et al., 2002).
Together these data suggest that MDSCs could inhibit B cell development
through arginase and iNos. However we found that ACM-generated MDSCs do
not inhibit B lineage development via these enzymes (Figure 3.7A).
MDSCs and the production of IL-1. MDSCs inhibited B lymphopoiesis
not by arginase or iNos, but by producing IL-1 (Figure 3.10). This finding
suggests that adipocytes induce inhibitory MDSCs with an inflammatory profile,
which was confirmed through cytokine array analysis of MDSC-CM (Figure 3.9).
IL-1 is a potent inflammatory molecule that was previously described to inhibit B
lymphopoiesis (Dorshkind, 1988a, Hirayama et al., 1994), although the
hematopoietic target was unknown until now. In BM cultures we found that IL-1
treatment promoted myelopoiesis, whereas B lymphopoiesis was lost in cultures
starting with HSCs and MPPs. In contrast, B cell development in cultures seeded
with CLPs appeared to be unaffected by IL-1 treatment. Because IL-1 treated
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HSC and MPP cultures exhibited this effect, IL-1 treatment likely acts on the
MPP to promote myeloid development. IL-1 has been shown to expand HSCs
(Ueda et al., 2009), but it is unknown if differentiation potential is affected before
the MPP stage. In addition to modulating expansion/differentiation of HSCs and
MPPs, IL-1 has been reported to act on additional cells in the BM
microenvironment. IL-1 promotes myelopoiesis in myeloid progenitors
(Nagareddy et al., 2014), as well as alters the secretion profile of BM stromal
cells. IL-1 induces BM stromal cells to produce GM-CSF, G-CSF, and M-CSF
which further inhibit B lymphopoiesis and amplify myelopoiesis (Billips et al.,
1990, Dorshkind, 1988a, Dorshkind, 1988b, Ueda et al., 2009). We conclude that
IL-1 is a master regulator of inflammation with multiple targets in the BM, and as
supported by a simple in vivo injection of IL-1 into mice (Ueda et al., 2004), this
molecule specializes the BM for myeloid development.
Rabbit bone marrow: An accelerated model of bone marrow aging.
Consistent with the above studies and our finding that adipocyte factors promote
IL-1 production, rabbit BM also exhibits increased expression of IL-1 in >2 month
old rabbits (Figure 3.19). This timing correlates with an accumulation of BM
adipocytes (Figure 3.17), the arrest of B lymphopoiesis (Jasper et al., 2003), and
an increased BM myeloid compartment that appears to be the source of IL-1
expression (Figure 3.19).
The characterization of rabbit BM starting at two months of age appears to
share multiple characteristics with BM from aged (2 years old) mice. Consistent
with our observations of BM from >2 month old rabbits, 2 year old mice have
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increased BM fat (Krings et al., 2012), declining B lymphopoiesis (Kirman et al.,
1998, Miller and Allman, 2003, Riley et al., 1991, Sherwood et al., 1998, Stephan
et al., 1996), and an expanded myeloid compartment (Enioutina et al., 2011). We
conclude that the rabbit is an accelerated model to study how changes in the BM
microenvironment affect hematopoiesis, as occurs in aged mice and presumably
elderly humans. In fact, the accumulation of BM fat in rabbits appears to mimic
that of elderly humans, where 40-50% of the proximal femur and 70% of the tibia
fill with adipose tissue (Li et al., 2013); further suggesting that rabbits are a good
model to understand these changes that occur later in life for humans and mice.
The mechanisms contributing to the arrest of B lymphopoiesis in rabbits
appear to be in contrast to intrinsic defects in hematopoietic progenitors, which
have been found, in part, to contribute to the decline of B lymphopoiesis in mice
(Rossi et al., 2005, Stephan et al., 1997, Sudo et al., 2000). Because the arrest
of rabbit B cell development is primarily due to changes in the BM
microenvironment (Figure 3.20 and Kalis et al., 2007), we suggest that the rabbit
is a great model to study the extrinsic regulation of B lymphopoiesis in the
absence of hematopoietic progenitor defects, which could confound results.
Our characterization of rabbit BM at the time when B lymphopoiesis is lost
(increased adipocytes, increased myeloid compartment, increased IL-1β
expression), implies that the mechanism of adipocyte-mediated inhibition of B
lymphopoiesis (elucidated in mouse BM cultures) could be occurring in rabbits by
two months of age. Similar to our studies of ACM and inhibitory MDSCs, we
found that rabbit BM fat-CM (contains factors from both adipocytes and myeloid
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cells) inhibits B cell development and promotes myelopoiesis in rabbit BM
cultures (Figure 3.20). Further, we identified an inhibitory myeloid population in
rabbit BM (Figure 3.21), that we suggest contains rabbit MDSCs. Additional
studies and reagents will be needed to confirm these observations in vivo and to
further characterize rabbit BM subpopulations.
Bone marrow suppressor cells and declining B cell development
BM stromal cells are commonly referred to as major component of the BM
microenvironment. Therefore changes to BM stromal cells are usually attributed
to changes in hematopoiesis (eg. decreased osteoblasts and increased
adipocytes). While BM stromal cells are important to the regulation of B
lymphopoiesis, our work highlights the contribution of additional cell types in the
BM microenvironment.
Our work has implicated MDSCs in the inhibition of B lymphopoiesis. We
expect in scenarios where MDSCs are present in the BM, B lymphopoiesis will
be negatively regulated. Interestingly, Enioutina et al. found that MDSCs are
increased in the BM of 22 month old mice (Enioutina et al., 2011), the time when
B lymphopoiesis is impaired (Kirman et al., 1998, Miller and Allman, 2003, Riley
et al., 1991, Sherwood et al., 1998, Stephan et al., 1996), and increased fat is
observed in the BM (Krings et al., 2012). MDSCs from the BM of aged mice were
found to have increased suppressive activity in T cell proliferation assays and
respond to inflammatory stimuli more robustly, compared to CD11b+Gr1+ myeloid
cells isolated from young BM (Enioutina et al., 2011). We suggest it is possible
that inflammatory molecules derived from BM fat (which is increased and has
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different properties in aged BM) (Krings et al., 2012) during aging could influence
these MDSCs to produce pro-inflammatory molecules that inhibit B cell
development.
It is unknown whether MDSCs isolated from the BM of aged mice inhibit B
lymphopoiesis, but the identification of an inhibitory myeloid population in the BM
of >2 month old rabbits (Figure 3.21) suggests it is possible. The idea that
MDSCs inhibit B lymphopoiesis is novel, and it is very interesting to think of how
this finding fits into the field as a whole. In fact our work is complemented very
well by a series of studies by Soderberg and colleagues, who identified two types
of suppressor cells in rabbit BM in the 1980’s.
One of the suppressor cells identified in rabbit BM was described as
having adherent properties and macrophage-like morphology (Soderberg,
1984a). These cells appear similar to the mouse monocytic MDSCs identified
after ACM treatment (Figure 3.5), and could be the suppressive population we
found to be contained within the rabbit CD11b+ BM fraction (Figure 3.21); as
CD11b is a common marker for macrophages.
Soderberg defined rabbit BM macrophage-like cells as suppressors based
on the ability to suppress BM responses to immune complex stimulation
(Soderberg, 1984a). While the target of this suppression is unknown, immune
complex stimulation has been reported to act on B lineage cells (Morgan and
Weigle, 1983). Additional studies and reagents will be needed to further
characterize the myeloid lineage suppressor cells identified by both Soderberg
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and our study, to determine the exact mechanism(s) of suppression (target cells
and effector molecules).
The other suppressor cell identified in rabbit BM was described as nonadherent, FcRγ+, and complement receptor negative (Soderberg, 1984a,
Soderberg, 1984b). These cells exhibited the ability to suppress baseline
proliferation of BM cells and could suppress T cell responses (Soderberg, 1985).
The mechanism in which they suppress T cells is through blockade of IL-2 (Maes
et al., 1988). Alternatively, the mechanism by which these cells suppress BM cell
proliferation is unknown. The authors suggest these are likely suppressor
lymphocytes of the B, T, or NK lineage, ruling them out as potential MDSCs.
Future studies are needed to determine the exact lineage of non-adherent
FcRγ+ BM suppressor cells. If they are of the B lineage, these could be IL-10producing Bregs (Tedder, 2015) or possibly inflammatory TNF-producing aged B
cells (ABCs) (Ratliff et al., 2013). In aged mice, ABCs were found to inhibit B cell
development through the production of TNF (Ratliff et al., 2013), a potent
inflammatory molecule known to synergize with IL-1 to induce granulopoiesis
(Ueda et al., 2004). In addition to adipocyte factors, it is possible that TNF
producing ABCs also promote IL-1 producing MDSCs in aged BM, as TNF is
known to promote MDSC accumulation (Zhao et al., 2012). Overall, our study in
combination with the referenced studies, highlight the importance of
hematopoietic lineage suppressor populations in the regulation of the BM state.

144

Inflammation and the regulation of lymphopoiesis
The BM as a source of inflammatory factors. The presence of systemic
inflammatory factors, such as IL-6, TNFα, and IL-1, is a hallmark of aging and
obesity (Baylis et al., 2013, Jung and Choi, 2014, Vasto et al., 2007). For
example, a study examining obese mice identified visceral adipose tissue as a
source of IL-1 and proposed that IL-1 can travel systemically to promote
myelopoiesis in the BM (Nagareddy et al., 2014). In addition to the increase in
systemic inflammatory factors, our study leads us to propose that the BM
microenvironment could become a local source of IL-6, TNFα, and IL-1, which
inhibit B lymphopoiesis (Figure 3.10, Dorshkind, 1988a, Hirayama et al., 1994,
Maeda et al., 2005, Maeda et al., 2009, Ratliff et al., 2013, Ueda et al., 2004).
This idea is supported by studies that suggest inflammatory cells accumulate in
the BM during aging and obesity. In fact, adipocytes accumulate in the BM during
aging and obesity (Adler et al., 2014, Krings et al., 2012), and can act as a
source of IL-6 (Figure 3.15 and Fried et al., 1998, Van Snick, 1990). TNF
producing ABCs also increase in the BM during aging (Ratliff et al., 2013), as do
MDSCs (Enioutina et al., 2011), which we suggest could be a source of IL-1 in
fatty BM. Overall, we propose that the presence of these cells make the BM
microenvironment a local source of inflammatory factors that alter hematopoiesis,
as well as a source of factors that potentially contribute to the increased systemic
inflammation seen in aging and obesity.
The effect of inflammasome activation on lymphopoiesis. A major
pathway shown to contribute to the inflammation observed in aging and obesity is
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through inflammasome activation (Vandanmagsar et al., 2011, Youm et al.,
2013). The NLRP3 inflammasome, for example, is critical for integrating danger
signals that accumulate during aging and obesity, and for triggering active IL-1
production by myeloid lineage cells. Since adipocyte-derived molecules induce
IL-1 producing myeloid cells (Figure 3.9), it is logical that inflammasome
activation is involved in the adipocyte-mediated induction of MDSCs and the loss
of B lymphopoiesis. In fact, blocking the NLRP3 inflammasome with
glybenclamide prevented MDSC accumulation, and effectively boosted B
lymphopoiesis (Figure 3.16). These data suggest that targeting the
inflammasome pathway, instead of individual molecules produced by adipocytes,
could be an effective means to enhance the production of naïve B cells.
One limitation of the above finding is that this experiment was only
performed in vitro. Additional studies will be needed to determine the
effectiveness of blocking the NLRP3 inflammasome in vivo. However, a study of
T lymphopoiesis and aging found that blocking the NLRP3 inflammasome in vivo
prevented thymic atrophy and the decline of T lymphopoiesis (Youm et al., 2012).
Similar to our findings, the authors suggested that adipocyte-derived
inflammasome activators initiated the decline of T lymphopoiesis, and could be
prevented through blockade to the NLRP3 inflammasome. These data, in
combination with our study, implicate NLRP3 inflammasome activation in the
negative regulation of both B and T lymphopoiesis.
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S100A9 and the amplification of inflammation
Characterization of BM from >2 month old rabbits allowed us to identify a
previously unrecognized negative regulator of B lymphopoiesis. We found that
S100A9+ myeloid cells increase in the BM of >2 month old rabbits (Figure 3.22),
which is consistent with studies that found increased expression of S100A8 and
S100A9 during aging and obesity (Sekimoto et al., 2012, Swindell et al., 2013).
While the expression of these inflammatory proteins increase in many tissues
with age (Sekimoto et al., 2012), it was unknown whether S100A8 and S100A9
also increase in the BM. Interestingly, we found that S100A9 increases in the BM
of >2 month old rabbits, correlating with increased BM fat and the loss of B cell
development.
We identified that S100A9 expression increases in the BM of >2 month old
rabbits by analyzing the SVF BM pellet containing BM cells separated from the
adipocyte layer. As S100A8 and S100A9 are known to be expressed by adipose
tissue, one possibility why we did not find increased expression of S100A8 could
be because we did not assay mature adipocytes. Consistent with this idea, a
recent study found while S100A8 and S100A9 are expressed in adipose tissue,
S100A8 expression was primarily from adipocytes and S100A9 expression came
from the SVF pellet (containing myeloid cells) (Sekimoto et al., 2012). In fact, we
suggest S100A8 does contribute to the adipocyte-induced inhibition of B
lymphopoiesis, as S100A8 is expressed by 3T3.L1 adipocytes (Hiuge-Shimizu et
al., 2011, Sekimoto et al., 2012), which we used as a source of ACM. Further,
S100A8 has been implicated in NLRP3 inflammasome activation (Simard et al.,
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2013) and MDSC induction (Sinha et al., 2008). Future studies will be needed to
confirm the contribution of S100A8 to adipocyte-mediated inhibition of B
lymphopoiesis.
The ability of S100A9 to inhibit B lymphopoiesis (Figure 3.23) further
supports the idea that inflammatory factors negatively regulate B cell
development. It was very interesting to us that S100A9 did not act on HSCs or
MPPs like IL-1 (Figure 3.24), but instead induced the expression of IL-6, TNF,
and IL-1β in BM myeloid progenitors (Figure 3.25). One interpretation of these
data is that S100A9 acts to amplify inflammation, a known role of S100A9 in
inflammatory processes (Cesaro et al., 2012). In fact one study found that while
S100A9 monomers are relatively unstable, stimulation of cells with the
inflammatory factors IL-1β and TNFα resulted in the formation of S100A9
homodimers that were incredibly stable and resistant to proteolytic digestion
(Riva et al., 2013). In combination with our findings, these data suggest S100A9
inhibits B lymphopoiesis indirectly acting through BM myeloid cells to amplify the
production of inflammatory factors that in turn inhibit B cell development.
Therapeutic strategies to boost B lymphopoiesis during aging and obesity
Our study has uncovered multiple targets for intervention to enhance B
lymphopoiesis in scenarios with fatty BM. The mechanism we identified can be
targeted at the level of the adipocyte, the MDSC, or at the downstream effector
molecules. Below are potential strategies that can be used individually, or in
combination, to target each step in the mechanism of adipocyte-mediated
inhibition of B cell development.
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Targeting the adipocyte
Calorie restriction. Adipocytes induce the mechanism of inhibition
described in this dissertation, and we suggest targeting adipocytes has the
potential to prevent all downstream events leading to inhibition. One mechanism
to target the adipocyte is through diet and exercise.
Calorie restriction was shown to be beneficial in the prevention of thymic
atrophy and the decline of T cell development. Calorie restriction delayed thymic
decline, while obesity accelerated this decline (Yang et al., 2009a, Yang et al.,
2009b). Additionally, one study found that high fat diet resulted in increased
adipocytes in the BM and reduced B cell development (Adler et al., 2014),
implying that calorie restriction might be beneficial to boost B lymphopoiesis.
Alternatively, calorie restriction appears to regulate the thymus and BM
marrow differently. Several studies in humans and mice found that calorie
restriction actually increased BM fat (Bredella et al., 2009, Cawthorn et al., 2014,
Devlin et al., 2010). Further, Cawthorn et al. found that during calorie restriction
BM adipose tissue expands and becomes the primary systemic source of
adiponectin (Cawthorn et al., 2014), a factor known to inhibit B cell development
(Yokota et al., 2003). Although adiponectin is an anti-inflammatory molecule
which might offset the negative regulation of B lymphopoiesis through
inflammatory factors, it is unknown if calorie restriction will restore B
lymphopoiesis in the presence of adiponectin.
Exercise. While calorie restriction increases BM fat, exercise was found to
reduce BM adipose tissue volume. In fact, Styner et al. found this to be true in

149

healthy as well as obese mice (Styner et al., 2014). The BM adipose tissue
reducing effects of exercise are probably due to mechanical stimulus. For
example in rabbits, Bilwani and Knight found that older rabbit MSCs were more
prone to differentiate into adipocytes (inhibit B cell development) instead of
osteoblasts (support B cell development) (Bilwani and Knight, 2012). Exercise
could reverse this effect as a study in mice found that in vivo mechanical
stimulation of MSCs promoted MSC differentiation into osteoblasts instead of
adipocytes (Rubin et al., 2007). Consistent with this observation mechanical
stimulation of MSCs was found to decrease PPAR-γ signaling, which is critical for
adipocyte differentiation (Case et al., 2013). Mechanical stimulus also negatively
regulates adipocyte differentiation by increasing β-catenin levels (Case et al.,
2010, Sen et al., 2008). Because β-catenin levels are induced downstream of
WNT receptors and MSCs from older rabbits have decreased expression of
frizzled 4 (WNT receptor), exercise could be beneficial to prevent/reduce
adipocyte accumulation in rabbit BM.
Diet and exercise. Diet and exercise in combination could be very
beneficial to enhance B cell development. The studies above suggest that antiinflammatory conditioning of BM adipose tissue through calorie restriction will
reduce the inflammatory state of the BM, in effect removing inhibitory molecules.
In addition, exercise appears to be beneficial in regulating the volume of marrow
adipose tissue and promoting osteoblast generation. This would provide more
space for hematopoiesis and potentially keep adiponectin levels at a manageable
level for B lymphopoiesis to occur.
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Targeting myeloid-derived suppressor cells
Since MDSCs have been identified as a therapeutic target in many
cancers, there are a plethora of strategies available to target these cells. Current
strategies act to deplete MDSCs, block MDSC development, inactivate MDSC
effector mechanisms, and induce differentiation of MDSCs into mature myeloid
cells that lack suppressive activity (Wesolowski et al., 2013).
Deplete MDSCs. Gemcitabine is one cytotoxic agent used to deplete
MDSCs in lung and mammary cancers (Suzuki et al., 2005). This drug has also
been used in combination with an anti-IL-6R neutralizing antibody to block the
accumulation of MDSCs (Sumida et al., 2012). Other drugs that are toxic to
MDSCs include 5-fluorouracil and Docetaxel (Kodumudi et al., 2010, Talmadge
and Gabrilovich, 2013, Vincent et al., 2010, Wesolowski et al., 2013). One study
using 5-fluorouracil to deplete MDSCs in mice with thymoma found that 5fluorouracil did not affect most other immune cell lineages. However 5fluorouracil treatment did result in an increased number of B cells (Vincent et al.,
2010), which the authors suggest is to compensate for the loss of MDSCs.
Overall, these drugs are an effective means to deplete MDSCs, although it will be
important to verify their safety at doses used to target cells in the BM.
Block MDSC development. Several strategies to block MDSC
development target signaling pathways responsible for MDSC formation. For
example MDSCs require STAT3 activation for development and survival,
therefore inhibiting this pathway will result in fewer MDSCs (Sansone and
Bromberg, 2012, Wesolowski et al., 2013). In fact, a small molecule has been
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developed to target STAT3 phosphorylation (Lin et al., 2010) and could be used
to target MDSCs.
Inactivate MDSC effector mechanisms. We found that MDSCs inhibit B
lymphopoiesis and suppress T cell responses via different mechanisms. While
there are many strategies to block MDSC-mediated suppression of T cell
responses, such as blocking arginase and iNos, the treatments developed to
target these mechanisms cannot be used to block the inhibition of B
lymphopoiesis. Targeting MDSC effector mechanisms in the context of B
lymphopoiesis will be discussed in the next section.
Promote MDSC differentiation into non-suppressive myeloid cells.
MDSCs are a population of immature myeloid cells, and it is now understood that
inducing differentiation into mature myeloid cells is an effective strategy to target
MDSCs in the context of cancer. One such agent capable of doing this is the
vitamin A metabolite all-trans-retinoic acid (ATRA). ATRA treatment of mice was
found to induce MDSC maturation into macrophages, granulocytes, and dendritic
cells (Kusmartsev et al., 2003). Overall, ATRA treatment reduced the number of
MDSCs in several tumor models (through inducing maturation), increased antitumor immune responses, and improved the effect of 2 different anti-tumor
vaccines. Another study found ATRA treatment of MDSCs isolated from cancer
patients induced differentiation in these cells (Kusmartsev et al., 2008),
implicating this as an effective strategy to use in humans. In addition to ATRA,
other agents that can be used to induce differentiation include vitamin A, vitamin
D, and CpG (TLR9 agonist) (Wesolowski et al., 2013). These are effective
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treatments to reduce MDSC numbers in cancers, however the molecule used to
enhance B lymphopoiesis must be chosen carefully. For example, while CpG can
induce the maturation of MDSCs to less suppressive myeloid cells, CpG
recognition by TLR9 was also found to induce CLPs to differentiate into dendritic
cells (Welner et al., 2008). Therefore adaptation of this and other strategies for
the modulation of hematopoiesis will require additional studies to identify any
undesirable outcomes.
Targeting adipocyte and/or MDSC effector molecules
IL-1. Adipocyte-induced MDSCs inhibit B lymphopoiesis through the
production of IL-1. One strategy to boost B lymphopoiesis is to target IL-1. This is
possible with the drug anakinra, which is an IL-1R antagonist commonly used to
treat rheumatoid arthritis (Kavanaugh, 2006). Anakinra may prove useful in
preventing the effects of IL-1, but perhaps is not the best strategy because this is
the most downstream target identified for adipocyte-mediated inhibition of B
lymphopoiesis. One of the most promising therapeutic strategies we identified will
be targeting adipocyte products.
Preventing inflammasome activation. Our results suggest that
preventing NLRP3 inflammasome activation to promote B lymphopoiesis could
be very effective. Glybenclamide treatment (NLRP3 inflammasome inhibitor) of
BM cultures containing adipocyte factors prevented MDSC accumulation and
enhanced B lymphopoiesis. Blocking the inflammasome acts at the level of
adipocyte products preventing downstream events to improve B cell development
(removing MDSCs and IL-1 from the equation). Preventing NLRP3 activation in
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aged mice was shown to block the atrophy of the thymus, improving T
lymphopoiesis (Youm et al., 2012). If targeting the inflammasome is also found to
be beneficial for B lymphopoiesis in vivo, modulating NLRP3 inflammasome
activation could be a powerful treatment to improve general lymphopoiesis. In
fact, aged NLRP3-/- mice have a significant increase in MPPs compared to aged
WT mice (Youm et al., 2012), which might provide a larger progenitor pool for
lymphocyte development. Additional studies will be needed to address this
question.
Statins, inflammasome activation, and B lymphopoiesis
Prior to the current study, our laboratory attempted to prevent/restore
rabbit B lymphopoiesis using lovastatin. Statins are widely prescribed for their
LDL-cholesterol lowering effects, which are mediated through inhibiting the
enzyme hydroxymethylglutaryl-CoA reductase. The logic for using lovastatin to
enhance B lymphopoiesis in rabbits came from studies that showed statins also
inhibit adipocyte differentiation (Nakata et al., 2006, Nicholson et al., 2007), and
therefore was used as a strategy to target the accumulation of adipocytes in
rabbit BM. While preliminary results using lovastatin treatment were promising,
the overall ability to enhance B lymphopoiesis was limited. This dissertation
provides new insight into why the effect on B lymphopoiesis was limited and a
potential strategy to improve B cell development using lovastatin.
In addition to the functions of statins described above, statins were found
to activate the NLRP3 inflammasome in macrophages leading to IL-1β
production (Henriksbo et al., 2014, Mandey et al., 2006). This mechanism
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appears to contribute to an increased incidence of type II diabetes seen in
patients using statins (Culver et al., 2012, Henriksbo et al., 2014, Ridker et al.,
2012). In fact, inflammasome activated myeloid cells are found in patients with
type II diabetes (Lee et al., 2013). Similar to using NLRP3-/- mice, Henricksbo et
al. found that statin induced insulin resistance and induction of IL-1β secretion by
macrophages could be blocked by preventing NLRP3 inflammasome activation
with glybenclamide treatment (inflammasome inhibitor) (Henriksbo et al., 2014).
These authors suggested that glybenclamide treatment (and other NLRP3
inflammasome inhibitors) in combination with statins will prevent insulin
resistance due to statin use. In light of our findings, a combination therapy using
statins to prevent adipocyte accumulation and NLRP3 inflammasome inhibitors to
prevent statin-induced IL-1β production could be a promising strategy to enhance
B lymphopoiesis.
The rabbit as a model system and remaining questions
We envision that the insights gained from this dissertation will be relevant
to many situations resulting in fatty BM, such as aging and obesity. As discussed
previously, characterization of rabbit hematopoiesis in our study and by others
suggests the rabbit is an accelerated model of aging hematopoiesis. The
phenotypes observed correlate with an increase in BM adipose tissue occurring
by two to four months of age, which is consistent with the accumulation seen in
elderly humans (Li et al., 2013). While the rabbit model is valuable to gain an
understanding of the processes that occur in aged BM, can the rabbit also be
used to model other BM situations?
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The rabbit as a model of bone marrow failure
Could rabbits be used as a model for other BM pathologies, such as BM
failure? Additional studies will be needed to assess the plausibility of this notion,
but available evidence suggests there are some similarities between the BM of
>2 month old rabbits and the BM of patients undergoing BM failure. Aplastic
anemia and myelodysplastic syndrome (MDS) are both forms of BM failure
leading to cytopenias in one or more hematopoietic lineages; including defective
production of B lineage cells (Ogata et al., 2006, Ribeiro et al., 2006, Sandes et
al., 2012). While ultimately different, the similarities between these diseases
often make aplastic anemia and MDS hard to distinguish in some patients. In
aplastic anemia, the BM fills with fat (Takaku et al., 2010). Originally it was
thought that fat fills the empty BM space, but it has now been posed that
adipocytes could cause or contribute to the disease (Islam, 1988, Young, 2013).
Certainly this is similar to the process that occurs naturally by two to four months
in rabbits. Rabbits shut down the production of new B lymphocytes at this time,
but it is unknown if the underlying mechanism could be considered a form of
preprogramed BM failure.
MDS also results in altered hematopoiesis that can progress into
leukemia, and sometimes exhibits infiltration of BM fat similar to that seen in
aplastic anemia (Rovo et al., 2013). Defective hematopoiesis in MDS is often
characterized by a large number of hematopoietic progenitors undergoing
apoptosis (Gersuk et al., 1998, Raza et al., 1995). The BM in these patients is
influenced by inflammatory factors such as IL-1β, TNFα, and Fas-ligand (Gersuk
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et al., 1998, Shetty et al., 1996), which can contribute to apoptosis seen in the
BM (Hirai, 2003). This is consistent with increased IL-1β expression in BM from
>2 month old rabbits and the increases of inflammatory factors seen during
aging.
How changes in BM MSCs influence the development of MDS is not fully
understood. Several studies suggest MSCs from patients with MDS have
chromosomal abnormalities (Blau et al., 2007, Flores-Figueroa et al., 2005).
Additionally, Borojevic et al. found that plating cord blood hematopoietic
progenitors on BM stromal cells from MDS patients resulted in altered
hematopoiesis, and suggest the BM stroma in MDS might promote the disease
(Borojevic et al., 2004). Further, Raajimakers et al. found that genetic deletion of
Dicer1 or Sbds (mutated in Schwachman-Bodian-Diamond syndrome) in mouse
osteoprogenitors resulted in a BM phenotype resembling MDS. Additional studies
will be needed to assess whether the changes that occur to MSCs in MDS are
similar to the changes occurring in MSCs by two months of age in rabbit BM.
While there are similarities between BM failure and the changes occurring
in rabbit BM, it may be too early to tell if the rabbit is a good model to study BM
failure. Aplastic anemia and MDS both contain a known autoimmune component
that contributes to BM failure (Barrett and Sloand, 2009), which is not known to
occur in rabbit BM. In terms of hematopoietic progenitors, there is a wealth of
information suggesting that genetic defects in hematopoietic progenitors
contribute to MDS (Hirai, 2003). Our data in rabbits (Figure 3.20 and Kalis et al.,
2007), suggest the loss of B lymphopoiesis is mediated by changes in the
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microenvironment as opposed to hematopoietic progenitor defects. Additional
differences between available information on rabbit hematopoiesis and BM
failure include; 1. MDS can progress into leukemia, but we rarely find leukemia
develop in our rabbit colony; 2. Rabbits continue to live for years after the arrest
of B lymphopoiesis that occurs at two months of age, while BM failure usually
results in death if untreated; and 3. Although B cell development is lost in rabbits,
decreases in peripheral white blood cell numbers are not known to occur.
Overall, while the rabbit might serve as a good model to assess how changes in
the BM microenvironment impact hematopoiesis, rabbit BM does not exhibit
other common features of BM failure. Most notably, even in the absence of B
lymphopoiesis the rabbit immune system remains intact.
Maintaining adaptive immunity in the absence of B lymphopoiesis
B lymphopoiesis shuts down early in the life of rabbits, generating a very
perplexing question. How do rabbits remain immune competent? In fact, the
arrest of B lymphopoiesis does not prevent rabbits from responding to new
antigens. Adult rabbits are commonly used to generate polyclonal antibodies to
various antigens. Additionally, rabbit monoclonal antibody technology, a powerful
tool developed by Knight and colleagues uses adult rabbits to generate highly
specific monoclonal antibodies (Spieker-Polet et al., 1995). This suggests the
rabbit must have a mechanism to maintain the ability to respond to a diverse
array of antigens in the absence of B lymphopoiesis. One possible explanation is
that rabbit GALT maintains antibody diversity throughout the life of rabbits. As
described in Figure 1.4, B cells made in the BM traffic to rabbit GALT and
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undergo further maturation. It is possible that unknown mechanisms in GALT
support the maintenance of B lineage cells. Alternatively, perhaps rabbit B
lineage cells can self-renew. One study found that rabbit B cells express the
molecule CD5 (Raman and Knight, 1992), a molecule used to identify B1a cells
in mice. Although it is unknown if rabbit B cells can self-renew, mouse B1a cells
are maintained throughout life by self-renewal (Forster and Rajewsky, 1987,
Hayakawa et al., 1985, Hayakawa et al., 1986, Herzenberg et al., 1986,
Herzenberg and Kantor, 1993). Future studies will be needed to understand how
B cells are maintained, as this may alleviate the demand for B lymphopoiesis in
the BM and contribute to the arrest of new B lymphocyte production.
Understanding changes in MSCs before and after two months of age
Bilwani and Knight found that there are fewer MSCs present in the BM of
>2 month old rabbits (the time when B lymphopoiesis arrests), and that the MSCs
are more prone to differentiate into adipocytes compared to MSCs from younger
rabbits (Bilwani and Knight, 2012). Because adipocytes initiate the mechanism of
inhibition described in this dissertation, preventing the accumulation of
adipocytes in the BM could result in enhanced B lymphopoiesis. It will be
important for future studies to identify what triggers changes in MSCs at two
months of age in rabbits.
Similar to hematopoietic progenitors, intrinsic changes to MSCs or
extrinsic changes in the systemic environment might contribute to increased
potential to become adipocytes over osteoblasts. While this altered potential is
not fully understood, one study found that serum from adult rabbits induced
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adipocyte differentiation in several human, mouse, and rat
osteoblast/osteosarcoma cell lines (Diascro et al., 1998). These data suggest a
systemic factor in rabbits could influence this differentiation decision. Further
analysis of adult rabbit serum identified the fatty acids palmitic, oleic, and linoleic
acids were responsible for inducing adipocyte differentiation (Diascro et al.,
1998). What causes these fatty acids to be present in adult rabbit serum, and the
genetic and epigenetic effects they have on MSCs is yet to be determined.
An alternative mechanism that may modulate MSC adipogenic vs
ostobalastic potential could come from altered WNT signaling in older rabbits.
RDA analysis comparing BM MSCs from a young and a 2 year old rabbit found
frizzled 4 (WNT ligand receptor) expression was decreased in MSCs isolated
from the 2 year old rabbit (Siewe et al., 2011). This is important because
decreased WNT signaling results in low β-catenin levels, and having low
amounts of active β-catenin in MSCs promotes adipocyte differentiation (Sen et
al., 2008). More studies will be needed to truly understand the mechanisms
initiating the accumulation of adipocytes in BM. This may be due to changes in
diet and exercise leading to changes in serum fatty acids, and/or currently
undefined genetic/epigenetic mechanisms.
Additional studies are also needed to better understand the features of
regulated BM adipose tissue (supports hematopoiesis) vs constitutive BM
adipose tissue (does not support hematopoiesis), and how these types of fat
contribute to the state of the BM microenvironment.
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Conclusion
This study has improved our understanding of how adipocytes influence
the BM microenvironment and affect hematopoiesis. We propose a model
occurring in fatty BM that is initiated by adipocytes and results in altered
hematopoiesis (Figure 4.2). Adipocytes produce inflammasome activating
molecules that promote the accumulation of MDSCs/inflammatory myeloid cells
which, in turn produce IL-1. IL-1 acts on hematopoietic progenitors and stromal
cells to produce an inflammatory state that drives MPPs to differentiate to the
myeloid lineage, instead of the B lineage. The inflammatory state negatively
regulating B lymphopoiesis and promoting myelopoiesis can be amplified by
S100A9 production from myeloid cells (Figure 4.3). S100A9 acts on BM myeloid
cells to induce IL-1, IL-6, and TNFα expression, known inhibitors of B
lymphopoiesis (Dorshkind, 1988a, Hirayama et al., 1994, Maeda et al., 2005,
Maeda et al., 2009, Ratliff et al., 2013, Ueda et al., 2004).
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Figure 4.2 Negative regulation of B lymphopoiesis in adipocyte-rich bone
marrow. Healthy BM is characterized by the presence of osteoblasts and stromal
cells that support B lymphopoiesis. In fatty BM, adipocytes accumulate while
supportive stromal cells are decreased in number. Adipocytes actively influence
hematopoiesis by producing inflammasome activating molecules, as well as
inflammatory cytokines. Adipocyte-rich BM exhibits an increased myeloid
compartment, which contains a population of cells that inhibit B lineage
development. Overall, inflammatory factors derived from adipocytes and
inflammatory MDSCs create an environment that promotes myelpoiesis and
negatively affects B cell development. Adapted from Kennedy et al. 2016.
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Figure 4.3 Effect of S100A9 on hematopoiesis. Inhibition of B lymphopoiesis is
initiated by inflammasome activating adipocyte factors (can be blocked with
glybenclamide) and mediated through IL-1 producing MDSCs (as described in
Figure 4.1). In addition to this mechanism, the presence of S100A9 further
amplifies inflammation in the BM. S100A9 derived from myeloid cells in fatty BM
does not act at the MPP stage like IL-1. Instead, S100A9 induces IL-1β
expression in BM myeloid progenitors cells which can feed into the inhibition of B
lymphopoiesis already described for IL-1. Further, S100A9 also induces the
production of IL-6, and TNFα in BM myeloid cells which can directly inhibit B
lymphopoiesis. Adapted from Kennedy and Knight, 2015.

B cells and antibodies are critical for generating productive immune
responses. Situations resulting in decreased output of new B cells into the
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periphery put the host at risk for infection. Our study highlights the importance of
the BM microenvironment (consisting of stromal and hematopoietic cells) in the
regulation of B lymphopoiesis, and how changes to this environment negatively
regulate B lineage development. We provide mechanistic insight into how
adipocytes and MDSCs inhibit B lymphopoiesis, and identified several
therapeutic targets for intervention. Accumulation of BM fat occurs in multiple
pathologies (eg. obesity, BM failure, aging), we expect the knowledge gained in
this dissertation will be used to develop treatments aimed at increasing B
lymphopoiesis in a broad context of pathologies resulting in altered white blood
cell development due to increased BM fat.
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